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ABSTRACT: Part 1 describes the synthesis and biological evaluation of small-molecule 
phosphatase inhibitors. The targets for the synthesized compounds are mainly Cdc25 
phosphatases, which play a key role in regulating cell cycle and are often over-expressed in 
cancers. Highlights of the synthesis are the amide bond formation, the synthesis of secondary 
amines via o-Ns chemistry, the ring opening of the lactam by the amine, the preparation of 
various (iso)quinolinediones and the substitution reactions of (iso)quinolinediones with amines 
and thiols. The synthesis and reaction of isoquinonlinediones are particularly highlighted in the 
total synthesis of caulibugulones A-E. Biological assays established the (iso)quinolinediones as 
new phosphatase inhibitors with considerable selectivity against the Cdc25 family of DSPases. 
Part 2 describes the synthetic studies toward the total synthesis of parvistemonine, which 
represents one of the most challenging synthetic targets among Stemona alkaloids.  The studies 
are mainly focused on the development of a fragmentation strategy aimed at the total synthesis of 
parvistemonine. Highlights of these studies are the synthesis of vinyl azides, the fragmentation 
reaction of tertiary alcohols and the use of the trimethylsilyl-methylene group as a directing 
group in the fragmentation reaction. These studies demonstrate a novel vinylogous azido alcohol 
fragmentation reaction in simple model systems and a regioselective fragmentation reaction of 
hydroxy indolines. 
 iii
ACKNOWLEDGEMENT 
 
I would like to express my great thanks to Professor Peter Wipf. He has been a great 
advisor during my whole graduate studies. I have been deeply impressed by the depth of his 
knowledge of chemistry and great enthusiasm toward scientific research and education. I believe 
that the experience in his group will be invaluable in my career as a research scientist because I 
have learned a great deal of techniques, knowledge and problem-solving skills. Thanks are 
extended to Professors Nelson, Floreancig, and Lazo for serving on my committee and for their 
assistance towards my education.  
I would also like to thank Dr. Lin for his help with NMR experiments and Dr. Somayajila 
for the mass spectra. 
I would like to thank Dr. Lazo and his group members for biological assays of my 
compounds.   
I would like to express my gratitude to all of the present and former members of the Wipf 
group. We shared great times and hard times together as members of an excellent research group. 
I believe that all of us have worked hard to overcome the hurdles and will have a bright future. 
My special thanks goes to Gil Ma who has been a good colleague for 5 years in Pittsburgh. 
I would like to thank the University of Pittsburgh for giving me the opportunity to study 
here and for its financial support. 
Finally, I would like to thank my wife and daughter for their continuous support and 
understanding while I was working hard to overcome the difficulties I have encountered during 
my Ph. D. studies.  
 
 
 iv
ABBREVIATIONS 
 
Ac Acetyl 
AIBN 2,2’-Azobisisobutyronitrile 
ADP Adenosine-5’-diphosphate 
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Asp Aspartic acid 
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EDCI 1-Ethyl-3-[3-(dimethylamino)propyl]-
carbodiimide hydrochloride 
EI Electron ionization 
 v
ERK Extracellular regulated kinase 
ESI Electron-spray ionization 
FDPP Pentafluorophenyl diphenylphosphinate 
Glu Glutamic acid 
GST Glutathion-S-transferase 
HPLC High performance liquid chromatography 
HMBC Heteronuclear multiple bond correlation 
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IC50 Median inhibition concentration 
Im Imidazole 
KHMDS Potasium bis(trimethylsilyl)amide 
LDA Lithium diisopropylamide 
LHMDS Lithium bis(trimethylsilyl)amide 
L-Selectride Lithium tri-sec-butylborohydride 
MAPK Mitogen-activated protein kinase 
MCPBA m-Chloroperoxybenzoic acid 
MOM Methoxymethyl 
MS Molecular sieves 
Ms Methanesulfonyl 
NBS N-Bromosuccinimide 
NCS N-Chlorosuccinimide 
NOESY Nuclear Overhauser enhancement and exchange 
spectroscopy 
Ns Nitrobenzenesulfonyl 
PIFA [Bis(trifluoroacetoxy)iodo] benzene 
PP Protein phosphatase 
PPTs Pyridinium p-toluenesulfonate 
PSTPaes  Protein serine threonine phosphatase 
PTP Protein tyrosine phosphatase 
PTPases Protein tyrosine phosphatases 
 vi
PyBrop Bromotrispyrrolidinophosphonium 
Hexafluorophosphate 
Pyr Pyridine 
RC Recognition complex 
SAR Structure activity relationship 
SEM Standard error of the mean 
Ser Serine 
TBDPS t-Butyldiphenylsilyl 
TBS (= TBDMS) t-Butyldimethylsilyl 
TEA Triethylamine 
Tf Trifluorosulfonyl 
THF Tetrahydrofuran 
THP 2-Tetrahydropyran 
Thr Threonine 
TIPS Triisopropylsilyl 
TMS Trimethylsilane 
TPAP Tetrapropylammonium perruthenate 
Ts    p-Toluenesulfonyl 
Tyr Tyrosine 
VHR Vaccina human-related 
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 1. Synthesis of Small-Molecule Phosphatase Inhibitors 
1.1.  Introduction 
1.1.1. Biological Background 
 
Covalent modification is one of the methods that can regulate enzyme activity.1 For 
example, simple covalent attachments of a functional group, such as a phosphoryl moiety can 
convert a fully active enzyme into an inactive form (Figure 1)1, although in many cases 
phosphorylation can activate an enzyme. 
 
OH O P
O
O
O
Enzyme Enzyme
protein
kinase
protein
phosphatase
ATP ADP
H2O
HO P
O
O
O
active form inactive form
 
Figure 1. Regulation of enzymes by covalent modification1 
 
This protein phosphorylation is a key process in cell signaling, metabolism, growth and 
differentiation and is controlled through kinases and phosphatases.2 Protein kinases catalyze 
phosphorylation of hydroxy groups on serine, threonine and/or tyrosine residues in target 
enzymes, whereas phosphatases catalyze dephosphorylation.2 Protein phosphorylation fulfills a 
major role in signal transduction pathways, highly controlled processes by which cells convey 
information from the cell surface to their nucleus or other remote subcellular sites.2 This 
information then regulates cell growth and differentiation, metabolism, cell cycle and 
cytoskeletal function.2 Phosphatases are generally classified in three families: Ser/Thr protein 
 1
 phosphatases (PSTPases), Tyr protein phosphatases (PTPases) and dual-specificity protein 
phosphatases (DSPases). 
Dual-specificity protein phosphatases (DSPases) are sub-classes of PTPases (Figure 2).3 
PSTPases have been classified according to their substrate specificity, metal ion dependence and 
sensitivity to inhibition. cDNA cloning has revealed at least 40 different enzymes of this type, 
including PP1, PP2A, PP2B, PP2C and PP3. PTPases have diverse biochemical and cellular 
roles. For example, PTP1B regulates both epidermal growth factor and insulin signaling 
pathways. The DSPase VHR (vaccina human-related) regulates mitogenic signaling by 
specifically dephosphorylating members of the MAPK  (mitogen-activated protein kinase) 
family, namely the extracellular regulated kinases ERK1 and ERK2. The Cdc25 (cell-division 
cycle 25) family of DSPases regulates cell-cycle progression by dephosphorylating and 
activating cyclin-dependent kinases (CDKs). CDKs are inactivated by phosphorylation at 
adjacent threonine and tyrosine residues near their amino termini, and dephosphorylation at both 
sites by Cdc25 phosphatases catalyses their activation and allows the CDKs to propagate cell-
cycle signal transduction.2,3,4 
 
Phosphatases
PTPases : PTP1B, CD45 etc.
PSTPases : PP1, PP2A, PP2B, PP2C, PP3, PP4(PPX), PP5 etc.
DSPases : Cdc25A/B/C, VHR, MAPK etc.
(phosphorylation occurs in serine or threonine residue)
(phosphorylation occurs in tyrosine residue)
(phosphorylation occurs in serine/threonine or tyrosine residue) 
Figure 2. Classification of phosphatases 
 
 2
 Cell duplication events associated with cell growth and division in eukaryotic cells fall 
into a four distinct phases, M, G1, S and G2 (Figure 3).5 
 
G1
S
G2
M : Mitosis and cell division
G1 : Gap 1. Longest period of cycle
Rapid growth and metabolic activity
S : DNA duplication
G2 : Gap 2. Growth and preparation for cell
        division
M
 
Figure 3. Cell cycle5 
 
In this cell cycle, phosphorylation acts as a replication switch since the post-RC 
(Recognition Complex) state comes after phosphorylation of proteins in the pre-RC. Since the 
post-RC state is incapable of re-initiating DNA replication, phosphorylation ensures that 
eukaryotic DNA replication happens only once per cell cycle.5 In this context, the Cdc25 
phosphatase family plays an important role in controlling cell cycle progression by activating 
cyclin-dependent kinases (Cdk).6 There are three homologues of Cdc25 in humans: Cdc25A, 
Cdc25B and Cdc25C.6 Cdc25B and C regulate the G2/M transition by dephosphorylating and 
activating the Cdk1/cyclinB mitotic kinase complex, whereas Cdc25A is involved in the G1/S 
phase transition. Over-expression of Cdc25A and B is often found in human tumors, so they are 
considered to be potential target for anti-tumor drugs.6 So far, two crystal structures of the Cdc25 
 3
 catalytic domain were disclosed (Figure 4 and Figure 5),4(a),7 however none exposes the nature of 
interactions with small-molecule phosphatase inhibitors. Therefore, it has been difficult to define 
rational parameters for potent inhibitors. 
 
Figure 4. X-ray crystal structure of the Cdc25A catalytic domain4(a)
 
Both Cdc25A and Cdc25B have the canonical His-Cys-Xaa5-Arg PTPase catalytic-site 
motif, which is a characteristic of all tyrosine phosphatases.4(a),6,7 Although the two Cdc25s are 
similar in overall structure of the catalytic domain, Cdc25B readily binds tungstate and sulfate in 
its catalytic site whereas Cdc25A fails to bind oxyanions in its catalytic site.7 This difference 
might result from the shallow nature of the Cdc25A active site compared with the active site of 
 4
 Cdc25B. Thus, Cdc25B is structurally more similar to other DSPases. Interestingly, Cdc25A has 
an identical topology to the bacterial sulfur-transferase protein rhodanese, however the 
significance of this homology is unclear.6 The differences in their active site crystal structures 
suggested that designing specific inhibitors for Cdc25 isoforms should be possible.6 
 
 
Figure 5. X-ray crystal structure of the Cdc25B catalytic domain7 
 
The mechanism of dephosphorylation of PTPases is considered to be a two-step sequence 
via phosphoenzyme intermediates.1(b),4(a),8 In the first step, the Cys residue of the phosphatase 
acts as a nucleophile to attack the phosphoryl group of substrates and forms a cysteinyl 
 5
 phosphate intermediate.8 The Arg residue of the enzyme makes bidentate hydrogen bonds with 
the phosphoryl group in the substrate through the guanidinium group.8 The Asp residue of the 
PTPases acts as a general acid by protonating the ester oxygen of the leaving group.8 In the 
second step, the attack of a water molecule to the phosphoenzyme intermediate occurs with the 
help of the same Asp residue, now functioning as a general base, to release the free enzyme and 
inorganic phosphate (Figure 6).8 
 
P
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O SubstrateO
O
H2N
NHH2N
Arg
Cys S
O
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HO
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Cys S
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P
O
O
O
HN NH2
NH2 OO
O
H
H
SubstrateHO
 
Figure 6. Mechanism of dephosphorylation of PTPases8 
 
More specifically, Rudolph proposed two possible mechanisms for Cdc25 shown in 
Figure 7.9 In the top reaction pathway, he proposed the classical mechanism using a bisanionic 
substrate leading to a meta-phosphate-like transition state. In this case, a leaving group is 
protonated by the Asp residue of the enzyme. In the bottom reaction pathway, he proposed a 
novel mechanism using a monoprotonated substrate, leading to the same meta-phosphate-like 
transition state. In this case, the leaving group is protonated by the substrate.  
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Figure 7. Reaction mechanisms for Cdc25 proposed by Rudolph9 
 
On the basis of the structure of the catalytic domain and the mechanism of 
dephosphorylation of Cdc25, two special characteristics of Cdc25 phosphatases are thought to be 
responsible for the lack of success in finding reversible active site directed inhibitors.10 The first 
characteristic is that Cdc25 is highly susceptible to inactivation by covalent modification and 
oxidation of the active site motif HCX5R. In this motif, H is a histidine residue, C is the catalytic 
cysteine, the five X residues form the loop, and R is an arginine residue. The catalytic cysteine 
exists as a thiolate anion in the free enzyme. This active site thiolate is considered to be the 
source of susceptibility of Cdc25s to covalent modification and oxidation.11 Assays of Cdc25s 
are likely to demonstrate covalent and irreversible inhibition with reactive compounds. This trait 
is generally avoided in medicinal chemistry.12 The second characteristic is the open and 
 7
 somewhat featureless architecture of the Cdc25 active site as depicted in Figure 4 and Figure 5. 
These exposed active site regions are not suitable for the structure-based design of compounds 
with complementary binding surfaces and result in a low and nonspecific activity toward 
phospho-peptide substrates and peptide mimetics.13 
According to recent studies, the active site of cysteine of Cdc25s could form a disulfide 
bond with a neighboring cysteine after H2O2 oxidation (Figure 8).14 It has also been reported that 
treatment of Cdc25s with H2O2 in vitro leads to oxidation of the active site cysteine to cysteine-
sulfenic acid (Cys-SOH) and results in inhibition of activity.15 The disulfide bond likely confers 
efficiency in the redox regulation of Cdc25s and protects further oxidation. It has also been 
shown that recovery of enzyme activity depends on the cellular reductant. These reports suggest 
that redox regulation of Cdc25 phosphatase activity may be important for cell cycle regulation.  
 
Cdc25C
377
330
SH
SH
H2O2 H2O
Cdc25C
377
330
SOH
SH
H2O
Cdc25C
377
330
S
S 
Figure 8. Oxidation of Cdc25C by H2O214 
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 1.1.2. Dual Specificity Phosphatase Inhibitors  
     
The over-expression of members of the Cdc25 family and their role in regulating cell-cycle 
progress and survival make them attractive targets for new, potent and selective small-molecule 
inhibitors.6,16 In particular, over-production of Cdc25A and B has often been found in breast 
cancer tissue.13 The Cdc25 over-expression has also been detected in other diseases such as 
gastric carcinomas, colon cancer, non-small cell lung carcinoma and aggressive non-Hogkin’s 
lymphomas.10,16 Therefore, potent and selective inhibitors of Cdc25 family are highly desirable 
and significant efforts have been made to identify such molecules.  
Natural products have been a major source of Cdc25 inhibitors (Figure 9). Sulfircin, which 
is produced by a deep-water sponge from the Ircinia genus, is a nonspecific phosphatase 
inhibitor originally identified as an antifungal agent.  Due to its relative structural and 
stereochemical simplicity, sulfircin has been used as a basic pharmacophore for the development 
of a small analog library.17 Sulfircin showed an inhibition against Cdc25A with an IC50 of 7.8 
µM and VHR with an IC50 of 4.7 µM. Another extract from a marine sponge, dysidiolide, was 
initially reported as the first natural product DSPase inhibitor, but a later study claimed that pure 
dysidolide did not inhibit Cdc25B.18 Recently, Shirai and co-workers indicated that the natural 
product was moderately active against Cdc25A with an IC50 value of 35µM.19 Nonetheless, Peng 
and colleagues synthesized analogs of dysidiolide by modifying another readily available natural 
product, cholesteryl acetate.20 Dephostatin, isolated from the Steptomyces strain MJ724-NF5, 
was identified as an active compound against PTPases.21 The benzoquinone antitumor antibiotics 
dnacins A and B, extracts form Nocardia strain C-14482, were found to be moderate inhibitors 
of glutathione-S-transferase (GST)-tagged-Cdc25B.22 RK-682 was isolated from the Penicillium 
strain NK374186 and showed activity against VHR with an IC50 value of 2.0 µM.23 Cyclic 
 9
 depsipeptides, stevastelines A and B, were isolated from the Penicillium strain NK374186 and 
shown to be good inhibitors of VHR, with IC50 values of 2.7 and 19.8 µM.24 Vitamin K3 
(menadione) was found to be an irreversible inhibitor of Cdc25B with an IC50 value of 3.6 ± 0.6 
µM.25 Nocardiones A and B were isolated from the Nocardis strain TP-A0248 and shown to 
inhibit the activity of Cdc25B with an IC50 of 17 µM.26 Coscinosulphate was isolated from the 
New Caledonian marine sponge Coscinderma mathewsi and proven to be a potent deactivator of 
Cdc25A with IC50 of 3.0 µM.27 Suramin is one of the oldest synthetic therapeutics and has been 
used for the treatment of sleeping sickness and onchocerciasis.28 Zhang and coworkers screened 
sumarin and 45 sumarin analogues against a panel of seven PTPases and found sumarin to be a 
potent inhibitor of Cdc25A with an IC50 of 1.5 µM.29 In addition, 3 analogues of sumarin were 
found to be potent (IC50 < 5 µM) and specific inhibitors of Cdc25A. Some polyprenyl-
hydroquinones and polyprenyl-furans, isolated and identified independently from three sponges 
(Spongia officinalis, Ircinia spinulosa, Ircinia muscarum) were found to be potent Cdc25 
phosphatase inhibitors.30 However, these compounds were found to be inactive against the 
PSTPase PP2C-α and the three kinases CDK1, CDK2 and CDK3, implying that a potent and 
selective inhibitor of the Cdc family could be derived from these structures.    
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Figure 9. Natural product DSPasese inhibitors 
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 In addition to natural products, a number of synthetic compounds were also tested for 
inhibitory activity against the Cdc25 family (Figure 10).6,16 Compound 1, which was produced by 
pyrolysis of a cholesteryl derivative, inhibits Cdc25A in the low µM range.20 Compound 2, 
which was developed in an effort to produce a simpler inhibitor structure, showed higher potency 
than the parent compound.31 Compound 3, an analog of vitamin D3, possesses Cdc25A-
inhibitory activity in vitro and causes G1 arrest in HL60 cells, as expected of Cdc25A 
inhibitors.32 Although, like with almost all of the described compounds, little is known about 
their selectivity against PTPases or even against other Cdc25 isoforms in vitro or within cells, 
synthetic quinones have also been found to have activity against Cdc25.  Cellular studies with 
compound 4, a vitamin K analog, indicate blockage of cell cycle progression at the G1/S 
checkpoint, an increase in Cdk2 phosphorylation and a concomitant decrease in Cdk2 activity, 
consistent with inhibition of Cdc25A.33 Another synthetic vitamin K analog, compound 5, was 
independently identified as a partial-competitive inhibitor of Cdc25.16(b) Bergnes and colleagues, 
in an effort to explore the active site of Cdc25, designed a group of mechanism-based inhibitors 
using a four-component Ugi reaction. One diamide, compound 6, was the first submicromolar 
inhibitor of Cdc25 reported to date and had a 7- and 120-fold selectivity for Cdc25A compared 
with VHR and PTP1B, respectively.34 Bockovich and coworkers prepared 24 analogues of 
sulfircin and reported compounds 7-10 as the most active analogues18b) This study revealed that 
compounds with the longest side chains were equipotent or more potent than the natural product, 
indicating the importance of the length of the side chain. The Sodeoka group derivatized RK-682 
by manipulating the substituents at C-3 and increasing the hydrophobicity at the C-5 position to 
produce potent inhibitors 11-14 with selectivity for Cdc25B.35 Two series of analogues of 
alkylphospholipids were prepared and evaluated for their ability to inhibit Cdc25 phosphatase by 
 12
 the Koufaki group.  The most active compound was the N-morpholino derivative 15, which was 
shown to cause very weak inhibition of Dspases.36 Rudolph and coworkers described that 
indolyldihydroxyquinones such as 16 and 17 bind reversibly to the active site of Cdcs with 
submicromolecular potency.10 SAR studies of the 50 derivatives show interesting and consistent 
trends, revealing features required for inhibition of Cdc25s. The compounds did not exhibit time-
dependent inhibition, indicating that they do not form covalent bonds or oxidize the active site 
thiol. BPR0L075 (18), a synthetic compound discovered in the course of identifying new 
microtubule inhibitors, showed cytotoxic activity in a variety of human tumor cell lines.37 
Additional studies indicate that the effect of this compound on the cell cycle is associated with an 
increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C. Therefore, BPR0L075 can 
be considered as an inhibitor of Cdc25C. Ham et al. reported that the fluorinated compound 19, 
derived from optimizing the electronic properties of the quinone system using the semi-empirical 
AM1 method, was 3-fold more potent than the parent compound 5 as an inhibitor of Hep3B cell 
growth.38 This compound is also possibly a potent inhibitor of the Cdc family.  
Unfortunately, selective and highly potent inhibitors of Cdc25 are still lacking in spite of 
considerable synthetic and biological studies with natural and synthetic compounds.  Therefore, 
it is worthwhile to find a potent and selective inhibitor of Cdc25 and use it to elucidate the cancer 
biology of Cdc25 subtypes. 
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Figure 10. Synthetic DSPases inhibitors 
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 1.1.3. Wipf Group Research on Phosphatase Inhibitors 
 
The Wipf group has been involved in the synthesis of several potent phosphatase inhibitors. 
Initially, a library of small-molecule PSTPase inhibitors was prepared using combinatorial 
synthetic methods (Figure 11). In this case, a natural product (calyculin A) was used in the 
design of pharmacophore platforms for combinatorial synthetic approaches.39 Among the library 
compounds, SC-ααδ9 was found to be a competitive inhibitor of all human Cdc25 isoforms in 
vitro with low µM Ki values. SC-ααδ9 also inhibits cell cycle progression at both the G1 and 
G2/M phases in synchronized murine mammary carcinoma cells, causes enhanced tyrosine 
phosphorylation of Cdk1, Cdk2, and Cdk4, and decreases Cdk4 kinases activity.39 Later, SC-
ααδ9 was found to be a phospholiphase inhibitor.40  
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Figure 11. SC-ααδ9 and its parent structure 
 
Rigidifying the SC-ααδ9 pharmacophore yielded FY21-αα09, which is slightly more 
potent as an inhibitor of Cdc25 and has improved selectivity for the Cdc25 class of 
phosphatases.2(a) The synthesis of FY-αα09 is illustrated in Scheme 1. D,L-Glutamic acid (20) 
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 was selectively esterified with TMSCl in allyl alcohol, N-protected with TrocCl, and benzylated 
with bezyl bromide to provide 21. Protected glutamate 21 was acylated after removal of the 
Troc-group at the N-terminus to give 22, which was deallylated under catalytic Pd conditions, 
and coupled to mono-Boc-protected diamine 23 to give 24 in 52% yield from 20.  Cleavage of 
the Boc group in 24 with hydrochloric acid and coupling with oxazole 25 using PyBroP as a 
coupling reagent gave 26, which was easily saponified with lithium hydroxide to give the desired 
FY21-αα09.  
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Scheme 1. Synthesis of FY21-αα092(a) 
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 The development of a new heterocyclic scaffold, compound 27, was inspired by the SAR 
of substituents at the oxazole moiety of SC-ααδ9 (Figure 12).41 A library of sulfonated 
aminothiazoles was prepared and screened for inhibitory activity against Cdc25B, VHR and PTB 
1B.  Among the best inhibitors, compounds were all substituted with halogenated aromatic rings 
at positions of R and R2.  
 
S
O
OR2
H
N
S
N
R1
R
27  
Figure 12. Aminothiazole scaffold 
 
Ninety-six synthetic intermediates related to the dnacin group of naphthyridinomycin 
antibiotics were screened for inhibition of the dual-specificity phosphatase Cdc25 and for DNA 
cleavage.42 Biological evaluation led to low-micromolecular inhibitors of DSPases, such as 
compound 28 and 29 (Figure 13). These results implied that the isoquinoline-5,8-dione 
functionality of the natural product might be responsible for the inhibition of Cdc25. 
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Figure 13. Representative structures of dnacin analogues 
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 1.2.  Strategy and Goals 
As mentioned in Section 1.1.3, FY21-αα09 showed slightly higher potency than SC-
ααδ9 as an inhibitor of Cdc25 as well as selectivity for the Cdc25 class of phosphatases.2(a) 
Although the difference in activity between FY21-αα09 and SC-ααδ9 was not significant, we 
thought that the cyclohexyl-diamine core might serve as a better spacer between the oxazole 
moiety and the carboxylic acid chain than the ethylene diamine linker. Thus, we selected 30 as a 
new pharmacophore and decided to synthesize some derivatives of this lead structure (Figure 
14).  
 
N
H
N
O
N
R4
CO2H
R1
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R3
R2, R3 = H, Bn
R1, R4 = SO2Ar, COHet, 
               COC9H1930
Ar = aromatic
Het = heterocyclic
 
Figure 14. Planned modifications of FY21-αα09 
 
As synthetic methods for compound 30, two routes were designed as shown in Scheme 2. 
For the first route, we decided to use a similar sequence as previously in the synthesis of FY21-
αα09 and SC-ααδ9, starting with D,L-glutamic acid. For the second route, we decided to use 
D,L-pyroglutamic acid as a starting material and a ring opening of the lactam as a key reaction. 
At that time, we decided to pursue both routes to select the best one for potential further use in 
scale-up. 
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Scheme 2. Two retrosynthetic approaches to 30 
 
The screening of NSC compounds43 by the Lazo group (Department of Pharmacology, 
University of Pittsburgh) identified some new potent phosphatase inhibitors.44,45 Among them, 
two compounds, namely NSC 663824 and NSC 95397, showed significant activity against 
Cdc25 (Figure 15). Therefore, syntheses of analogues of these two compounds were highly 
desirable.  
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Figure 15. NSC 663284 and 95397 
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 We decided to synthesize analogues of NSC 663824 first with isoquinoline and 
phthalazine moieties in place of the quinoline in NSC 663824, in order to probe the effect of the 
location of the nitrogen atom in the aromatic ring (Figure 15). Also, we decided to synthesize a 
regioisomer of NSC 663824 and analogues with different substituents to see how substitution 
patterns affected the activity. For another series of analogues of NSC 663824, we planned to 
synthesize compounds with different substituents at the C-6 position in the (iso)quinoline-dione 
to explore the possibility to reduce the toxicity of compounds in animal cells. 
For the synthesis of analogues of FY21-αα09, some key (iso)quinoline-dione 
intermediates would be prepared mainly according to known literature procedures. Then, the 
desired analogues would be obtained from these key intermediates via addition-elimination or 
addition-oxidation reactions (Figure 16). 
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Figure 16. Analogues of NSC 663284  
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 For the synthesis of (iso)-quinoline analogs of NSC 95397, we envisioned that the direct 
addition of 2-mercaptoethanol to dichloro-(iso)quinoline-dione would lead to a complex mixture, 
which would be difficult to separate, due to competitive O- and S-alkylations. Thus, we planned 
a stepwise sequence, which involved a selective O-protection of 2-mercaptoethanol, addition-
elimination, and removal of the alcohol protective group (Scheme 3). 
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Scheme 3. Planned synthesis of (iso)-quinoline analogs of NSC 95397 
 
  Even though quinone compounds have exhibited good inhibitory activities against 
Cdc25, they are thought to be irreversible inhibitors presumably due to the covalent adduct 
formations with active site residues of Cdc25.46 This trait is generally avoided in medicinal 
chemistry.10,12 Thus, we also decided to synthesize some heterocyclic analogues with 2-
aminoethanol-morpholine moieties to avoid the possibility of covalent adduct formation between 
quinones and active site residues of enzymes (Figure 17). The goal of our synthesis was therefore 
to remove the opportunity for covalent binding between the active site residues and the inhibitor 
while simultaneously increasing the affinity for this site by establishing new noncovalent 
interactions. 
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Figure 17. Targets for analogue synthesis 
 
Finally, we decided to synthesize several natural caulibugulones, novel cytotoxic 
isoquinoline diones and iminoquinones, isolated from an extract of the marine bryozoan 
Caulibugula intermis  (Figure 18) and evaluate their biological activities against phosphatases.47 
Caulibugulones attracted our attention because they had isoquinoline moieties, which have been 
found in potent phosphatase inhibitors. Moreover, we envisioned that their exhibited 
cytotoxicities might be related to their inhibitory activity against phosphatases. 
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Figure 18. Caulibugulones 
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 1.3. Results and Discussion 
1.3.1. Synthesis of Analogues of FY21-αα09 
 
As the first analogues of FY21-αα09, we selected JUN 1 and JUN 2, the hybrid 
compounds of FY21-αα09 and SC-ααδ9, in the hope that the hybridization of two active 
compounds would lead to a potent inhibitor against Cdc25 (Figure 19).  
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Figure 19. Design of JUN 1 and 2 
 
 
The synthesis of 35 (JUN 1)48 began with the known compound 24,2(a) which was used as 
a key intermediate for the synthesis of FY21-αα09 (Scheme 4). After deprotection of the Boc 
group of 24 with HCl in dioxane, several attempts for reductive amination with benzaldehyde 
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 were made, but failed to produce the desired product 33.  Therefore, other protocols for the 
benzylation of 24 were investigated and we found that an indirect route49 worked well. 
Nosylation of the amine derived from 24 gave 31, and N-benzylation followed by removal of the 
nosyl group gave 33 in good yield. The coupling reaction of 33 with oxazole fragment 2550 in the 
presence of PyBrop as a coupling reagent, followed by saponification of 34, afforded the target 
compound 35 (JUN 1). 
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Scheme 4. Synthesis of JUN 1 
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 For the synthesis of JUN 2 (a regioisomer of JUN 1), the mono-Boc protected diamine 
36 was prepared from 1,4-diaminocyclohexane and the primary amine in 36 was benzylated to 
give 39 via a 3-step protocol described in the synthesis of JUN 1 (Scheme 5). The coupling of 
benzyl amine 39 with the acid derived from 222(a) in the presence of PyBrop and Hünig’s base 
led to amide 40. Deprotection of the Boc group in 40, followed by coupling with oxazole 25 
provided 41 in moderate yield. Finally, saponification of 41 provided 42 (JUN 2) in 91% yield. 
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Scheme 5. Synthesis of JUN 2 
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 In other analogues of FY21-αα09, we decided to replace the oxazole moiety of FY21-
αα09. For the synthesis of JUN 3, acid 4351 was required (Scheme 6). After several attempts to 
hydrolyze 9-cyanophenanthrene, we found that heating at reflux in diethylene glycol with 10% 
NaOH gave the desired product acid 43 in good yield. Under alternative conditions, the reaction 
often stopped at the amide intermediate, and the use of diethylene glycol as a solvent was critical 
to accomplish the desired conversion. Subsequently, a reaction sequence analogous to the 
synthesis of JUN 1 was used to prepare compound 45 (JUN 3). The low yield in the coupling 
reaction may be due to the low solubility of 43 in THF. 
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Scheme 6. Synthesis of JUN 3 
 
 
For the synthesis of JUN 4, the α,β-unsaturated sulfonyl chloride 46 was prepared 
according to literature procedures.52 Recently, 46 had been also used by our group in the 
synthesis of sulfonylated aminothiazoles, which were identified as new small molecule inhibitors 
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 of protein phosphatases.41 The coupling reaction of Boc-deprotected 24 with 46 proved to be not 
trivial. After considerable experimentation, we found that the use of TEA as a base and DMAP 
as an additive gave 47 at least in satisfactory yield (Scheme 7). Subsequent saponification of 47 
gave 48 (JUN 4) in 75% yield.  
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Scheme 7. Synthesis of JUN 4, 6, 7 and 8 
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   Syntheses of JUN 6, JUN 7 and JUN 8 were accomplished analogously to synthesis of 
JUN 4 (Scheme 6). α,β-Unsaturated sulfonyl chlorides 49, 52 and 55 were also prepared 
according to literature protocols.41,52
The synthesis of JUN 5 was mainly initiated to investigate the new synthetic route 
described in Scheme 2. Thus, for the synthesis of JUN 5, a different route using D,L-
pyroglutamic acid as a starting material instead of glutamic acid was selected (Scheme 8). 
Initially, this new route was expected to be more concise than the previous one because the 
number of steps to amine 60 was smaller, however, the feasibility of this route had not been 
established. The key reaction was the lactam ring opening of pyroglutamic acid. Several attempts 
to open lactam 59 with 1,4-diaminocyclohexane or mono-protected 1,4-diaminocyclohexane 
were made, including alane-assisted and ultrasound-mediated reaction conditions. As the first 
step toward JUN 5, benzylation of D,L-pyroglutamic acid was performed to give 54 in moderate 
yield, and Boc-protection of the lactam nitrogen in 58 gave 5953 in good yield. After considerable 
experimentation, lactam-ring opening with 1,4-diaminocyclohexane was accomplished in THF 
after 7 d in the presence of 1 equiv. of KCN to give the desired product 60 in moderate yield. 
The long reaction time has to be considered a major drawback of this procedure.  With 60 in 
hand, the coupling reaction with oxazole 25 was performed using PyBrop as a coupling reagent 
to provide 61. Deprotection of the Boc group in 61, followed by coupling with sulfonyl chloride 
46 in the presence of TEA provided 62. The low yield in this coupling reaction was presumably 
due to the elimination of SO2 from 27 in the presence of a base such as TEA.  Finally, 
saponification of 62 and acid extraction gave 63 (JUN 5). Although the synthesis of JUN 5 was 
achieved successfully using this new route, further optimization of some reaction conditions 
would be desirable. 
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Scheme 8. Synthesis of JUN 5 
 
For the synthesis of JUN 9, isoquinolinedione 64 was prepared according to literature 
procedures54 and reacted with γ-aminobutyric acid in the presence of KOH to give 65 as an 
inseparable ~4:1 mixture of regioisomers (Scheme 9). All separation efforts failed and the 
structure assignment for these regioisomers was based on NMR analysis.55 Coupling of this 
mixture with Boc-deprotected 66 using PyBrop as a coupling reagent failed to give the desired 
pure product. Substitution of PyBroP with DEPC provided 66, however, and saponification 
afforded 67 (JUN 9). During the entire sequence, the regioisomers could not be separated, and 
67 was characterized and assayed as a mixture.  
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Scheme 9. Synthesis of JUN 9 
 
  In summary, 9 analogues of FY-αα09 were synthesized. These compounds were tested 
against Cdc25B2 and some of them were also tested against VHR. All biological assays were 
performed by the Lazo group at the Department of Pharmacology, University of Pittsburgh and 
assay methods are described in the experimental section of references 44 and 45. The results are 
summarized in Table 1. In this case, IC50 represents the concentration of a sample that inhibits 
50% of enzyme activity. 
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 Table 1. Biological assay results for analogues of FY21-αα09 
Sample 
IC50a vs. Cdc25B2 (n=2) 
(µM) 
Percent Inhibition at 
30 µM vs. VHR 
FY21-αα09 7 N. D. 
JUN 1 29.0 18 
JUN 2 25.0 15 
JUN 3 76.7 N. D. 
JUN 4 345.5 N. D. 
JUN 5 27.5 23 
JUN 6 329.0 N, D. 
JUN 7 78.0 4 
JUN 8 165.5 N. D. 
JUN 9b 9.4 6 
JUN  197 (65)b 0.33 N. D. 
N. D., not determined 
a average value 
b a mixture of regioisomers was tested. 
 
As shown in Table 1, JUN 1, 2 and 5 exhibited less potent biological activity than FY21-
αα09 and JUN 3, 4, 6, 7 and 8 showed much less activity. Though a limited number of 
compounds were tested, these results suggested that the oxazole moiety in FY21-αα09 might be 
important for the activity against Cdc25B2 and that addition of a benzyl group to FY21-αα09 did 
not improve activity. Although, JUN 9 was identified as the most potent phosphatase inhibitor in 
this series, this activity appeared to derive mainly from the isoquinolinedione moiety rather than 
the shared subunit with FY21-αα09. This was proven by the fact that isoquinolinedione JUN 
197, which was prepared for the synthesis of JUN 9, showed greater potency than JUN 9. In 
conclusion, despite considerable synthetic efforts to modify FY21-αα09, no significant 
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 improvement of the biological activity was achieved in this series of compounds (Figure 20). 
Therefore, we decided to select other molecules as potential Cdc25 phosphatase inhibitors. 
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Figure 20. IC50 values (µM) of analogues of FY21-αα09 against Cdc25B2  
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 1.3.2. Synthesis of Analogues of NSC 663284 
 
As mentioned in Section 1.2, NSC 663284 showed potent activity against Cdc25. Thus, we 
decided to synthesize NSC 663284 for scale-up and prepare analogues as shown in Figure 21.  
 
N
O
O
N
H
N
O
Cl
change the location of nitrogen
replace with H or Br or Ph
replace with other rings
change substitution patterns  
Figure 21. Modifications of NSC 663284 
 
  For the synthesis of NSC 663284, compound 68 (JUN 248) was prepared from quinolin-
8-ol according to literature procedures.54 Compound 69 (JUN 254a = NSC 663284 = DA3003-1) 
and 70 (JUN 254b = DA3003-2) were prepared from the coupling reaction of 68 with 2-
morpholin-4-yl-ethylamine in the presence of TEA. The complete separation of these two 
regioisomers proved to be extremely difficult and only a small amount of pure isomer was 
obtained by chromatography on SiO2.  The exact structure assignment was mainly based on a 
literature study.55 According to that study, we depended on the difference in 1H NMR chemical 
shift between H(2) and H(4) of 69 and 70 for the assignment of each regioisomer (the chemical 
shift difference in the 6-isomer is larger than in the 7-isomer) (Scheme 10).  
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Scheme 10. Synthesis of NSC 663284 and its regioisomer 
 
Coupling of 68 with 2-piperidin-1-yl-ethylamine and indan-1-ylamine, respectively, gave 
71 (JUN 267) and 73 (JUN 250). In case of JUN 250, one regioisomer was obtained after work-
up and chromatography on SiO2, even though JUN 267 was separated from a mixture of 
regioisomers (Scheme 11). 
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Scheme 11. Syntheses of JUN 254a, 254b, 267 and 250 
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Treatment of 64 with 2-morpholin-4-yl-ethylamine in the presence of TEA provided 74 
(JUN 338) along with the regioisomer 75 (Scheme 12). Separation of these two regioisomers 
was performed by chromatography on SiO2 to give 74 as the major product.  The tentative 
assignment of the regiochemistry of 74 was achieved by 1H-NMR analysis based on the same 
principles as for the assignment of 69 and 70, and the putative electronic preference for the 
formation of the 7-regioisomer.55,56 This assignment was later confirmed in the course of the 
synthesis of caulibugulones (vide infra). For the synthesis of 77 (JUN 284), 76 (JUN 282) was 
prepared from phthalazine in a three-step sequence according to literature procedures.56 Exposure 
of 76 to 2-morpholin-4-yl-ethylamine in the presence of TEA provided 77. The purity of all 
compounds was checked by reverse phase HPLC and almost uniformly exceeded 99%.44 
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Scheme 12. Synthesis of JUN 338 and 284 
         
Biological assays for these compounds were performed by the Lazo group and are 
summarized in Table 2.  
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 Table 2. Biological assay results for first analogues of NSC 663284 
Sample 
IC50 vs. Cdc25B2  
(µM) 
IC50 vs. VHR  
(µM) 
IC50 vs. PTP1B 
(µM) 
JUN 248 4.6 ± 1.0 >10 >10 
JUN 183 1.5 ± 0.7 >10 >10 
JUN 282 8.9 ± 5.0 >10 >10 
JUN 250 0.30 ± 0.03 N. D. N. D. 
JUN 254a 0.18 ± 0.02a 4.0 ± 0.1 >10 
JUN 254b 0.78 ± 0.44a >10 >10 
JUN 267 0.17 ± 0.03a N. D. N. D. 
JUN 284 0.45 ± 0.07 >10 >10 
JUN 338 0.59 ± 0.18 1.1b 9.8b
* IC50 values were from 3 or more determinations with SEM indicated. 
a Values are different from the report44 since purer samples were retested. 
b Single determination. 
N. D. = not determined. 
 
As shown in Table 2, all compounds in this series showed good activity against Cdc25B2. 
Especially, JUN 254a (structurally identical to NSC 663284) was identified as one of the most 
potent inhibitors of Cdc25B2 known to date.  JUN 267 also showed high activity against 
Cdc25B2. JUN 254a and 254b were also tested in antiproliferative and chemical 
complementation assays.44 JUN 254a had a mean IC50 value of 1.5 ± 0.6 µM in the NCI 60 Cell 
Human Tumor Panel after 48 h. Human breast cancer MDA-MB-435 and MDA-N cells, which 
had IC50 value of 0.2 µM, were most sensitive. Also, 48-h continuous treatment of human breast 
MCF-7 cells in culture with JUN 254a showed an IC50 value of 1.7 µM. Even after only 3 h 
exposure to JUN 254a, an IC50 for growth inhibition of ~35 µM was observed. Consistent with 
its in vitro inhibition, JUN 254a was 3-fold more potent for growth inhibition after a 3 h 
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 exposure than its regioisomer, JUN 254b. A chemical complementation assay was used to probe 
for inhibition of cellular Cdc25 activity by JUN 254a. This assay revealed the ability of a small 
molecule to complement or reverse a biochemical effect caused by ectopic Cdc25A expression. 
The results supported the hypothesis that JUN 254a blocked the biological effects of Cdc25A 
within cells. Some more biological assays were performed with JUN 254a and 254b (vide infra).  
On the basis of the results we described earlier in this section, we can suggest that 
quinolinediones have a rich potential as lead structures for the development of Cdc25 inhibitors 
and that they might serve as biochemical probes or even as pharmacophores in new agents for 
the treatment of cancer or other diseases.44 Thus, we decided to synthesize more analogs of NSC 
663284, which was identified as the most potent inhibitor of Cdc25B.  At this time, we decided 
to replace the chlorine atom at the 6-position in NSC 663284 with other substituents such as 
hydrogen, bromine and phenyl groups, mainly because the replacement of chlorine may reduce 
liver toxicity in mice. First, we decided to synthesize the dechlorinated analog JUN 1111 and we 
prepared quinoline-5.8-dione 78 by PIFA-oxidation of 8-hydroxyquinone in moderate yield 
according to a literature procedure57 as a key intermediate for the synthesis of JUN 1111 
(Scheme 13). The PIFA oxidation proved to be much better for the preparation of 78 than 
Fremy’s salt oxidation since we obtained 78 in only 10% yield with latter reagent. Dione 78 had 
to be used immediately for the next conversion because it decomposed readily. With 78 in hand, 
we tried the addition of 4-(2-aminoethyl)-morpholine, followed by air oxidation to give 79 (JUN 
1111) along with its regioisomer 80 (JUN 1120-2) in ~2:3 ratio. Repeated separation of 
regioisomers by chromatography on SiO2 provided pure JUN 1111 and JUN 1120-2 in several 
hundred mg quantities. The regiochemistry was assigned by the 1H NMR chemical shift of the 
vinyl proton.58 
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Scheme 13. Synthesis of JUN 1111 and 1120-2 
 
Although the regioisomers could be separated by chromatography, we decided to 
investigate another route to produce JUN 1111 selectively. Initially, we envisioned that the 
reaction of the known bromo compound 8359 with 4-(2-aminoethyl)-morpholine in the presence 
of TEA would give JUN 1111 as the major product via an addition-elimination sequence. For 
that purpose, we prepared compound 83 in 3 steps according to literature procedures.59 
Bromination of 5-nitroquinolin-8-ol with NBS, reduction of the nitro group in 81 and oxidation 
of amine 82 provided bromo compound 83 (Scheme 14). With 7-bromoquinolinedione 83 in 
hand, we tried the conjugate addition-elimination reaction. However, in contrast to our 
expectation, the reaction of 83 with 4-(2-aminoethyl)-morpholine provide the bromo compound 
84 (JUN 1129) as the major product instead of JUN 1111 via an addition-oxidation sequence 
even in the presence of the base TEA.  Based on this result, a regioselective synthesis of JUN 
1111 was not pursued any further.60 
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Scheme 14. Synthesis of JUN 1129 
 
Next, we synthesized JUN 1142, the regioisomer of JUN 1129 (Scheme 15). The 
dibromo compound 85 was prepared in 39% yield by the bromination of 78 in the presence of 
pyridine. Then, 6,7-dibromoquinolinedione 85 was reacted with 4-(2-aminoethyl)-morpholine in 
the presence of TEA to give 86 (JUN 1142) and 87 (JUN 1129) in a ~2:1 ratio. Two 
regioisomers were separated by chromatography on SiO2, and the regiochemistry of the two 
compounds was unambiguously determined based on the assignment for JUN 1129. This 
assignment matched well with the previous assignment of the regiochemistry of JUN 1111 and 
1120-2 because the 1H NMR spectrum of JUN 1142 is very close to that of JUN 1111 whereas 
the 1H spectrum of JUN 1129 is very close to that of JUN 1120-2.  
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Scheme 15. Synthesis of JUN 1142 
 
In addition to the replacement of the chlorine substituent in NSC 663824 with hydrogen 
or bromine, we wanted to introduce a phenyl group at this position (Scheme 16). Stille coupling 
of 83 with phenyl tri-butyl-tin, followed by addition of 4-(2-aminoethyl)-morpholine provided 
the phenyl-substituted derivative 88 (JUN 1177) in very low yield and purity even after several 
separation processes.  
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Scheme 16. Synthesis of JUN 1177 
 
The isoquinolinedione 89 (JUN 1360) was synthesized from 5-hydroxyisoquinoline in 
17% yield via a two step – one pot sequence shown in Scheme 17. Noteworthy is that a single 
regioisomer was isolated after the reaction and purification. The low yield can be attributed to 
the poor solubility of the product in organic solvents. 
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Scheme 17. Synthesis of JUN 1360 
 
All analogues of NSC 663284 and their precursors were evaluated for biological 
activities against Cdc25A, Cdc25B, Cdc25C, VHR and PTB 1B by the Lazo group.61 Table 3 
summarizes the biological data for analogues of NSC 663284. 
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Table 3. Summary of IC50 values (µM concentration) of analogues of NSC 663284 and their 
precursors 
Compounds Cdc25A Cdc25B Cdc25C VHR PTB1B 
JUN254a 0.50 ± 0.02 1.33 ± 0.59 0.6614a 10.1 ± 0.33 15.1 ± 0.52 
JUN 254b 1.19 ± 0.11 3.69a 3.54a 180 ± 58 87.9 ± 7.3 
JUN 1111 0.38 ± 0.10 2.78 ± 0.96 1.186a 27.9 ± 2.9 36.6 ± 0.26 
JUN 1120-2 3.03 ± 0.09 44.6 ± 0.27 15.86a 329 ± 17.2 366 ± 40 
JUN 1142-1 0.52 ± 0.07 1.18 ± 0.61 0.8589a 6.61 ± 1.1 11.9 ± 0.56 
JUN 1129 1.92 ± 0.01 10.7 ± 4.17 3.736a 86.1 ± 12 93 ± 2.7 
JUN 1177 5.45 ± 1.1 13.7 ± 2.5 6.27 ± 0.26 216 ± 42 273 ± 60 
JUN 1360 1.76 ± 0.8 3.06 ± 0.7 1.99 ± 0.2 187 ± 33 424 ± 86 
JUN 1141 7.45 ± 0.79 9.49 ± 1.4 8.08 ± 0.24 111 ± 30 203 ± 61 
JUN 1128 9.21 ± 0.47 11.1 ± 0.85 10.1 ± 0.43 87 ±21 152 ± 15 
JUN 1109 9.39 ± 1.9 11.8 ± 0.73 9.81 ± 1.6 132 ± 19 114 ± 23 
* IC50 values were from 3 or more determinations with SEM indicated. 
* Specifically, activities against Cdc25A1, Cdc25B2 and Cdc25C1 were measured. 
a Single determination 
         
Some aspects of the in vitro biological data were quite interesting. All compounds are 
potent inhibitors of Cdc25 phosphatases. The results show consistently that the 7-regioisomers 
(JUN 254a, 1111 and 1142-1) are more potent but less selective than the 6-regioisomers (JUN 
254b, 1120-2 and 1129), and that compounds substituted with the 2-aminoethylmorpholine 
moiety are more potent than nonsubstituted precursors (JUN 1109, 1128 and 1141). IC50 values 
are increased in the order Cdc25A < Cdc25C < Cdc25B, and the considerable range indicates 
that the synthesis of isomer-specific inhibitors is possible. Also, the substituents increase in 
potency in the order hydrogen ≈ chlorine > bromine > phenyl. Comparison of JUN 1360 to JUN 
254a demonstrated that the quinoline scaffold is more potent than the isoquinoline. Besides these 
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 in vitro assays, some additional biological tests61 were performed for JUN 254a, 254b, 1111, 
1120-2 and 1360. Reversibility assays using solid support (nickel bead) were performed by the 
Lazo group to determine whether these compounds are reversible inhibitors. The results 
suggested that they were all irreversible inhibitors, but JUN 1111 and 1120-2 did not seem to 
form a tight covalent adduct. Flow cytometry experiments were also performed to determine if 
compounds arrested tsFT210 cells in G1 by inhibiting Cdc25A, or G2 by inhibiting Cdc25B or 
Cdc25C. The results showed that compounds might partially arrest the cell cycle at both G1 and 
G2. Especially, JUN 1120-2 and 1360 caused a stronger G2 arrest. Cdc25C MEF cells were 
treated with JUN 254a and 1111 and cell viability (using trypan blue dye) was counted after 3 
days of treatment. However, no clear differential effect on Cdc25C knockout and wild type MEF 
cells was found. More biological experiments are still in progress and will be reported in due 
course.61 
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 1.3.3. Synthesis of Analogues of NSC 95397 
 
Syntheses of analogues of the NSC 95397 started with the selective protection of the 
hydroxy groups of 2-mercaptoethanol and 3-mercaptopropane-1,2-diol (Scheme 18). Successful 
mono-O-protection of 2-mercaptoethanol was achieved with THP, Bz and TBDPS groups, but in 
most cases sulfur-protected compounds were also formed and removed readily by column 
chromatography because the O-protected compounds were less polar than the S-protected 
compounds. It was also noted that the silicon-protecting group was the best in terms of 
selectivity due to the high affinity of silicon toward oxygen. Thus, 90,62 91 and 92 were obtained 
in moderate to good yields. Finally, protection of 3-mercaptopropane-1,2-diol by acetone in the 
presence of PPTs and MgSO4 gave 93.62 
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Scheme 18. Synthesis of intermediates for the analogues of NSC 95397 
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 With the O-protected compounds in hand, we tried the coupling reaction with 6,7-
dichloroquinolinedione 68 in the presence of TEA (Scheme 19). Consequently, compounds 94 
(JUN 255), 95 (JUN276), 96 (JUN 266) and 97 (JUN 289) were obtained in good yields.  
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Scheme 19. Synthesis of JUN 255, JUN 276, JUN 266 and JUN 289 
 
Unfortunately, all attempts for deprotection of these compounds failed to generate the 
desired free alcohol 98 as described inTable 4. In entries 1-3 and 6, substrates decomposed 
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 slowly after addition of acidic reagents, presumably due to protonations of the nitrogen atom in 
the quinoline rings.  In entries 4, 5 and 7, unidentified polar product(s) were mainly obtained 
after purifications.   
 
94, 95, 96 and 97
N
O
O
S
S
OH
OH
98
conditions
 
Table 4. Attempts for the synthesis of 98 
Entry Substrate Reaction Conditions Results 
1 94 HOAc-THF-H2O (4:2:1) Decomposed 
2 94 PPTS, EtOH Decomposed 
3 94 p-TsOH, MeOH Decomposed 
4 95 LiOH•H2O, THF-H2O Unidentified polar product(s) 
5 95 NaOH, MeOH Unidentified polar product(s) 
6 96 p-TsOH, MeOH Decomposed 
7 97 TBAF, THF Messy reaction 
 
 
Compounds 99 (JUN 289), 100 (JUN 307) and 101 (JUN 309) were also prepared from 
the coupling reaction of 6,7-dichloroisoquinolinedione 64 with 90, 91 and 93, respectively 
(Scheme 20).  The reaction of 64 with 92 in the presence of TEA led to decomposition. 
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Scheme 20. Synthesis of JUN 260, 307 and 309 
 
We also failed in obtaining the desired free alcohol 102 from 99, 100 and 101. Thus, we 
tried direct coupling reactions of 64 and 68 with 2-mercaptoethanol in the presence of TEA, but 
we could not isolate any desired products 98 and 102. In most cases, we observed a complex 
mixture of products, which were not easily separated by standard chromatography conditions 
(Scheme 21). 
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Scheme 21. Attempted coupling of 64 and 68 with 2-mercaptoethanol 
 
Despite our failure to prepare the highly desired free alcohols 98 and 102, all synthetic 
compounds were tested against Cdc25B2 by Lazo group. The results are summarized in Table 
5.45 
Table 5. Biological assay results for analogues of NSC 95397 
Sample IC50 (µM) vs. Cdc25B2 (n=2) 
JUN 255 7.9 
JUN 260 2.1 
JUN 266 6.3 
JUN 276 4.9 
JUN 289 Inactive at 10 µM 
JUN 307 1.5 
JUN 309 1.7 
 
All analogues showed a lower activity than NSC 95397 (IC50 vs. Cdc25B2 < 1 µM) 
presumably due to the increased steric hindrance by bulky alcohol protecting groups. It is also 
possible that the protection of the hydroxy group might reduce some interaction with an amino 
acid residue in Cdc25B. 
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 1.3.4. Synthesis of Morpholine Derivatives 
 
Based on the chemical structure of NSC 663284, three possible interactions between NSC 
663284 and Cdc25A could be hypothesized. First, NSC 663284 might form a covalent bond with 
amino acid residues because it is an electrophile. For example, sulfhydryl arylation of a cysteine 
or etherification of a serine in the catalytic domain of Cdc25A might be possible. Second, NSC 
663284 might strongly interact with Cdc25A by noncovalent bonding, such as hydrogen 
bonding. Finally, Cdc25A might be inactivated by NSC 663284 by inducing a disulfide linkage 
through a quinone redox reaction. Recent studies by the Lazo group supported the first 
hypothesis that NSC 663284 bound covalently in the Cdc25A catalytic domain as shown in 
Figure 2246 and also suggested that the NSC 663284 modification likely occurred at Ser114. 
However the possibility that other hydroxyl- or thiol- containing species were involved cannot be 
eliminated. 
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Figure 22. The schematic reaction model of NSC 663284 interacting with Cdc25A 
 
Ham et al. also proposed a possible covalent bond formation of Vitamin K with enzyme 
as shown in Figure 23. 25(a) 
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Figure 23. Possible covalent bond formation of Vitamin K with enzyme25(a)
 
Even though quinone compounds have exhibited good inhibitory activities against 
Cdc25, covalent bond formation should be avoided in drug discovery. Thus, we decided to 
prepare alternative heterocycles with 4-(2-aminoethyl)-morpholine substituents to remove the 
possibility for covalent binding between the reactive residues (such as Cys or Ser) of Cdc25 and 
inhibitors while simultaneously increasing the affinity for the active site by establishing new 
noncovalent interactions. For this purpose, compound 103 (JUN 379) was prepared from 
dichloromaleic anhydride according to literature procedures63 and treated with 2-morpholin-4-yl-
ethylamine in the presence of TEA to afford 104 (JUN 382) (Scheme 22). In this case, more 
vigorous conditions such as heating at reflux in EtOH were required to get the desired addition-
elimination product because of the low reactivity of 103.  
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Scheme 22. Synthesis of JUN 382 
 
Intermediate 106 (JUN 390) was prepared from 3-cyanochromone in two steps according 
to literature procedures64 and iodide 105 was obtained from the substitution reaction of 4-(2-
chloroethyl)-morpholine with sodium iodide (Scheme 23). After several attempts to couple 106 
with 105, the desired product 107 (JUN 413) was obtained in very low yield.  
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Scheme 23. Synthesis of JUN 413 
 
 
For the preparation of quinazolonodione JUN 1072, anthranilic acid was condensed with 
benzyl carbamate to give intermediate 10865 (Scheme 24). Coupling of 108 with 4-(2-
aminoethyl)-morpholine in the presence of EDCI and HOBT led to amide 109, which was 
 51
 cyclized to the desired heterocycle 110 (JUN 1072) under mild basic conditions.65,66 
Subsequently, 110 was converted to 111 (JUN 1086) by N-alkylation with iodomethane. 
 
HO2C
H2N
CbzCl, K2CO3
THF/H2O
HO2C
CbzHN
55%
O
N
NH2
EDCI, HOBt
TEA, DMF 59%
N
H
CbzHN
N
O O
TEA, MeOH
reflux, 83%
N
N
N
O O
O
H
110 (JUN 1072)
MeI, NaH
THF, 58%
N
N
N
O O
O
Me
108
109
111 (JUN 1086)  
Scheme 24. Synthesis of JUN 1072 and 1086 
 
After completing the syntheses of JUN 1072 and JUN 1086, the phthalazine-1,4-dione 
JUN 1089 was prepared (Scheme 25). Initially, we attempted the N-alkylation of 
phthalhydrazide with iodide 105 in the presence of NaH. However, the reaction gave the O-
alkylated compound 112 (JUN 1085) as the only isolable product. Next, we tried a 
hydrazinolysis of phthalic anhydride with hydrazine 113,67 which was prepared in crude form 
from the reaction of 4-chloroethylmorpholine with hydrazine in the presence of NaOH in EtOH, 
and indeed the desired 114 (JUN 1089) was obtained in moderate yield.  
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Scheme 25. Synthesis of JUN 1085 and 1089 
 
114 (JUN 1089) was O-alkylated with dimethyl sulfate in the presence of potassium 
carbonate to give 115 (JUN 1090) (Scheme 26). Pyridazinedione 116 (JUN 1102) was prepared 
according to the synthesis of JUN 1089. In this case, two regioisomers were obtained in a ~5:1 
ratio and the major regioisomer was separated by chromatography on SiO2. A tentative 
assignment of the two regioisomers was made based on the speculation that the more 
electrophilic68 carbonyl group of pyridine-dicarboxylic anhydride reacts with the more 
nucleophilic69 secondary amine of hydrazine 113. Hydrazinolysis of pyrazine-dicarboxylic 
anhydride with hydrazine 113 led only to severe decomposition in refluxing toluene and xylene 
solution without producing the desired product. 
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Scheme 26. Synthesis of JUN 1090 and 1102 
 
In conclusion, we prepared eight heterocyclic scaffolds with the 4-(2-aminoethyl)-
morpholine side chains as analogues of the (iso)quinolinedione NSC 663284. All compounds 
were tested against Cdc 25B2 and found to be inactive. Accordingly, the morpholine portion of 
NSC 663284 is not sufficient for biological activity against phosphatases. These results allowed 
us to conclude that the quinone ring of NSC 663284 is essential for the activity against Cdc25B 
and mediates a covalent bond formation with enzymes. Based on the bioassay results for the 
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 analogues of NSC663284 and morpholine derivatives, we could summarize the SAR as shown in 
Figure 24.  
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Figure 24. SAR model for NSC663284 
  
The quinone moiety was essential for activity against Cdc25. This result strongly supported 
the hypothesis that NSC 663284 might bind covalently with Cdc25.  The quinoline derivatives 
are more potent than the isoquinoline derivatives, indicating that the electronic properties of the 
aromatic ring in the analogues might be important. The substituted analogues showed increased 
activities over their precursors and the 7-regioisomer was more potent than the 6-regioisomer. 
Thus, substitution patterns were also important in terms of activity. The replacement of chlorine 
with hydrogen did not reduce the activity, whereas the replacement with bromine and phenyl 
decreased the biological effects. 
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 1.3.5. Synthesis of Caulibugulones 
 
Recently, the Gustafson group at the NCI isolated caulibugulones A-F, a series of novel 
cytotoxic isoquinoline diones and iminoquinones, from an extract of the marine bryozoan 
Caulibugula intermis (Figure 18).47 They also reported that caulibugulones A-F exhibited IC50’s 
of 0.03 – 1.67 µg/mL against murine tumor cells in an in vitro cytotoxicity assay (Table 6). 
These compounds attracted our attention because they showed close structural similarity with 
heterocyclic scaffolds that we had identified as potent phosphatase inhibitors.44,45 Moreover, we 
envisioned that their demonstrated cytotoxicities could be related to their inhibition of 
phosphatases. Thus, we decided to synthesize several caulibugulones and evaluate their 
biological activity against Cdc25 phosphatases.70 
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Figure 18. Caulibugulones 
 
Table 6. IC50 of caulibugulones A-E against murine IC-2wt cell line in an in vitro 
antiproliferative assay 
Compound IC50 (µg/mL) Compound IC50 (µg/mL) 
Caulibugulone A 0.34 Caulibugulone D 1.67 
Caulibugulone B 0.22 Caulibugulone E 0.03 
Caulibugulone C 0.28 Caulibugulone F 0.10 
 
Our synthesis of caulibugulones began with the preparation of the isoquinolinedione 117 
(Scheme 27). According to a literature procedure,57 we prepared compound 117 from 
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 isoquinolin-5-ol, but to our disappointment, 117 was too unstable to be isolated in high yield and 
purity.  
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Scheme 27. Synthesis of 117 
 
Therefore, we proceeded without isolation of this compound. Oxidation of 5-hydroxyl-
isoquinoline by PIFA in H2O-EtOH solution and the subsequent in situ addition of CeCl371 and 
methyl amine were performed without intermediate work-up and provided a ~ 4:1 mixture of 
caulibugulone A and its regioisomer in 51% yield after aqueous quench and chromatography 
(Scheme 28). The regiochemistry was determined by 1H NMR spectroscopy as shown Scheme 
28. The chemical shift of the vinyl proton of the 7-regioisomer (i.e. caulibugulone A) is more 
downfield than that of the 6-regioisomer.  Further separation by repeated chromatography 
provided pure caulibugulone A as a red solid.72 Caulibugulone D was subsequently synthesized 
from 5-hydroxyisoquinoline via a related two step – one pot sequence using 2-aminoethanol. The 
low yield can be attributed to the poor solubility of the product in organic solvents. 
 
 57
 N
OH 1. PIFA
H2O-EtOH, rt, 1 h
2. CeCl3, MeNH2
20 h, 51%90% 5-hydroxy-
isoquinoline
N
O
O
NHMe
 regioisomer
( ~ 4 : 1 )
Caulibugulone A
N
OH 1. PIFA
H2O-EtOH, rt, 2 h
2. CeCl3.7H2O
20 h, 25%
90% 5-hydroxy-
isoquinoline
N
O
O
N
H
regioisomer
( ~ 7 : 1 )Caulibugulone DH2N
OH
OH
+
+
N
O
O
NHMe
H
Caulibugulone A
5.83 ppm in CDCl3
N
O
O
H
NHMe
Regioisomer of caulibugulone A
5.78 ppm in CDCl3
 
Scheme 28. Synthesis of caulibugulone A and D 
 
 
Caulibugulones B and C were synthesized by halogenations of caulibugulone A 
according to literature procedures (Scheme 29).47 Thus, treatment of caulibugulone A with NBS 
and NCS provided caulibugulone B in 74% yield and caulibugulone C in 82% yield, 
respectively. For the synthesis of caulibugulone C, MeOH was a better solvent than dioxane in 
terms of reaction time and yield. 1H NMR and 13C NMR spectra matched the reported data.47 
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Scheme 29. Synthesis of caulibugulone B and C 
 
Finally, caulibugulone E was prepared by treatment of caulibugulone A with ammonia in 
the presence of Ti(O-iPr)4 (Scheme 30). Although the reaction was sluggish, we obtained 
caulibugulone E in 74% yield, along with recovered calibugulone A in 15% yield. The 
regioselectivity of this reaction could be explained by steric hindrance around the C8-carbonyl 
group and a hydrogen-bond formation of the C8-carbonyl with the NHMe of caulibugulone A in 
CH2Cl2 solution. The structure assignment was confirmed by the HMBC spectrum of 
caulibugulone E.  
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Scheme 30. Synthesis of caulibugulone E 
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 It is noteworthy that we failed to synthesize caulibugulone F despite significant efforts.  
First, we tried several reactions of caulibugulone A with 2-aminoethanol or 2-azidoethanol to 
obtain caulibugulone F, but failed to get the desired product as shown in Table 7. Interestingly, 
we isolated caulibugulone E instead of caulibugulone F in entry 3 and entry 4.  
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Table 7. Attempts toward the synthesis of caulibugulone F from caulibugulone A 
Entry Reagents Reaction Conditions Results 
1 2-Aminoethanol (5 equiv.) 
p-TsOH•H2O (0.1 equiv.) 
CH2Cl2
Rt, 20h 
No reaction 
S. M. (100%) 
2 2-Aminoethanol (5 equiv.) 
p-TsOH•H2O (1 equiv.) 
Benzene 
Reflux, 18h 
No reaction 
 
3 2-Aminoethanol (5 equiv.) 
Ti(O-iPr4) (0.1 equiv.) 
CH2Cl2
Rt, 4d 
S. M. (40%) + 
Caulibugulone E (20%) 
4 2-Aminoethanol (5 equiv.) 
Ti(O-iPr4), 4 A° M. S. 
CH2Cl2
Rt, 3d 
S. M. (48%) + 
Caulibugulone E (11%) 
5 2-Azidoethanol (2.8 equiv.) 
PPh3 (2.8 equiv.) 
CH2Cl2
Rt to reflux 
No reaction 
 
6 2-Azidoethanol (5 equiv.) 
PPh3 (5 equiv.) 
Toluene 
Reflux, 20h 
No reaction 
 
7 2-Aminoethanol (10 equiv.) 
POCl3 (5 equiv.) 
CH2Cl2
Rt, 2h 
Unidentified polar 
product + S. M. (48%) 
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 Next, we also tried several reactions of caulibugulone E with 2-iodoethanol in the 
presence of bases, but also failed to obtain caulibugulone F as shown in Table 8. 
 
N
NH
O
NHMe
conditions
caulibugulone E
N
N
O
NHMe
caulibugulone F
OH
 
 
Table 8. Attempts toward the synthesis of caulibugulone F from caulibugulone E 
Entry Reagents Reaction Conditions Results 
1 2-Iodoethanol (10 equiv.) 
TEA (5 equiv.) 
CH2Cl2
Rt to reflux, 18h 
No reaction 
S. M. (80%) 
2 2-Iodoethanol (10 equiv.) 
K2CO3 (5 equiv.) 
CH3CN 
 Reflux, 20h 
Undesired product(s) 
S. M. (trace) 
3 2-Iodoethanol (10 equiv.) 
NaH (5 equiv.) 
THF 
Rt, 30min 
Undesired product(s) 
S. M. (83%) 
4 2-Iodoethanol (10 equiv.) 
LHMDS (1.5 equiv.) 
THF 
-78 °C to rt, 2h 
No reaction 
S. M. (100%) 
5 2-Iodoethanol (1 equiv.) 
Cs2CO3 (5 equiv.) 
DMF 
Rt, 20h 
No reaction 
 
 
As illustrated in Table 9, all five caulibugulones inhibited full-length human Cdc25B in 
vitro with IC50 values ranging from 2.7 to 32.5 µM, with caulibugulone B and E being the most 
and least potent, respectively.73 Moreover, all caulibugulones exhibited a great preference for 
inhibition of the dual specificity phosphatase Cdc25B.  
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 Table 9. IC50 values of caulibugulones (µM) 
 Cdc25A Cdc25B Cdc25C VHR PTP1B 
Caulibugulone A 3.4 ± 0.6 6.7 ± 1.3 5.4 ± 1.2 >500 >1000 
Caulibugulone B 1.5 ± 0.2 2.7 ± 0.5 2.7 ± 0.2 130 ± 23 183 ± 24 
Caulibugulone C 2.6  ± 0.6 5.4 ± 0.7 3.3 ± 0.3 175 ± 2 322 ± 32 
Caulibugulone D 4.9 ± 0.8 19.1 ± 0.3 10.8 ± 0.5 >1000 >1000 
Caulibugulone E 18.2 ± 1.1 32.5 ± 3.6 16.6 ± 1.0 >1000 >1000 
IC50 values were from 3 or more determinations with SEM indicated. 
Specifically, activities against Cdc25A1, Cdc25B2 and Cdc25C1 were measured. 
 
IC50 values increased in the order Cdc25A < Cdc25C < Cdc25B. In addition to in vitro 
assays, more biological testings74 were performed for caulibugulone A and E. The reversibility 
assays using solid support (nickel bead) were performed by the Lazo group to determine whether 
compounds were reversible inhibitors. The results suggested that caulibugulone A and E were 
irreversible inhibitors. Flow cytometry experiments were also performed to determine if 
compounds arrested tsFT210 cells in G1 by inhibiting Cdc25A, or G2 by inhibiting Cdc25A or 
Cdc25B. The results showed that caulibugulone A and E induced growth inhibition and produced 
a strong arrest at G2 of the cell cycle.  In addition, inhibition of Cdc25A in Hela cells was 
assayed with caulibugulone A and E.  The results indicated that caulibugulone A and E directly 
inhibited Cdc25A in Hela cells, and Cdc25A protein levels decreased after treatment of Hela 
cells with caulibugulone A. More biological assays are still in progress and will be reported 
soon.74 
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 1.4. Conclusion 
We prepared 9 compounds as analogues of FY21-αα09 by diverse synthetic methods in 
the hope that modification of the FY21-αα09 structure would improve the activity against the 
Cdc25 family. However, no significant improvements were achieved in this series, and therefore 
we selected other target molecules.  
In the meantime, in the course of screening NSC compounds, the Lazo group identified 
new potent compounds, namely NSC 663284 and NSC 95397, which served as new lead 
structures. We prepared several analogs of NSC 663284 that proved to be potent inhibitors of 
Cdc25B. Since these compounds were highly potent against Cdc25B, they were also evaluated 
against Cdc25A, Cdc25C, VHR and PTBIB. The results showed that they were all specific 
inhibitors of Cdc25. Moreover, reversibility and flow cytometry experiments were performed. 
The results suggested that all compounds were irreversible inhibitors and induced cell arrest cell 
cycle at the G2 level. 
For the synthesis of (iso)-quinoline analogs of NSC 95397, we prepared some key 
intermediates and tested their biological activities. However, the potency of these compounds did 
not exceed that of NSC 95397, and several desired derivatives could not be obtained despite 
considerable efforts.  
We also prepared eight alternative heterocycles with 4-(2-aminoethyl)-morpholine 
substituents to remove the possibility for covalent binding between reactive residues (such as 
Cys or Ser) of Cdc25 and inhibitors while simultaneously increasing the affinity for the active 
site by establishing new noncovalent interactions. Accordingly, the major modification was 
directed toward the quinone ring. However, none of these compounds showed activity against 
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 Cdc25B.  These results allowed us to conclude that the quinone ring of NSC 663284 was 
essential for activity against Cdc25B. 
Finally, the total synthesis of the naturally occurring cytotoxic caulibuguones proceeded 
efficiently in high overall yields from readily available isoquinolin-5-ol via hypervalent 
oxidation, regioselective halogenations and amination reactions. Biological assays established 
this new class of natural products as phosphatase inhibitors with considerable selectivity against 
the Cdc25 family of DSPases.  
Based on the results of all synthesized and tested compounds, compound 118 can be 
proposed as a possible potent reversible inhibitor of Cdc25 as shown in Figure 25.  The main 
motif for the proposal of 118 is to develop a reversible inhibitor without loss of activity against 
Cdc25. This goal might be achieved by the reversible intramolecular addition of thiol after 
covalent bond formation of enzyme with 118. Moreover, the generation of HCl or H2O2, which 
might be harmful to cells, could be avoided in this reaction. 
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Figure 25. Proposal of 118 as a reversible inhibitor for Cdc25 
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 1.5. Experimental Section 
 
General Methods. All moisture-sensitive reactions were performed under an atmosphere 
of dry nitrogen and all glassware was dried in an oven prior to use. THF and ether were dried by 
distillation over Na/benzophenone and CH2Cl2 was dried by distillation over CaH2. Unless 
otherwise stated, all commercially available materials were used without purification. IR spectra 
were recorded neat using NaCl cells. NMR spectra were obtained at 300MHz/75MHz (1H/13C 
NMR) in CDCl3 unless noted otherwise. High and low resolution mass spectra were determined 
by introduction with a direct insertion probe into a VG- 70-70 HF spectrometer operating in the 
electron ionization (EI) mode.  
 
4-(4-tert-Butoxycarbonylaminocyclohexylcarbamoyl)-2-decanoylaminobutyric acid 
benzyl ester (24). Prepared according to literature procedures:2(a) 1H NMR δ 7.40-7.30 (m, 5 H), 
6.75-6.65 (br, 1 H), 6.30-6.20 (br, 1 H), 5.19 (d, 1 H, J = 12 Hz), 5.13 (d, 1 H, J = 12 Hz), 4.60-
4.50 (m, 1 H), 4.50-4.40 (m, 1 H), 3.80-3.60 (m, 1 H), 3.50-3.30 (m, 1 H), 2.27-2.10 (m, 5 H), 
2.08-1.90 (m, 5 H), 1.70-1.50 (m, 2 H), 1.43 (s, 9 H), 1.40-1.20 (m, 16 H), 0.88 (t, 3 H, J = 6.8 
Hz). 
2-Decanoylamino-4-[4-(2-nitrobenzenesulfonylamino)-cyclohexylcarbamoyl]-butyric 
acid benzyl ester (31). HCl (conc., 0.3 mL) was added dropwise to a solution of 24 (294 mg, 
0.500 mmol) in dioxane (10 mL) at room temperature. The solution was stirred for 4 h at room 
temperature and concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (10 
mL). To this solution was added collidine (0.40 mL, 3.0 mmol) and o-NsCl (0.12 g, 0.55 mmol). 
The reaction mixture was stirred for 18 h, diluted with CH2Cl2 (50 mL) and washed with 1 N 
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 HCl solution (25 mL). The organic layer was dried (Na2SO4), concentrated and purified by 
chromatography on SiO2 (Hexanes/EtOAc, 10:1) to give 31 (120 mg, 36%) as a white solid: 1H 
NMR δ 8.20-8.05 (m, 1 H), 7.95-7.20 (m, 8 H), 6.59 (d, 1 H, J =7.5 Hz), 6.37 (d, 1 H, J = 7.6 
Hz), 5.46 (d, 1 H, J = 7.6 Hz), 5.17 (d, 1 H, J = 12.4 Hz), 5.13 (d, 1 H, J = 12.4 Hz), 4.60-4.40 
(m, 1 H), 3.72-3.52 (m, 1 H), 3.35-3.18 (m, 1 H), 2.23-2.04 (m, 5 H), 2.00-1.75 (m, 5 H), 1.70-
1.45 (m, 2 H), 1.4-1.0 (m, 16 H), 0.90-0.70 (m, 3 H). 
4-{4-[Benzyl-(2-nitrobenzenesulfonyl)-amino]-cyclohexylcarbamoyl}-2-
decanoylaminobutyric acid benzyl ester (32). To a solution of 31 (86 mg, 0.13 mmol) in DMF 
(1 mL) was added K2CO3 (71 mg, 0.51 mmol) and BnBr (0.060 mL, 0.51 mmol). The reaction 
mixture was stirred for 40 h, diluted with EtOAc (50 mL) and washed with 1N HCl solution (25 
mL×3). The organic layer was dried (Na2SO4), concentrated and purified by chromatography on 
SiO2 (Hexanes/EtOAc, 10:1) to give 32 (57 mg, 58%) as a white solid: IR (neat) 3301, 3064, 
2927, 2855, 1732, 1638, 1544, 1438, 1372, 1170 cm-1; 1H NMR δ 7.78-7.21 (m, 14 H), 6.59 (d, 1 
H, J = 7.5 Hz), 6.23 (d, 1 H, J = 7.8 Hz), 5.18 (d, 1 H, J = 12.2 Hz), 5.13 (d, 1 H, J = 12.2 Hz), 
4.60-4.40 (m, 1 H) 4.49 (s, 2 H), 3.92-3.78 (m, 1 H), 3.62-3.46 (m, 1 H), 2.23-2.05 (m, 5 H), 
1.89-1.77 (m, 3 H), 1.77-1.73 (m, 2 H), 1.63-1.59 (m, 2 H), 1.51-1.40 (m, 2 H), 1.40-1.15 (m, 14 
H), 0.88 (t, 3 H, J = 6.2 Hz). MS (EI) m/z  (relative intensity) 762 (M+, 20), 576 (5), 270 (100); 
HRMS (EI) m/z calcd for C41H54N4O8S 762.3662, found 762.3644. 
4-(4-Benzylaminocyclohexylcarbamoyl)-2-decanoylaminobutyric acid benzyl ester 
(33).  To a solution of 32 (57 mg, 0.075 mmol) in DMF (0.2 mL) was added PhSH (15 µL, 0.15 
mmol) and K2CO3 (31 mg, 0.23 mmol) at 0 °C. The reaction mixture was stirred for 3 h at room 
temperature, diluted with EtOAc (20 mL) and washed with saturated NaHCO3 solution (20 mL). 
The organic layer was dried (Na2SO4), concentrated and purified by chromatography on SiO2 
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 (CH2Cl2/MeOH, 10:1) to give 33 (38 mg, 88%) as a white solid: 1H NMR δ 7.41-7.22 (m, 10 H), 
6.57 (d, 1 H, J = 7.4 Hz), 6.02 (d, 1 H, J = 7.8 Hz), 5.20 (d, 1 H, J = 12.1 Hz), 5.15 (d, 1 H, J = 
12.1 Hz), 4.56-4.49 (m, 1 H), 3.81 (s, 2 H), 3.80-3.65 (m, 1 H), 2.55-2.40 (m, 1 H), 2.25-2.10 (m, 
5 H), 2.10-1.85 (m, 5 H), 1.70-1.50 (m, 3 H), 1.4-1.1 (m, 14 H), 0.88 (t, 3 H, J = 6.3 Hz). 
2,5-Diphenyloxazole-4-carboxylic acid (25). Prepared according to literature 
procedures:50 1H NMR δ 8.36-8.34 (m, 2 H), 8.20-8.10 (m, 2 H), 7.60-7.40 (m, 6 H). 
4-{4-[Benzyl-(2,5-diphenyloxazole-4-carbonyl)-amino]-cyclohexylcarbamoyl}-2-
decanoylaminobutyric acid benzyl ester (34). To a solution of 33 (38 mg, 0.066 mmol) and 25 
(19 mg, 0.072 mmol) in THF (1 mL) was added PyBrop (61 mg, 0.13 mmol) and i-Pr2NEt (23 
µL, 0.13 mmol) at room temperature.  The reaction mixture was stirred overnight at room 
temperature, diluted with EtOAc (20 mL) and washed with of 1N HCl solution (10 mL). The 
organic layer was dried (Na2SO4), concentrated and purified by chromatography on SiO2 
(Hexanes/EtOAc, 1:1) to give 34 (41 mg, 76%) as a white solid: 1H NMR (~1:1 mixture of 
rotamers) δ 8.20-7.10 (m, aromatic, 20 H), 6.58, 6.47 (2d, 1 H, J = 7.4 Hz), 6.11, 6.02 (2d, 1 H, J 
= 7 Hz), 5.19-5.12 (m, 2 H), 4.79, 4.62 (2s, 2 H), 4.60-4.40 (m, 1 H) 3.95-3.80, 3.75-3.50 (2m, 1 
H), 2.30-1.50 (m, 14 H), 1.40-1.15 (m, 14 H), 0.90-0.75 (m, 3 H).  
4-{4-[Benzyl-(2,5-diphenyloxazole-4-carbonyl)-amino]-cyclohexylcarbamoyl}-2-
decanoylaminobutyric acid (35).  To a solution of 34 (40 mg, 0.048 mmol) in THF (0.4 mL) 
was added a solution of LiOH•H2O (6.0 mg, 0.15 mmol) in H2O (0.4 mL) at 0 °C.  The reaction 
mixture was stirred for 10 min at 0 °C and for 20 min at room temperature, diluted with H2O (20 
mL) and washed with Et2O (20 mL). The aqueous layer was acidified to pH 1 with 10 % HCl 
solution, salted out with NaCl and extracted with EtOAc (25 mL×3). The resulting organic layer 
was dried (Na2SO4) and concentrated under reduced pressure to give 35 (21 mg, 60%) as a white 
 67
 solid: Mp 170 oC (dec) IR (neat) 3307, 3061, 2918, 2851, 1735, 1632 cm-1; 1H NMR (rotamers) 
δ 8.02-7.10 (m, aromatic, 15 H), 6.75 (bd, 1 H, J = 7.3 Hz), 6.26 (bd, 1 H, J = 7.5 Hz) 4.78, 4.62 
(2s, 2 H), 4.55-4.25 (m, 2 H) 4.00-3.80, 3.70-3.50 (m, 1 H), 2.50-1.50 (m, 14 H), 1.50-1.15 (m, 
14 H), 0.95-0.80 (m, 3 H); MS (EI) m/z  (relative intensity) 716 ([M−H2O]+, 2) 625 (15), 468 
(30), 248 (100); HRMS (EI) m/z calcd for C44H52N4O5 (M−H2O)  716.3938, found 716.3947. 
(4-Aminocyclohexyl)-carbamic acid tert-butyl ester (36). Prepared according to 
literature procedures:2(a) 1H NMR δ 4.50-4.30 (br, 1 H), 3.40-3.20 (m, 1 H), 2.70-2.50 (m, 1 H), 
2.10-1.70 (m, 4 H), 1.60-1.40 (br, 2 H), 1.42 (s, 9 H), 1.30-1.00 (m, 4 H). 
4-(2-Nitrobenzenesulfonylamino)-cyclohexyl]-carbamic acid tert-butyl ester (37). To 
a solution of 36 (93 mg, 0.43 mmol) in THF (5 mL) was added NaHCO3 (146 mg, 1.74 mmol) 
and o-NsCl (96 mg, 0.43 mmol). The reaction mixture was stirred for 24 h at room temperature, 
concentrated, diluted with EtOAc (50 mL) and washed with H2O (30 mL). The organic layer was 
dried (Na2SO4) and concentrated under reduced pressure to give 37 (147 mg, 85%) as a white 
solid: 1H NMR δ 8.19–8.15 (m, 1 H), 7.90-7.86 (m, 1 H), 7.77-7.74 (m, 2 H), 5.20 (d, 1 H, J = 
7.7 Hz), 4.40-4.30 (m 1 H), 3.45-3.20 (m, 2 H), 2.05-1.85 (m, 4 H), 1.43 (s, 9 H), 1.40-1.05 (m, 4 
H). 
{4-[Benzyl(2-nitro-benzenesulfonyl)-amino]-cyclohexyl}-carbamic acid tert-butyl 
ester (38). To a solution of 37 (133 mg, 0.333 mmol) in DMF (5 mL) was added K2CO3 (184 
mg, 1.33 mmol) and BnBr (0.16 mL, 1.3 mmol). The reaction mixture was stirred for 14 h, 
diluted with EtOAc (50 mL) and washed with H2O (30 mL×2). The organic layer was dried 
(Na2SO4), concentrated and purified by chromatography on SiO2 (Hexanes/EtOAc, 1:2) to give 
38 (160 mg, 97%) as a white solid: 1H NMR δ 7.81-7.78 (m, 1 H), 7.63-7.59 (m, 2 H), 7.54-7.49 
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 (m, 1 H), 7.31-7.21 (m, 5 H), 4.49 (s, 2 H), 4.34-4.32 (m, 1 H), 3.90-3.82 (m, 1 H), 3.32-3.12 (m, 
1 H), 2.02-1.90 (m, 2 H), 1.85-1.75 (m, 2 H), 1.41 (s, 9 H), 1.5-1.1 (m, 4 H). 
(4-Benzylaminocyclohexyl)-carbamic acid tert-butyl ester (39). To a solution of 38 
(158 mg, 0.323 mmol) in DMF (2 mL) was added PhSH (66 µL, 0.65 mmol) and K2CO3 (0.13 g, 
0.97 mmol) at 0 °C.  The reaction mixture was stirred for 24 h at room temperature, diluted with 
of EtOAc (50 mL) and washed with saturated aqueous NaHCO3 solution (25 mL). The organic 
layer was dried (Na2SO4), concentrated and purified by chromatography on SiO2 (CH2Cl2/ 
MeOH, 15:1) to give 39 (89 mg, 91%) as a white solid: 1H NMR δ 7.35-7.20 (m, 5 H), 4.51-4.34 
(br, 1 H), 3.79 (s, 2 H), 3.51-3.31 (m, 1 H), 2.54-2.37 (m, 1 H), 2.05-1.90 (m, 4 H), 1.44 (s, 9 H), 
1.35-1.00 (m, 4 H). 
2-Decanoylaminopentanedioic acid 5-allyl ester 1-benzyl ester (22). Prepared 
according to the literature:2(a) 1H NMR δ 7.40-7.20 (m, 5 H), 6.18 (d, 1 H, -NH, J = 7.6 Hz), 
6.00-5.80 (m, 1 H), 5.35-5.10 (m, 2 H), 5.17 (s, 2 H), 4.75-4.60 (m, 1 H), 4.56 (d, 2 H, J = 5.6 
Hz), 2.60-1.90 (m, 6 H), 1.75-1.55 (m, 2 H), 1.40-1.10 (m, 12 H), 1.00-0.80 (m, 3 H). 
4-[Benzyl-(4-tert-butoxycarbonylaminocyclohexyl)-carbamoyl]-2-decanoylamino-
butyric acid benzyl ester (40). To a solution of 22 (150 mg, 0.348 mmol) in THF (2 mL) was 
added morpholine (0.30 mL, 3.4 mmol) and Pd(PPh3)4 (12 mg, 0.010 mmol) at room 
temperature. The reaction mixture was stirred for 1 h, concentrated under reduced pressure. The 
crude residue was diluted with EtOAc (50 mL) and washed with 10% aqueous HCl solution (20 
mL) and brine (20 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure to give crude deallylated product (136 mg, ~100%). The crude product was dissolved in 
THF and treated with 39 (89 mg, 0.29 mmol), PyBrop (272 mg, 0.584 mmol) and i-Pr2NEt (0.10 
mL, 0.58 mmol) at room temperature.  The reaction mixture was stirred overnight at room 
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 temperature and concentrated to remove THF. The residue was diluted with EtOAc (50 mL) and 
washed with H2O (25 mL). The organic layer was dried (Na2SO4), concentrated and purified by 
chromatography on SiO2 (Hexanes/EtOAc, 4:1 → 1:1) to give 40 (142 mg, 72%) as a white 
solid: IR (neat) 3311, 3061, 3030, 2927, 2856, 1741, 1711, 1646 cm-1; 1H NMR (rotamers) δ 
7.35-7.10 (m, aromatic, 10 H), 6.92, 6.71 (2d, 1 H, J = 6.4, 6.7 Hz), 5.18-5.10 (m, 2 H), 4.65-
4.25 (m, 4 H), 3.56-3.29 (m, 1 H), 2.68-2.32 (m, 1 H), 2.30-1.90 (m, 9 H), 1.75-1.49 (m, 4 H), 
1.42 (s, 9 H), 1.35-1.15 (m, 14 H), 0.95-0.80 (m, 3 H); MS (EI) m/z  (relative intensity) 677 (M+, 
20), 486 (40), 303 (100); HRMS (EI) m/z calcd for C40H59N3O6 677.4404, found 677.4404. 
4-(Benzyl-{4-[(2,5-diphenyloxazole-4-carbonyl)-amino]-cyclohexyl}-carbamoyl)-2-
decanoylaminobutyric acid benzyl ester (41). HCl (conc., 0.1 mL) was added dropwise to a 
solution of 40 (118 mg, 0.174 mmol) in dioxane (3 mL) at room temperature. The solution was 
stirred for 4 h at room temperature and concentrated under reduced pressure. The residue was 
dissolved in THF (3 mL). To this solution was added 25 (51 mg, 0.19 mmol), PyBrop (162 mg, 
0.348 mmol) and i-PrNEt2 (0.09 mL, 0.5 mmol) at room temperature. The reaction mixture was 
stirred for 14 h, concentrated under reduced pressure, diluted with EtOAc (50 mL) and washed 
with 1N aqueous HCl solution (20 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
1:1) to give 41 (92.0 mg, 85%) as a white solid: 1H NMR (rotamers) δ 8.40-8.30 (m, 2 H), 8.15-
8.05 (m, 2 H), 7.53-7.16  (m, 16 H), 6.95, 6.73 (2d, 1 H, J = 7.1 Hz), 5.25-5.05 (m, 2 H), 4.70-
4.35 (m, 4 H), 3.95-3.60 (m, 2 H), 2.75-2.45 (m, 1 H), 2.40-2.05 (m, 6 H), 1.90-1.40 (m, 7 H), 
1.35-1.15 (m, 14 H), 0.95-0.80 (m, 3 H). 
4-(Benzyl-{4-[(2,5-diphenyloxazole-4-carbonyl)-amino]-cyclohexyl}-carbamoyl)-2-
decanoylaminobutyric acid (42). To a solution of 41 (55 mg, 0.067 mmol) in THF (0.5 mL) 
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 was added a solution of LiOH•H2O (8.0 mg, 1.9 mmol) in H2O (0.5 mL) at 0 °C.  The reaction 
mixture was stirred for 10 min at 0 °C and for 60 min at room temperature, diluted with H2O (30 
mL) and washed with Et2O (20 mL). The aqueous layer was acidified to pH 1 with 10 % aqueous 
HCl solution, salted out with NaCl and extracted with EtOAc (25 mL×3). The resulting organic 
layer was dried (Na2SO4) and concentrated under reduced pressure to give 42 (45 mg, 91 %) as a 
white solid: Mp 170 oC (dec); IR (neat) 3402, 3314, 3065, 3034, 2927, 2855, 1734, 1635 cm-1; 
1H NMR (rotamers) δ 8.40-8.30 (m, 2 H), 8.15-8.05 (m, 2 H), 7.52-7.16 (m, 11 H), 4.70-4.30 (m, 
3 H), 3.95-3.70 (m, 2 H), 3.25-1.40 (m, 14 H), 1.35-1.15 (m, 14 H), 0.95-0.80 (m, 3 H); 13C 
NMR δ 175.4, 174.7, 174.6, 173.3, 161.0, 158.7, 152.6, 152.5, 138.4, 137.1, 131.2, 130.4, 130.3, 
130.1, 129.2, 128.8, 128.5, 127.9, 127.5, 127.2, 126.8, 126.6, 125.9, 57.2, 54.1, 53.1, 47.7, 36.5, 
32.1, 31.5, 30.5, 30.3, 29.9, 29.7, 29.6 (2C), 29.5 (2C), 29.0, 28.5, 25.8, 22.9, 14.4; MS (EI) m/z  
(relative intensity) 716 ([M−H2O]+, 2), 672 (3), 625 (5); HRMS (EI) m/z calcd for C44H52N4O5 
(M−H2O)  716.3938, found 716.3940. 
Phenanthrene-9-carboxylic acid (43). A solution of 9-cyanophenanthrene (375 mg, 
1.80 mmol) and NaOH (175 mg, 43.0 mmol) in diethylene glycol/H2O (6 mL/2 mL) was heated 
at reflux for 14 h, cooled to room temperature and acidified to pH 1 with 1N aqueous HCl 
solution. The precipitate was filtered and concentrated under reduced pressure to give 43 (380 
mg, 95%) as a white solid: 1H NMR (DMSO-d6) δ 8.84 (d, 1 H, J = 8.4 Hz), 8.81 (d, 1 H, J = 9.2 
Hz), 8.31 (d, 1 H, J = 7.5 Hz), 8.02 (d, 1 H, J = 6.7 Hz), 7.96 (s, 1 H), 7.77-7.62 (m, 4 H); MS 
(EI) m/z  (relative intensity) 222 (M+, 100), 205 (50), 177 (65). 
2-Decanoylamino-4-{4-[(phenanthrene-9-carbonyl)-amino]-cyclohexylcarbamoyl}-
butyric acid benzyl ester (44). According to the procedure described for the synthesis of 34, 44 
(28 mg, 20%) was obtained from 22 (120 mg, 0.200 mmol) and 43 (44 mg, 0.20 mmol): 1H 
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 NMR (MeOH-d4) δ 8.80 (d, 1 H, J = 7.7 Hz), 8.76 (d, 1 H, J = 8.2 Hz), 8.17 (d, 1 H, J = 7.7 Hz), 
7.97 (d, 1 H, J = 7.4 Hz), 7.90 (s, 1 H), 7.66-7.53 (m, 9 H), 5.18 (d, 1 H, J = 12.2 Hz), 5.10 (d, 1 
H, J = 12.2 Hz), 4.45-4.35 (m, 1 H), 3.63-3.35 (m, 5 H), 2.43-2.36 (m, 1 H), 2.25-2.09 (m, 5 H), 
2.00-1.90  (m, 2 H), 1.60-1.40 (m, 4 H), 1.35-1.15 (m, 14 H), 0.88 (t, 3 H, J = 6.6 Hz). 
2-Decanoylamino-4-{4-[(phenanthrene-9-carbonyl)-amino]-cyclohexylcarbamoyl}-
butyric acid (45). According to the procedure described for the synthesis of 35, 45 (14 mg, 
57%) was obtained from 44 (28 mg, 0.040 mmol) as a white solid: Mp 210 oC (dec); IR (neat) 
3646, 3412, 3282, 3058, 2921, 2848, 1724, 1631, 1524 cm-1; 1H NMR (MeOH-d4) δ 8.80 (d, 1 
H, J = 8.8 Hz), 8.76 (d, 1 H, J = 8.3 Hz), 8.16 (d, 1 H, J = 7.9 Hz), 7.97 (d, 1 H, J = 7.6 Hz), 7.86 
(s, 1 H), 7.72-7.59 (m, 4 H), 4.35-4.30 (m, 1 H), 4.05-3.95 (m, 1 H), 3.70-3.45 (m, 4 H), 2.50-
2.40 (m, 1 H), 2.30-1.90 (m, 8 H), 1.90 (m, 9 H), 1.70-1.40 (m, 5 H), 1.35-1.15 (m, 14 H), 0.95-
0.80 (m, 3 H); MS (EI) m/z  (relative intensity) 583 ([M−H2O]+, 20), 378 (15), 302 (15), 221 
(35), 205 (100); HRMS (EI) m/z calcd for C36H45N3O4 (M−H2O) 583.3410, found 583.3391. 
2-Phenylethenesulfonyl chloride (46). Prepared according to literature procedures:41,52 
1H NMR δ 7.76 (d, 1 H, J = 15.1 Hz), 7.60-7.45 (m, 5 H), 7.26 (d, 1 H, J = 15.0 Hz). 
2-Decanoylamino-4-[4-(2-phenylethenesulfonylamino)-cyclohexylcarbamoyl]-
butyric acid benzyl ester (47). HCl (conc., 0.1 mL) was added dropwise to a solution of 24 (110 
mg, 0.187 mmol) in dioxane (1 mL) at room temperature. The solution was stirred for 4 h at 
room temperature and concentrated under reduced pressure. The residue was dissolved in 
CH2Cl2 (2 mL), treated with 46 (77 mg, 0.38 mmol), TEA (0.080 mL, 0.60 mmol) and DMAP 
(23 mg, 0.19 mmol), stirred for 18 h at room temperature, diluted with EtOAc (30 mL) and 
washed with 1N aqueous HCl solution (20 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
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 (Hexanes/EtOAc, 1:2) to give 47 (38 mg, 31%) as a white solid: 1H NMR δ 7.65-7.30 (m, 11 H), 
6.76 (d, 1 H, J = 15.4 Hz), 6.49 (d, 1 H, J = 7.6 Hz), 6.21 (d, 1 H, J = 7.6 Hz), 5.20 (d, 1 H, J = 
12.1 Hz), 5.14 (d, 1 H, J = 12.2 Hz), 4.55-4.52 (m, 1 H), 4.47 (d, 1 H, J = 7.8 Hz), 3.75-3.60 (m, 
1 H), 3.30-3.15 (m, 1 H), 2.24-1.80 (m, 10 H), 1.70-1.50 (m, 4 H), 1.35-1.15 (m, 14 H), 0.88 (t, 3 
H, J = 6.5 Hz). 
2-Decanoylamino-4-[4-(2-phenylethenesulfonylamino)-cyclohexylcarbamoyl]-
butyric acid (48). According to the procedure described for the synthesis of 35, 48 (18 mg, 
75%) was obtained from 47 (28 mg, 0.043 mmol) as a white solid: Mp 195 oC (dec); IR (neat) 
3302, 3252, 3060, 2913, 2842, 1736, 1636, 1593, 1533, 1444, 1319, 1133, 1026, 869, 768 cm-1; 
1H NMR (MeOH-d4) δ 7.70-7.50 (m, 2 H), 7.50-7.30 (m, 4 H), 6.99 (d, 1 H, J = 15 Hz), 4.40-
4.30 (m, 1 H), 3.70-3.55 (m, 1 H), 3.20-3.05 (m, 1 H), 2.30-1.50 (m, 12 H), 1.50-1.15 (m, 16 H), 
0.95-0.80 (m, 3 H); MS (EI) m/z  (relative intensity) 545 ([M−H2O]+, 3), 378 (40), 96 (100); 
HRMS (EI) m/z calcd for C29H43N3O5S (M−H2O) 545.2923, found 545.2931. 
2-(3,4-Difluorophenyl)ethenesulfonyl chloride (49). Prepared according to literature 
procedures:41,52 1H NMR δ 7.66 (d, 1 H, J = 15.1 Hz), 7.41–7.27 (m, 3 H), 7.18 (d, 1 H, J = 15.1 
Hz). 
2-Decanoylamino-4-{4-[2-(3,4-difluorophenyl)-ethenesulfonylamino]-
cyclohexylcarbamoyl}-butyric acid benzyl ester (50). According to the procedure described 
for the synthesis of 47, 50 (60 mg, 43%) was obtained from 49 (48 mg, 0.20 mmol) and 24 (118 
mg, 0.201 mmol) as a white solid: 1H NMR (acetone-d6) δ 7.80-7.30 (m, 8 H), 7.15 (d, 1 H, J = 
15.1 Hz), 7.2-7.1, 6.4-6.3 (2m, 1 H), 5.13 (bs, 2 H), 4.50-4.35 (m, 1 H), 3.70-3.40 (m, 1 H), 3.25-
3.05 (m, 1 H), 2.10-1.80 (m, 10 H), 1.65-1.38 (m, 4 H), 1.30-1.10 (m, 14 H), 0.95-0.80 (m, 3 H). 
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   2-Decanoylamino-4-{4-[2-(3,4-difluorophenyl)-ethenesulfonylamino]-
cyclohexylcarbamoyl}-butyric acid (51). According to the procedure described for the 
synthesis of 35, 51 (45 mg, 87%) was obtained from 50 (60 mg, 0.090 mmol) as a white solid: 
Mp 200 oC (dec); IR 3293, 3232, 3048, 2912, 2842, 1732, 1630, 1593, 1508, 1283 cm-1; 1H 
NMR (MeOH-d4) δ 7.63-7.50 (m, 1 H), 7.40-7.25 (m, 2 H), 7.34 (d, 1 H, J = 15.6 Hz), 7.02 (d, 1 
H, J = 15.6 Hz), 4.36-4.28 (m, 1 H), 3.60-3.50 (m, 1 H), 3.15-3.05 (m, 1 H), 2.25-2.02 (m, 5 H), 
2.00-1.80 (m, 5 H), 1.62-1.50 (m, 2 H), 1.40-1.15 (m, 16 H), 0.87 (t, 3 H, J = 6.6 Hz); MS (EI) 
m/z  (relative intensity) 581 ([M−H2O]+, 1), 378 (40); HRMS (EI) m/z calcd for C29H41N3O5F2S 
(M−H2O) 581.2735, found 581.2746. 
2-Decanoylamino-4-[4-(2-naphthalen-2-ylethenesulfonylamino)-
cyclohexylcarbamoyl]-butyric acid benzyl ester (53). According to the procedure described 
for the synthesis of 47, 53 (60 mg, 43%) was obtained from 52 (38 mg, 0.15 mmol) and 24 (88 
mg, 0.15 mmol) as a white solid: 1H NMR (acetone-d6) δ 8.20-7.20 (m, 13 H), 7.22 (d, 1 H, J = 
15.5 Hz), 7.02 (d, 1 H, J = 7.3 Hz), 6.30 (d, 1 H, J = 7.5 Hz), 5.16-5.10 (m, 2 H), 4.50-4.30 (m, 1 
H), 3.70-3.30 (m, 3 H), 3.25-3.10 (m, 1 H), 2.20-1.88 (m, 12 H), 1.70-1.40 (m, 2 H), 1.30-1.10 
(m, 14 H), 0.95-0.80 (m, 3 H). 
2-Decanoylamino-4-[4-(2-naphthalen-2-yl-ethenesulfonylamino)-
cyclohexylcarbamoyl]-butyric acid (54). According to the procedure described for the 
synthesis of 35, 54 (27 mg, 69%) was obtained from 53 (45 mg, 0.064 mmol) as a white solid: 
Mp 210 oC (dec); IR 3253, 3053, 2918, 2846, 1729, 1630, 1545, 1437, 1315, 1134 cm-1; 1H 
NMR (MeOH-d4) δ 8.02 (s, 1 H), 7.92-7.84 (m, 2 H), 7.75-7.70 (m, 1 H), 7.67-7.50 (m, 3 H), 
7.56 (d, 1 H, J = 16 Hz), 7.10 (d, 1 H, J = 15.4 Hz), 4.34-4.32 (m, 1 H), 3.75-3.50 (m, 2 H), 3.15-
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 3.05 (m, 1 H), 2.22-1.95 (m, 6 H), 1.95-1.80 (m, 3 H), 1.65-1.50 (m, 2 H), 1.40-1.05 (m, 16 H), 
0.86 (t, 3 H, J = 6.1 Hz); MS (EI) m/z (relative intensity) 595 ([M-H2O]+,  <1). 
2-(2-Chlorophenyl)ethenesulfonyl chloride (55). Prepared according to literature 
procedures:41,52 1H NMR δ 8.16-8.11 (d, 1 H, J = 15 Hz), 7.63–7.28 (m, 4 H), 7.28 (d, 1 H, J = 
15 Hz). 
2-Decanoylamino-4-{4-[2-(2-chlorophenyl)-ethenesulfonylamino]-
cyclohexylcarbamoyl}-butyric acid benzyl ester (56). According to the procedure described 
for the synthesis of 47, 56 (61 mg, 27 %) was obtained from 55 (78 mg, 0.33 mmol) and 24 (193 
mg, 0.329 mmol) as a white solid: 1H NMR (acetone-d6) δ 7.82 (d, 1 H, J = 7.5 Hz), 7.75-7.26 
(m, 10 H), 7.13 (d, 1 H, J = 15.5 Hz), 7.07 (d, 1 H, J = 7.7 Hz), 6.50-6.40 (m, 1 H), 5.20-5.05 (m, 
2 H), 4.50-4.35 (m, 1 H), 3.65-3.36 (m, 2 H), 3.20-3.05 (m, 1 H), 2.21-2.13 (m, 4 H), 2.03-1.96 
(m, 4 H), 1.88-1.85 (m, 2 H), 1.60-1.38 (m, 4 H), 1.30-1.10 (m, 14 H), 0.90-0.80 (m, 3 H).  
2-Decanoylamino-4-{4-[2-(2-chlorophenyl)-ethenesulfonylamino]-
cyclohexylcarbamoyl}-butyric acid (57). According to the procedure described for the 
synthesis of 35, 57 (40 mg, 75 %) was obtained from 56 (61 mg, 0.089 mmol) as a white solid: 
Mp 195 oC (dec); IR 3301, 3077, 2920, 2849, 1740, 1640, 1534, 1441, 1323 cm-1; 1H NMR 
(MeOH-d4) δ 7.89-7.34 (m, 5 H), 7.05 (d, 1 H, J = 15.4 Hz), 4.33 (dd, 1 H, J = 9.0, 4.6 Hz), 
3.70-3.45 (m, 2 H), 3.15-3.05 (m, 1 H), 2.25-1.85 (m, 10 H), 1.65-1.50 (m, 2 H), 1.45-1.15 (m, 
16 H), 0.92-0.80 (m, 3 H); MS (EI) m/z  (relative intensity) 579 ([M−H2O]+, 1), 562 (7); HRMS 
(EI) m/z calcd for C29H42N3O5SCl (M−H2O) 579.2534, found 579.2531. 
5-Oxopyrrolidine-2-carboxylic acid benzyl ester (58). To a solution of DL-
pyroglutamic acid (1.3 g, 10 mmol) in DMF (10 mL) was added KHCO3 (1.5 g, 15 mmol) and 
BnBr (1.2 mL, 10 mmol). The reaction mixture was stirred for 14 h at room temperature, diluted 
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 with EtOAc (50 mL) and washed with 1N aqueous HCl solution (25 mL), saturated aqueous 
NaHCO3 solution (25 mL) and brine (25 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
(EtOAc) to give 58 (1.4 g, 63%) as a colorless oil: 1H NMR δ 7.45-7.27 (m, 5 H), 6.51 (br, 1 H), 
5.19 (s, 2 H), 4.31-4.23 (m, 1 H), 2.55-2.15 (m, 4 H). 
5-Oxopyrrolidine-1,2-dicarboxylic acid 2-benzyl ester 1-tert-butyl ester (59). 
Prepared according to the literature procedures:53 1H NMR (rotamers) δ 7.36-7.27 (m, 5 H), 5.20-
5.15 (m, 2 H), 4.65-4.55 (m, 1 H), 2.70-2.25 (m, 3 H), 2.05-1.90 (m, 1 H), 1.40, 1.37 (2s, 9 H),  
MS (EI) m/z  (relative intensity) 263 ([M-C4H8]+, 25), 219 (20); HRMS (EI) m/z calcd for 
C13H13NO5 (M-C4H8)  263.0794, found 263.0792. 
4-(4-Aminocyclohexylcarbamoyl)-2-tert-butoxycarbonylaminobutyric acid benzyl 
ester (60). To a solution of 59 (320 mg, 1.00 mmol) in THF (5 mL) was added 1,4-trans-
diaminocyclohexane (685 mg, 6.00 mmol) and KCN (65 mg, 1.0 mmol) at room temperature. 
The reaction mixture was stirred for 7 d at room temperature, concentrated, diluted with water 
(25 mL) and treated with 4N aqueous NaOH solution until the pH reached 13-14. The solution 
was extracted with EtOAc (50 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure to give 60 (330 mg, 77%) as a white solid: 1H NMR δ 7.30-7.15 (m, 5 
H), 6.06 (d, 1 H, J = 6.8 Hz), 5.55 (d, 1 H, J = 6.8 Hz), 5.15 (d, 1 H, J = 12.6 Hz), 5. 08 (d, 1 H, J 
= 12.6 Hz), 4.60 (s, 2 H), 4.30-4.15 (m, 1 H), 3.70-3.55 (m, 1 H), 2.65-2.45 (m, 1 H) 2.20-1.70 
(m, 8 H) 1.43 (s, 9 H), 1.25-1.05 (m, 4 H); 13C NMR δ 172.3, 171.4, 155.9, 141.9, 135.4, 128.6, 
128.3, 127.1, 126.8, 79.9, 67.1, 64.1, 53.3, 49.9, 49.8, 47.9, 35.0 (2C), 31.5 (2C), 28.4, 28.3; MS 
(EI) m/z (relative intensity) 433 (M+, 5); HRMS (EI) m/z calcd for C23H35N3O5 433.2576, found 
433.2570. 
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 2-tert-Butoxycarbonylamino-4-{4-[(2,5-diphenyloxazole-4-carbonyl)-amino]-
cyclohexylcarbamoyl}-butyric acid benzyl ester (61). To a solution of 60 (320 mg, 0.743 
mmol) in THF (10 mL) was added acid 25 (200 mg, 0.743 mmol), PyBrop (520 mg, 1.11 mmol) 
and i-PrNEt2 (0.20 mL, 1.1 mmol) at room temperature. The reaction mixture was stirred for 18 
h at room temperature and concentrated under reduced pressure. The residue was diluted with 
EtOAc (50 mL) and washed with H2O (20 mL). The organic layer was dried (Na2SO4), 
concentrated and purified by chromatography on SiO2 (Hexanes/EtOAc, 1:1 → EtOAc) to give 
61 (210 mg, 42%) as a white solid: 1H NMR δ 8.40-8.37 (m, 2 H), 8.15-8.12 (m, 2 H), 7.53 7.25 
(m, 11 H), 5.92 (bd, 1 H, J = 7.2 Hz), 5.31 (d, 1 H, J = 7.5 Hz), 5.23 (d, 1 H, J = 12.2 Hz), 5.14 
(d, 1 H, J = 12.2 Hz), 4.38-4.18 (m, 1 H), 4.00-3.90 (m, 1 H), 3.89-3.70 (m, 1 H), 2.30-1.85 (m, 
8 H), 1.8-1.2 (m, 13 H), 1.45 (s, 9 H). 
4-{4-[(2,5-Diphenyloxazole-4-carbonyl)-amino]-cyclohexylcarbamoyl}-2-(2-
phenylethenesulfonylamino)-butyric acid benzyl ester (62). According to the procedure 
described for the synthesis of 49, 62 (20 mg, 18%) was obtained from 61 (100 mg, 0.150 mmol) 
and 46 (61 mg, 0.30 mmol) as a white solid: 1H NMR δ 8.45-8.30 (m, 2 H), 8.20-8.05 (m, 2 H), 
7.52-7.00 (m, 17 H), 6.80-6.60 (m, 1 H), 5.70-5.50 (br, 1 H), 5.50-5.30 (m, 1 H), 5.10-4.90 (m, 2 
H), 4.1-3.7 (m, 3 H), 2.5-1.8 (m, 7 H), 1.7-1.0 (m, 5 H). 
4-{4-[(2,5-Diphenyloxazole-4-carbonyl)-amino]-cyclohexylcarbamoyl}-2-(2-
phenylethenesulfonylamino)-butyric acid (63). According to the procedure described for the 
synthesis of 35, 63 (9.0 mg, 56%) was obtained from 62 (18 mg, 0.024 mmol) as a white solid: 
Mp 195 oC (dec); IR (neat) 3302, 3252, 3060, 2913, 2842, 1736, 1636, 1593 cm-1, 1H NMR 
(DMSO-d6) δ 8.30-8.27 (m, 2 H), 8.20-8.05 (m, 2 H), 7.80 (d, 1 H, J = 7.3 Hz), 7.63-7.24 (m, 11 
H), 7.27 (d, 1 H, J = 15.4 Hz), 7.08 (d. 1 H, J = 15.4 Hz), 3.79-3.62 (m, 2 H), 3.46-3.44 (m, 1 H), 
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 2.20-2.12 (m, 2 H), 2.00-1.72 (m, 4 H), 1.59-1.40 (m, 2 H), 1.30-1.00 (m, 4 H); MS (EI) m/z  
(relative intensity) 638 ([M−H2O]+, <1); HRMS (EI) m/z calcd for C35H35N4O6S (M−H2O) 
638.2199, found 638.2183. 
6,7-Dichloroisoquinoline-5,8-dione (64).  Prepared according to literature procedures:54 
1H NMR (MeOH-d4) δ 9.33 (s, 1 H), 9.08 (d, 1 H, J = 5.1 Hz), 8.08 (d, 1 H, J = 5.0 Hz); 13C 
NMR  (MeOH-d4) δ 173.8 (2C), 153.5, 146.7, 141.8, 141.7, 135.8, 123.4, 118.0; MS (EI) m/z  
(relative intensity) 227 (M+, 100), 199 (20), 192 (80), 164 (80); HRMS (EI) m/z calcd for 
C9H3NO2Cl2 226.9541, found 226.9544. 
  4-(6-Chloro-5,8-dioxo-5,8-dihydroisoquinolin-7-ylamino)-butyric acid (65).  A 
solution of 64 (280 mg, 1.20 mmol) and 4-aminobutyric-acid (0.13 g, 1.2 mmol) in MeOH (20 
mL) was treated with a solution of KOH (70 mg, 1.2 mmol) in H2O (5 mL). The reaction mixture 
was stirred for 24 h, acidified with 10% aqueous HCl solution and extracted with EtOAc (50 
mL). The resulting organic layer was dried (Na2SO4) and concentrated under reduced pressure. 
The crude residue was purified by column chromatography on SiO2 (CH2Cl2/MeOH, 15:1) to 
give 65 (0.24 g, 69%) as a dark yellow sticky oil (4:1 mixture of regioisomers): 1H NMR (major 
isomer) δ 9.13 (s, 1 H), 8.94 (d, 1 H, J = 4.9 Hz), 7.92 (d, 1 H, J = 5.0 Hz), 3.91-3.83 (m, 2 H), 
2.42-2.37 (m, 2 H), 2.03-1.93 (m, 2 H); MS (EI) m/z  (relative intensity) 294 (M+, 26), 221 (100); 
HRMS (EI) m/z calcd for C13H11N2O4Cl 294.0407, found 294.0413. 
4-{4-[4-(6-Chloro-5,8-dioxo-5,8-dihydroisoquinolin-7-ylamino)-butyrylamino]-
cyclohexylcarbamoyl}-2-decanoylaminobutyric acid (66). HCl (conc., 0.12 mL) was added 
dropwise to a solution of 24 (118 mg, 0.200 mmol) in dioxane (1.2 mL) at room temperature. 
The solution was stirred for 4 h at room temperature and concentrated under reduced pressure. 
The residue was dissolved in THF (3 mL), treated with 65 (24 mg, 0.081 mmol), TEA (0.08 mL, 
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 0.6 mmol) and DEPC (0.036 mL, 0.24 mmol) and stirred for 14 h at room temperature. The 
reaction mixture was diluted with EtOAc (30 mL) and washed with of 1N aqueous HCl solution 
(20 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The 
residue was purified by chromatography on SiO2 (CH2Cl2/MeOH, 10:1) to give crude 66 (110 
mg) as a dark red amorphous sticky solid (mixture of regioisomers): 1H NMR (MeOH-d4) δ 9.13 
(s, 1 H), 8.95 (d, 1 H, J = 5.1 Hz), 7.93 (d, 1 H, J = 5.0 Hz), 7.35-7.30 (m, 5 H), 5.13 (s, 2 H), 
4.45-4.34 (m, 1 H), 3.90-3.80 (m, 2 H), 3.65-3.50 (m, 2 H), 2.30-2.05 (m, 6 H), 2.00-1.85 (m, 8 
H), 1.60-1.50 (m, 2 H), 1.35-1.15 (m, 16 H), 0.88 (t, 3 H, J = 6.4 Hz). 
4-{4-[4-(6-Chloro-5,8-dioxo-5,8-dihydroisoquinolin-7-ylamino)-butyrylamino]-
cyclohexylcarbamoyl}-2-decanoylamino-butyric acid (67). According to the procedure 
described for the synthesis of 35, 67 (42 mg, two steps 76%) was obtained from 66 (110 mg) as a 
dark red amorphous sticky solid (mixture of regioisomers): Mp 210 oC (dec); IR 3282, 3074, 
2918, 2849, 1705, 1636, 1543 cm-1; 1H NMR (MeOH-d4) δ 9.21 (bs, 1 H), 9.00 (br, 1 H), 7.98 
(d, 1 H, J = 4.9 Hz), 4.40-4.30 (m, 1 H), 3.65-3.50 (m, 2 H), 2.30-2.10 (m, 6 H), 1.95-1.80 (m, 8 
H), 1.65-1.50 (m, 2 H), 1.35-1.15 (m, 16 H), 0.95-0.80 (m, 3 H). 
  6,7-Dichloroquinoline-5,8-dione (68).  Prepared in 30-40% yield from quinoline-8-ol 
according to a literature procedure:54 1H NMR δ 9.11 (dd, 1 H, J = 3.8, 1.2 Hz), 8.54 (dd, 1 H, J 
= 7.3, 1.2 Hz), 7.77 (dd, 1 H, J = 7.3, 3.8 Hz); 13C NMR δ 175.8, 174.5, 156.0, 147.0, 144.5, 
143.3, 135.8, 128.5 (2C); MS (EI) m/z  (relative intensity) 227 (M+, 100), 199 (80), 192 (25), 
136(100); HRMS (EI) m/z calcd for C9H3NO2Cl2 226.9541, found 226.9545. 
6-Chloro-7-(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione (69) and 7-chloro-6-
(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione (70). A solution of 68 (228 mg, 1.00 
mmol) and 2-morpholin-4-ylethylamine (130 mg, 1.00 mmol) in THF (5 mL) was treated with 
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 TEA (0.14 mL, 1.0 mmol) at room temperature. The reaction mixture was stirred for 20 h at 
room temperature, concentrated under reduced pressure, diluted with EtOAc (50 mL) and 
washed with water (25 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (CH2Cl2/MeOH, 
15:1) to give a mixture of 69 and 70 (260 mg, 80%). The ratio of isomers in this mixture was 
determined by 1H NMR (69:70 = 2:1). Further separation of isomers by chromatography on SiO2 
(CH2Cl2/MeOH, 50:1) gave pure 69 and 70 as dark red amorphous sticky solids. 69:  IR (neat) 
3275, 2958, 2855, 1695, 1636, 1600, 1568, 1109 cm-1; 1H NMR δ 8.92 (dd, 1 H, J = 4.7, 1.6 Hz), 
8.48 (dd, 1 H, J = 7.8, 1.6 Hz), 7.66 (dd, 1 H, J = 7.8, 4.7 Hz), 7.09 (br, 1 H), 4.10-3.90 (m, 2 H), 
3.80-3.70 (m, 4 H), 2.70 (t, 2 H, J = 5.7 Hz), 2.60-2.50 (m, 4 H); 13C NMR (CDCl3) δ 179.0, 
175.4, 153.4, 146.2, 145.3, 134.6, 129.8, 128.4, 67.0(2C), 56.7, 53.0(2C), 40.9; MS (EI) m/z  
(relative intensity) 323 ([M+2H]+, 7), 210 (25); HRMS (EI) m/z calcd for C15H18N3O3Cl (M+2H) 
323.1037, found 323.1034. 70: IR (neat) 3275, 2958, 2851, 1687, 1647, 1600, 1564, 1106 cm-1; 
1H NMR δ 9.02 (dd, 1 H, J = 4.6, 1.6 Hz), 8.36 (dd, 1 H, J = 8.0, 1.6 Hz), 7.59 (dd, 1 H, J = 8.0, 
4.6 Hz), 6.98 (br, 1 H), 4.0-3.9 (m, 2 H), 3.85-3.70 (m, 4 H), 2.70 (t, 2 H, J = 5.4 Hz), 2.62-2.48 
(m, 4 H); 13C NMR δ 180.3, 175.2, 155.4, 148.6, 144.4, 134.8, 127.0, 126.7, 67.1 (2C), 56.8, 
53.1 (2C), 40.8; MS (EI) m/z  (relative intensity) 323 ([M+2H]+, 40), 285 (8) 267 (10); HRMS 
(EI) m/z calcd for C15H18N3O3Cl (M+2H) 323.1037, found 323.1027. 
6-Chloro-7-(2-piperidin-1-ylethylamino)-quinoline-5,8-dione (71). According to the 
procedure described for 69 and 70, a mixture of 71 and its regioisomer 72 (2:1, 286 mg, 89%) 
was obtained from 68 (228 mg, 1.00 mmol) and 1-(2-aminoethyl)-piperidine (128 mg, 1.00 
mmol). Further separation of isomers by chromatography on SiO2 (CH2Cl2/MeOH, 50:1) gave 
pure 71 as an amorphous red sticky solid:  IR (neat) 3267, 2922, 2856, 1699, 1607, 1563, 1497, 
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 1325, 1296, 728 cm-1; 1H NMR (MeOH-d4) δ 8.90 (d, 1 H, J = 3.5 Hz), 8.42 (d, 1 H, J = 7.6 Hz), 
7.73 (dd, J = 7.6, 3.5 Hz), 3.97 (m, 2 H), 2.68 (t, 2 H, J = 6.2 Hz), 2.60-2.40 (m, 4 H), 1.80-1.60 
(m, 4 H), 1.60-1.40 (m, 2 H); 13C NMR (CDCl3) δ 179.2, 175.4, 153.4, 146.4, 145.5, 134.7, 
130.0, 128.4, 57.0, 54.2 (2C), 41.4, 25.9 (2C), 24.3; MS (EI) m/z  (relative intensity) 319 (M+, 
15), 281 (40), 220 (92), 208 (37); HRMS (EI) m/z calcd for C16H18N3O2Cl 319.1087, found 
319.1080. 
6-Chloro-7-(indan-2-ylamino)-quinoline-5,8-dione (73). According to the procedure 
described for 69 and 70, pure 73 (192 mg, 59%) was obtained from 68 (228 mg, 1.00 mmol) and 
1-aminoindane (133 mg, 1.00 mmol) as a dark red amorphous sticky solid:  IR (neat) 3323, 3065, 
2939, 2844, 1695, 1640, 1592, 1560, 1315, 721 cm-1; 1H NMR δ 8.92 (dd, 1 H, J = 4.6, 1.4 Hz), 
8.49 (dd, 1 H, J = 7.8, 1.4 Hz), 7.67 (dd, 1 H, J = 7.8, 4.6 Hz), 7.40-7.20 (m, 4 H), 6.40 (br, 1 H), 
6.14 (dd, 1 H, J = 15.2, 7.2 Hz), 3.13-3.04 (m, 1 H), 3.00-2.92 (m, 2 H), 2.78-2.72 (m, 1 H), 
2.13-2.06 (m, 2 H); 13C NMR δ 178.6, 175.6, 153.4, 145.9, 144.1, 143.5, 142.4, 134.7, 129.8, 
128.7, 128.5, 127.2, 125.1, 124.4, 59.7, 36.2, 20.2; MS (EI) m/z  (relative intensity) 324 (M+, 6), 
287 (3), 220 (15), 205 (35), 117 (100); HRMS (EI) m/z calcd for C18H13N2O2Cl 324.0666, found 
324.0656.    
6-Chloro-7-(2-morpholin-4-yl-ethylamino)-isoquinoline-5,8-dione (74). A solution of 
64 (114 mg, 0.500 mmol) and 2-morpholin-4-yl-ethylamine (65 mg, 0.50 mmol) in THF (5 mL) 
was treated with TEA (0.07 mL, 0.5 mmol) at room temperature. The reaction mixture was 
stirred for 20 h at room temperature, concentrated under reduced pressure, diluted with EtOAc 
(50 mL) and washed with water (25 mL). The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(CH2Cl2/MeOH, 15:1) to give a mixture of 74 and its regioisomer 75 (4:1, 110 mg, 69%). The 
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 regiochemistry of each isomer was tentatively determined by 1H NMR.55 Further separation of 
isomers by chromatography on SiO2 (CH2Cl2/MeOH, 50:1) or recrystallization gave 74 (~90% 
purity) as a dark red amorphous sticky solid:  IR (neat) 3271, 2958, 2851, 1683, 1640, 1600, 
1564, 1113 cm-1; 1H NMR δ 9.24 (s, 1 H), 9.00 (d, 1 H, J = 5.0 Hz), 7.94 (d, 1 H, J = 5.0 Hz), 
7.13 (br, 1 H), 4.02-3.96 (m, 2 H), 3.78-3.75 (m, 4 H), 2.71-2.67 (m, 2 H), 2.60-2.50 (m, 4 H); 
13C NMR δ 179.9, 175.0, 156.3, 154.3, 148.5, 148.2, 123.7, 119.1, 118.2, 67.0 (2C), 56.6, 53.0 
(2C), 40.9; MS (EI) m/z  (relative intensity) 323 ([M+2H]+, 2), 221 (35), 101 (100); HRMS (EI) 
m/z calcd for C15H18N3O3Cl (M+2H) 323.1037, found 323.1037. 
6,7-Dichlorophthalazine-5,8-dione (76). Prepared according to a literature procedure:56 
1H NMR δ 9.93 (s, 1 H); MS (EI) m/z  (relative intensity) 228 (M+, 100), 200 (30); HRMS (EI) 
m/z calcd for C8H2N2O2Cl2 227.9493, found 227.9492. 
6-Chloro-7-(2-morpholin-4-ylethylamino)-phthalazine-5,8-dione (77). A solution of 
76 (67 mg, 0.29 mmol) and 2-morpholin-4-yl-ethylamine (38 mg, 0.29 mmol) in THF (5 mL) 
was treated with TEA (0.04 mL, 0.3 mmol) at room temperature. The reaction mixture was 
stirred for 2 h at room temperature, concentrated under reduced pressure, diluted with EtOAc (50 
mL) and washed with water (25 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(CH2Cl2/MeOH, 15:1) to give pure 77 (42 mg, 45%): IR (neat) 3271, 2958, 2923, 2855, 2808, 
1695, 1636, 1556, 1311, 1295, 1113 cm-1; 1H NMR δ 9.83 (s, 1 H), 9.65 (s, 1 H), 7.18 (br, 1 H), 
4.10-3.90 (m, 2 H), 3.80-3.65 (m, 4 H), 2.69 (t, 2 H, J = 6.0 Hz), 2.60-2.45 (m, 4 H); 13C NMR δ 
180.5, 174.2, 171.4, 147.2, 145.3, 144.5, 124.8, 123.3, 67.1 (2C), 56.3, 53.0 (2C), 41.0; MS (EI) 
m/z  (relative intensity) 324 ([M+2H]+, 10), 286 (12), 256 (8), 235 (12) 100 (100); HRMS (EI) 
m/z calcd for C14H17N4O3Cl (M+2H) 324.0989, found 323.0989. 
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 Quinoline-5,8-dione (78). Prepared from isoquinoline-8-ol according to literature 
procedures:57 IH NMR δ8.88  (s, 1 H), 8.23 (d, 1 H, J = 7.8 Hz), 7.60 (d, 1 H, J = 7.8 Hz), 7.00, 
6.91 (AB, 2 H, J = 10.4 Hz). 
7-(2-Morpholin-4-yl-ethylamino)-quinoline-5,8-dione (79) and 6-(2-Morpholin-4-yl-
ethylamino)-quinoline-5,8-dione (80). To a solution of quinoline-5,8-dione 78 (0.33 g, 2.1 
mmol) in EtOH (20 mL) was added 4-(2-aminoethyl)-morpholine (0.27 mL, 2.1 mmol) at room 
temperature. The reaction mixture was stirred for 16 h and concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:30) to give a ~2:3 
mixture of 79 and 80 (0.36 g, 60%). Pure 79 and 80 were obtained as red solids by further 
chromatography separation on SiO2 (MeOH/CH2Cl2, 1:100) as red solids. 79: Mp. 180 °C (dec.); 
IR (neat) 3329, 2966, 2837, 1696, 1618, 1598 cm-1; 1H NMR δ 8.88 (dd, 1 H, J = 4.5, 1.6 Hz), 
8.39 (dd, 1 H, J = 7.9, 1.6 Hz), 7.63 (dd, 1 H, J = 7.9, 4.5 Hz), 6.62 (bs, 1 H), 5.75 (s, 1 H), 3.80-
3.60 (m, 4 H), 3.27-3.21 (m, 2 H), 2.69 (t, 2 H, J = 6.1 Hz), 2.55-2.35 (m, 4 H); 13C NMR δ 
181.5, 180.1, 153.0, 148.3, 146.8, 134.3, 130.8, 128.3, 100.6, 66.9 (2C), 55.5, 53.3 (2C), 38.8; 
MS (EI) m/z  (relative intensity) 289 ([M+2]+, 1), 189 (4), 160 (2), 100 (100); HRMS (EI) m/z 
calcd for C15H19N3O3 (M+2H) 289.1426, found 289.1427. 80: Mp. 182 °C (dec.); IR (neat) 3293, 
2945, 2837, 1685, 1588, 1562, 1490 cm-1; 1H NMR δ 8.97 (dd, 1 H, J = 4.8, 1.6 Hz), 8.33 (dd, 1 
H, J = 8.0, 1.6 Hz), 7.55 (dd, 1 H, J = 8.0, 4.8 Hz), 6.53 (bs, 1 H), 5.87 (s, 1 H), 3.80-3.60 (m, 4 
H), 3.27-3.18 (m, 2 H), 2.69 (t, 2 H, J = 6.0 Hz), 2.55-2.35 (m, 4 H); 13C NMR δ 181.5, 181.2, 
155.1, 149.3, 147.6, 134.2, 127.4, 126.3, 102.1, 66.9 (2C), 55.5, 53.2 (2C), 38.4; MS (EI) m/z  
(relative intensity) 289 ([M+2]+, 2), 261 (2), 100 (75), 91 (100); HRMS (EI) m/z calcd for 
C15H19N3O3 (M+2H) 289.1426, found 289.1429. 
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 7-Bromo-5-nitroquinolin-8-ol (81). Prepared according to literature procedures:59 IH 
NMR (DMSO-d6) δ9.32 (d, 1 H, J = 8.9 Hz), 8.97 (d, 1 H, J = 4.4 Hz), 8.74 (s, 1 H), 7.98 (dd, 1 
H, J = 8.9, 4.4 Hz). 
5-Amino-7-bromoquinolin-8-ol (82). Prepared according to literature procedures:59 IH 
NMR (DMSO-d6) δ  bs, 1 H), 8.79 (d, 1 H, J = 4.2 Hz), 8.48 (d, 1 H, J = 8.5 Hz), 7.48 (dd, 1 
H, J = 8.5, 4.2 Hz), 6.84 (s, 1 H), 5.53 (bs, 2 H). 
7-Bromoquinoline-5,8-dione (83). Prepared according to literature procedures:59 Mp. 
175-178 °C (dec.); IR (neat) 3053, 1695, 1650, 1568, 1296, 1245 cm-1; 1H NMR (DMSO-d6) δ 
9.02 (dd, 1 H, J = 3.2, 1.6 Hz), 8.36 (dd, 1 H, J = 7.9, 1.6 Hz), 7.87 (dd, 1 H, J = 7.9, 3.2 Hz), 
7.80 (s, 1 H); 13C NMR δ 182.5, 176.0, 154.1, 146.8, 140.1, 139.2, 134.3, 128.9, 128.2; MS (EI) 
m/z  (relative intensity) 237 (M+, 91), 209 (12), 158 (32), 130 (45), 102 (100); HRMS (EI) m/z 
calcd for C9H4NO2Br 236.9425, found 236.9421. 
7-Bromo-6-(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione (84).  A solution of 83 
(0.14 g, 0.59 mmol) in THF (5 mL) was treated with TEA (82 µL, 0.59 mmol) and 4-(2-
aminoethyl)-morpholine (77 µL, 0.59 mmol) at room temperature. The reaction mixture was 
stirred for 3 h at room temperature, diluted with EtOAc (50 mL) and washed with brine (25 mL). 
The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:30) to give 84 (0.15 g, 69%) 
as a red sticky amorphous solid: IR (neat) 3247, 2955, 2848, 1680, 1562, 1122 cm-1; 1H NMR δ 
8.92 (dd, 1 H, J = 4.5, 1.4 Hz), 8.24 (dd, 1 H, J = 7.7, 1.4 Hz), 7.54 (dd, 1 H, J = 7.7, 4.5 Hz), 
7.03 (bs, 1 H), 3.95-3.85 (m, 2 H), 3.80-3.60 (m, 4 H), 2.63 (t, 2 H, J = 5.9 Hz), 2.55-2.35 (m, 4 
H); 13C NMR δ 179.7 (2C), 174.4, 154.9, 147.9, 146.4, 134.6, 126.8, 126.4, 67.0 (2C), 56.3, 52.8 
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 (2C), 41.2; MS (EI) m/z  (relative intensity) 365 (M+, 3); HRMS (EI) m/z calcd for 
C15H14N3O2Br (M-2H) 363.0219, found 363.0214. 
6,7-Dibromoquinoline-5,8-dione (85).  To a solution of 78 (0.80 g, 5.0 mmol) in CH2Cl2 
(50 mL) was added slowly Br2 (0.77 mL, 15 mmol) in CH2Cl2 (20 mL) for 30 min at room 
temperature. The reaction mixture was stirred for 20 h at room temperature and treated with 
pyridine (1.2 mL, 15 mmol) at room temperature. The reaction mixture was stirred for 20 h, 
diluted with CH2Cl2 (200 mL) and washed with H2O (100 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure to give crude 85 (620 mg, 39%) as a dark 
yellow solid. Crude 85 was recrystallized from EtOAc to give pure 85 (225 mg, 14%) as a 
yellow solid: Mp. 225 °C (EtOAc); IR (neat) 1685, 1665, 1541, 1568, 1265, 1188, 1107 cm-1; 1H 
NMR (DMSO-d6) δ 9.01 (dd, 1 H, J = 4.6, 1.6 Hz), 8.42 (dd, 1 H, J = 7.9, 1.6 Hz), 7.86 (dd, 1 H, 
J = 7.9, 4.6 Hz); 13C NMR δ 176.1, 174.2, 154.3, 146.7, 142.6, 140.9, 135.3, 135.0, 128.2; MS 
(EI) m/z  (relative intensity) 315 (M+, 5); HRMS (EI) m/z calcd for C9H3NO2Br2 314.8531, found 
314.8521. 
6-Bromo-7-(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione (86). A solution of 85 
(74 mg, 0.23 mmol) in THF (3 mL) was treated with TEA (0.033 L, 0.23 mmol) and 4-(2-
aminoethyl)-morpholine (0.030 L, 0.23 mmol) at room temperature. The reaction mixture was 
stirred for 18 h at room temperature, diluted with EtOAc (25 mL) and washed with brine (10 
mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:30) to give a ~2:1 mixture 
of regioisomers 86 and 84 (50 mg, 58%). Further separation by chromatography on SiO2 
(MeOH/CH2Cl2, 1:100) gave pure 86 as a red sticky amorphous solid: IR (neat) 3257, 2955, 
2848, 1690, 1588, 1547, 1122 cm-1; 1H NMR δ 8.91 (dd, 1 H, J = 4.7, 1.7 Hz), 8.47 (dd, 1 H, J = 
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 7.9, 1.7 Hz), 7.63 (dd, 1 H, J = 7.9, 4.7 Hz), 7.18 (bs, 1 H), 4.03-3.97 (m, 2 H), 3.85-3.65 (m, 4 
H), 2.69 (t, 2 H, J = 5.9 Hz), 2.65-2.50 (m, 4 H); 13C NMR δ 178.7 (2C), 175.1, 153.5, 147.8, 
146.3, 135.0, 129.6, 128.4, 67.1 (2C), 56.7, 53.0 (2C), 41.5; MS (EI) m/z  (relative intensity) 365 
(M+, 4), 228 (20), 100 (100); HRMS (EI) m/z calcd for C15H16N3O2Br 365. 0375, found 365. 
0389. 
6-(2-Morpholin-4-yl-ethylamino)-7-phenyl-quinoline-5,8-dione (88). To a   solution of 
83 (0.24 g, 1.0 mmol) in dioxane (10 mL) was added n-Bu3SnPh (370 mg, 1.0 mmol), Pd(PPh3)4  
(58 mg, 0.050 mmol) and CuBr (7.2 mg, 0.050 mmol) at room temperature. The reaction mixture 
was heated at reflux for 14 h, cooled to room temperature and filtered through a silica gel pad. 
The filtered solution was concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give crude 87, which was dissolved in THF 
(1.5 mL). To this solution was added 4-(2-aminoethyl)-morpholine. The reaction mixture was 
stirred for 3 h at room temperature and purified by chromatography on SiO2 (MeOH/CH2Cl2, 
1:50) several times to give 88 (~3 mg, <1%) as a red sticky amorphous solid: IR (neat) 3324, 
2955, 2929, 2858, 1680, 1562 cm-1; 1H NMR δ 9.03 (dd, 1 H, J = 3.2, 1.6 Hz), 8.40 (dd, 1 H, J = 
7.8, 1.6 Hz), 7.58 (dd, 1 H, J = 7.8, 3.2 Hz), 7.46-7.30 (m, 5 H), 6.80 (bs, 1 H), 3.75-3.65 (m, 4 
H), 2.80-2.60 (m, 2 H), 2.50-2.30 (m, 6 H); MS (EI) m/z  (relative intensity) 365 ([M+2]+, 30), 
262 (45), 100 (100); HRMS (EI) m/z calcd for C21H23N3O3 365.1739, found 365.1731. 
7-(2-Morpholin-4-yl-ethylamino)-isoquinoline-5,8-dione (89). To a solution of 5-
hydroxyisoquinoline (90%, 200 mg, 1.25 mmol) in EtOH/H2O (10 mL/1 mL) was added PIFA 
(1.07 g, 2.50 mmol) at room temperature. The reaction mixture was stirred for 2 h and treated 
with CeCl3 (0.60 g, 2.5 mmol) and 4-(2-aminoethyl)-morpholine (1.3 mL, 10 mmol) at room 
temperature.  The solution was stirred for 20 h, diluted with EtOAc (100 mL) and washed with 
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 brine (50 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (CH2Cl2/MeOH, 50:1) to give a 
crude product. Further separation by chromatography on SiO2 (EtOAc) gave 89 as a red sticky 
solid. IR (film) 3346, 2960, 2849, 2815, 1683, 1631, 1601, 1554, 1511, 1352, 1327, 1262, 1112 
cm-1; 1H NMR (CDCl3) δ 9.25 (s, 1 H), 9.00 (d, 1 H. J = 5.0 Hz), 7.90 (d, 1 H, J = 5.0 Hz), 6.67 
(bs, 1 H, -NH), 5.79 (s, 1 H), 3.80-3.65 (m, 4 H), 3.30-3.15 (m, 2 H), 2.71 (t, 2 H, J = 6.1 Hz), 
2.60-2.40 (m, 4 H); 13C NMR (CDCl3) δ 181.3, 181.0, 156.4, 148.0 (2C), 132.3, 124.4, 119.0, 
101.6, 67.0 (2C), 55.5, 53.2 (2C), 38.4; MS (EI) m/z  (relative intensity) 288 (M+, 3), 199 (3.5), 
100 (100); HRMS (EI) m/z calcd for C15H18N3O3 288.1348, found 288.1338. 
2-(Tetrahydropyran-2-yloxy)-ethanethiol (90). Prepared according to literature 
procedures:62 IR (neat) 2939, 2871, 2558, 1446, 1346, 1203, 1137, 1034, 974, 906 cm-1; 1H NMR 
δ 4.61 (t, 1 H, J = 2.9 Hz), 3.87 – 3.81 (m, 2 H), 3.55 – 3.49 (m, 2 H), 2.69 (dt, 2 H, J = 6.5, 5 
Hz), 1.69 – 1.49 (m, 7 H); 13C NMR δ 98.8, 69.2, 62.3, 30.5, 25.4, 24.6, 19.4; MS (CI) m/z  
(relative intensity) 163 ([M+H]+, 30), 85 (100), 61 (45). 
Benzoic acid 2-mercaptoethyl ester (91). A solution of 2-mercaptoethanol (1.4 mL, 20 
mmol) and benzoylchloride (2.3 mL, 20 mmol) in CH2Cl2 (20 mL) was treated with pyridine (2.0 
mL, 20 mmol). The reaction mixture was stirred for 5 h at room temperature, diluted with 
CH2Cl2 (50 mL) and washed with 1N HCl solution (50 mL). The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 10:1) to give 91 (900 mg, 25%) as a colorless oil: IR 
(neat) 3065, 2954, 2895, 2578, 1715, 1608, 1580, 1453, 1378, 1279, 1184, 1101 cm-1; 1H NMR δ 
8.05 – 8.06 (m, 2 H), 7.61–7.55 (m, 1 H), 7.48–7.43 (m, 2 H), 4.52 (t, 2 H, J = 6.7 Hz), 2.93–
2.86 (m, 2 H), 1.58 (t, 1 H, J = 14.5 Hz); 13C NMR δ 166.4, 133.3, 130.0, 129.9, 129.8 (2C), 
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 128.6, 66.3, 23.6; MS (EI) m/z  (relative intensity) 182 (M+, 1), 149 (2), 123 (26), 105 (85), 77 
(100), 60 (35); HRMS (EI) m/z calcd for C9H10NO2S 182.0402, found 182.0407. 
2-(tert-Butyldiphenylsilanyloxy)-ethanethiol (92). A solution of 2-mercaptoethanol 
(0.70 mL, 10 mmol) and TBDPSCl (2.8 g, 10 mmol) in DMF (20 mL) was treated with 
imidazole (0.68 g, 10 mmol). The reaction mixture was stirred for 5 h at room temperature, 
quenched with saturated NH4Cl solution (1 mL), diluted with EtOAc (50 mL) and washed with 
of saturated NaHCO3 solution (25 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(Hexanes/EtOAc, 10:1) to give 92 (2.95 g, 93%) as a colorless oil: IR (neat) 3069, 2946, 2859, 
1473, 1434, 1117, 832, 709 cm-1; 1H NMR δ 7.75–7.72 (m, 4 H), 7.48–7.41 (m, 6 H), 3.83 (t, 2 
H, J = 6.4 Hz), 2.75-2.65 (m, 2 H), 1.64 (t, 1 H, J = 8.3 Hz), 1.13 (s, 9 H); 13C NMR δ 135.7 
(4C), 133.5 (2C), 129.9 (2C), 127.8 (4C), 65.7, 27.3, 27.0 (3C), 19.4; MS (EI) m/z  (relative 
intensity) 259 ([M-tBu]+, 15), 199 (10), 181 (65), 84 (100); HRMS (EI) m/z calcd for 
C14H15OSSi (M-tBu) 259.0613, found 259.0607. 
  (2,2-Dimethyl-[1,3]dioxolan-4-yl)-methanethiol (93). Prepared according to literature 
procedures:62 IR (neat) 2990, 2930, 2883, 2554, 1453, 1378, 1228, 1152, 1065, 859cm-1; 1H 
NMR δ 4.16-4.12 (m, 1 H), 4.07-4.01 (m, 1 H), 3.72-3.68 (m, 1 H), 2.70-2.63 (m, 1 H), 2.59-
2.51 (m, 1 H), 1.43 (t, 1 H, J = 8.5 Hz), 1.37 (s, 3 H), 1.29 (s, 3 H); 13C NMR δ 109.8, 77.1, 68.4, 
27.7, 27.0, 25.6; MS (EI) m/z  (relative intensity) 148 (M+, 6), 133 (40), 101 (70), 73 (100); 
HRMS (EI) m/z calcd for C6H12O2S 148.0558, found 148.0560. 
6,7-Bis-[2-(tetrahydropyran-2-yloxy)-ethylsulfanyl]-quinoline-5,8-dione (94). A 
solution of 68 (98 mg, 0.43 mmol) and 90 (210 mg, 1.30 mmol) in THF (8 mL) was treated with 
TEA (0.18 mL, 1.3 mmol) at room temperature. The reaction mixture was stirred at room 
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 temperature for 20 h, concentrated under reduced pressure, diluted with EtOAc (50 mL) and 
washed with water (25 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
2:1) to give 94 (270 mg, 58%) as a dark red amorphous sticky oil: IR (neat) 2943, 2863, 1663, 
1580, 1485, 1287, 1204, 1125, 1073, 1022 cm-1; 1H NMR δ 8.96 (dd, 1 H, J = 4.7, 1.6 Hz), 8.37 
(dd, 1 H, J = 7.8, 1.6 Hz), 7.63 (dd, 1 H, J = 7.8, 4.6 Hz), 4.64-4.54 (m, 2 H), 4.05-3.90 (m, 2 H), 
3.85-3.44 (m, 10 H), 1.65-1.26 (m, 12 H); 13C NMR δ 178.1, 177.4, 154.2, 149.5, 148.6, 146.3, 
134.8, 129.9, 127.3, 98.7 (2C), 67.5, 67.4, 62.0 (2C), 34.6, 34.4, 30.3 (2C), 25.3 (2C), 19.1, 18.9; 
MS (EI) m/z  (relative intensity) 479 (M+, 6), 397 (6), 351 (5), 313 (40), 85 (100); HRMS (EI) 
m/z calcd for C23H29NO6S2  479.1436, found 479.1438. 
6,7-Bis-[2-(benzoyloxy)-ethylsulfanyl]-quinoline-5,8-dione (95). According to the 
procedure described for 94, 95 (220 mg, 86 %) was obtained from 68 (114 mg, 0.500 mmol) and 
91 (228 mg, 1.25 mmol) as a dark red amorphous sticky oil: IR (neat) 3061, 2951, 2883, 1723, 
1663, 1271, 1113, 709 cm-1; 1H NMR δ 8.93 (dd, 1 H, J = 4.6, 1.7 Hz), 8.24 (dd, 1 H, J = 7.8, 
1.7 Hz), 7.96-7.90 (m, 3 H), 7.58-7.46 (m, 4 H), 7.34-7.28 (m, 4 H), 4.62-4.48 (m, 4 H), 3.71-
3.57 (m, 4 H); 13C NMR δ 178.1, 177.3, 166.1 (2C), 154.4, 148.8, 148.3, 146.2, 134.9, 133.3, 
133.2, 129.8 (8C), 128.5 (2C), 127.6 (2C), 64.6, 64.4, 33.9, 33.7; MS (EI) m/z  (relative 
intensity) 519 (M+, 7), 397 (12), 369 (10), 84 (100); HRMS (EI) m/z calcd for C27H21NO6S2  
519.0810, found 519.0821. 
6,7-Bis-(2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl)-quinoline-5,8-dione (76). 
According to the procedure described for 94, 96 (160 mg, 71 %) was obtained from 68 (114 mg, 
0.500 mmol) and 93 (222 mg, 1.50 mmol) as a dark red amorphous sticky oil: IR (neat) 2943, 
2863, 1663, 1580, 1485, 1287, 1204, 1125, 1073, 1022 cm-1; 1H NMR δ 8.98 (d, 1 H, J = 4.1 
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 Hz), 8.38 (dd, 1 H, J = 7.8 Hz), 7.65 (dd, 1 H, J = 7.8, 4.6 Hz), 4.43-4.30 (m, 2 H), 4.15-4.10 (m, 
2 H), 3.85-3.77 (m, 2 H), 3.62-3.25 (m, 4 H), 1.31 (s, 6 H), 1.27 (s, 6 H); 13C NMR δ 178.0, 
177.3, 154.3, 149.4, 148.5, 145.9, 134.8, 129.9, 127.5, 109.8 (2C), 75.6 (2C), 68.4 (2C), 37.1 
(2C), 26.7 (2C), 25.4 (2C); MS (EI) m/z  (relative intensity) 451 (M+, 20), 337 (40), 236 (100); 
HRMS (EI) m/z calcd for C21H25NO6S2  451.1123, found 451.1125. 
6,7-Bis-[2-(tert-butyldiphenylsilanyloxy)-ethylsulfanyl]-quinoline-5,8-dione (97). 
According to the procedure described for 94, 97 (390 mg, 99%) was obtained from 68 (114 mg, 
0.500 mmol) and 92 (228 mg, 1.25 mmol) as a dark red amorphous sticky oil:  IR (neat) 3049, 
2956, 2890, 2860, 1657, 1587, 1468, 1423, 1278, 1204, 1100, 1026, 903, 818, 714 cm-1; 1H 
NMR δ 8.94 (dd, 1 H, J = 4.6, 1.6 Hz), 8.28 (dd, 1 H, J = 7.9, 1.6 Hz), 7.67-7.58 (m, 9 H), 7.67-
7.58 (m, 12 H), 3.93, 3.90 (2t, 4 H, J = 6.1 Hz), 3.55, 3.49 (2t, 4 H, J = 5.9 Hz), 1.00 (s, 18 H); 
13C NMR δ 177.7, 177.0, 153.8, 148.7, 148.1, 145.7, 135.3 (8C), 134.4, 132.9 (4C), 129.5 (4C), 
127.5 (8C), 127.0 (2C), 63.7, 63.5, 37.2, 36.8, 26.5 (6C), 18.9 (2C); MS (EI) m/z  (relative 
intensity) 789 ([M+2H]+, 10), 732 (20), 448 (15), 225 (100); HRMS (EI) m/z calcd for 
C45H51NO4Si2S2  (M+2H) 789.2798, found 789.2813. 
6,7-Bis-[2-(tetrahydropyran-2-yloxy)-ethylsulfanyl]-isoquinoline-5,8-dione (99). A 
solution of 64 (74 mg, 0.32 mmol) and 90 (160 mg, 0.960 mmol) in THF (5 mL) was treated 
with TEA (0.13 mL, 0.96 mmol) at room temperature. The reaction mixture was stirred at room 
temperature for 20 h, concentrated under reduced pressure, diluted with EtOAc (50 mL) and 
washed with water (25 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
1:2) to give 99 (31 mg, 20%) as a dark red amorphous sticky oil: IR (neat) 2936, 2863, 1663, 
1580, 1282, 1119, 1026 cm-1; 1H NMR δ 9.28 (s, 1 H), 8.98 (d, 1 H, J = 5 Hz), 7.83 (d, 1 H, J = 
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 5 Hz), 4.63-4.55 (m, 2 H), 3.98–3.46 (m, 8 H), 1.60-1.25 (m, 8 H); 13C NMR δ 178.3, 177.9, 
155.0, 149.3, 148.9, 147.2, 138.4, 126.4, 119.0, 98.9 (2C), 67.7(2C), 62.2 (2C), 34.7, 34.5, 30.5 
(2C), 25.4 (2C), 19.3, 19.2; MS (EI) m/z  (relative intensity) 479 (M+, 40), 313 (100), 85 (85); 
HRMS (EI) m/z calcd for C23H29NO6S2  479.1436, found 479.1429. 
6,7-Bis-[2-(benzoyloxy)-ethylsulfanyl]-isoquinoline-5,8-dione (100). According to the 
procedure described for 99, 100 (190 mg, 84 %) was obtained from 64 (98 mg, 0.43 mmol) and 
91 (222 mg, 1.30 mmol) as a dark red amorphous sticky oil: IR (neat) 3065, 2943, 2887, 1723, 
1659, 1580, 1450, 1283, 1109, 705 cm-1; 1H NMR δ 9.15 (s, 1 H), 8.92 (d, 1 H, J = 4.1 Hz), 
7.94-7.88 (m, 4 H), 7.70 (d, 1H, J = 4.1 Hz), 7.48-7.46 (m, 2 H), 7.34-7.26 (m, 4 H), 4.58, 4.56 
(2t, 4 H, J = 5.9 Hz), 3.69, 3.64 (t, 4 H, J = 6.0 Hz); 13C NMR δ 177.9, 177.6, 166.0 (2C), 154.9, 
148.7, 148.6, 146.6, 137.8, 133.3, 133.2, 129.6 (8C), 128.4 (4C), 125.8, 118.8, 64.4, 64.3, 33.8, 
33.5; MS (EI) m/z  (relative intensity) 519 (M+, 4), 397 (18), 105 (100); HRMS (EI) m/z calcd for 
C27H21NO6S2  519.0810, found 519.0829. 
6,7-Bis-(2,2-dimethyl-[1,3]dioxolan-4-ylmethylsulfanyl)-isoquinoline-5,8-dione (101). 
According to the procedure described for 99, 101 (37 mg, 69%) was obtained from 64 (27 mg, 
0.12 mmol) and 93 (53 mg, 0.36 mmol) as a dark red amorphous sticky oil: IR (neat) 2986, 2923, 
2851, 1659, 1279, 1061 cm-1; 1H NMR δ 9.30 (bs, 1 H), 9.02 (bs, 1 H), 7.84 (d, 1 H, J = 4.2 Hz), 
4.38-4.26 (m, 2 H), 4.15-4.09 (m, 2 H), 3.84-3.79 (m, 2 H), 3.60-3.25 (m, 4 H), 1.30 (s, 6 H), 
1.25 (s, 6 H); 13C NMR δ 178.0, 177.7, 154.8, 149.0, 148.7, 146.8, 138.5, 126.5, 119.2, 110.0 
(2C), 75.8 (2C), 68.5, 68.4, 37.2 (2C), 26.8, 26.7, 25.5, 25.4; MS (EI) m/z  (relative intensity) 
451 (M+, 12); HRMS (EI) m/z calcd for C21H25NO6S2  451.1123, found 451.1132. 
4,5-Dichloro-1,2-dimethyl-1,2-dihydro-pyridazine-3,6-dione (103). Prepared 
according to literature procedures:62 IR (neat) 3272, 3042, 2959, 2917, 1671, 1635, 1585, 1471 
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 cm-1; 1H NMR δ 3.68 (s, 6 H); 13C NMR δ 152.6 (2C), 138.2 (2C), 34.3 (2C); MS (EI) m/z  
(relative intensity) 208 (M+, 100), 180 (55); HRMS (EI) m/z calcd for C6H6N2O2Cl2 207.9806, 
found 207.9802. 
4-Chloro-1,2-dimethyl-5-(2-morpholin-4-yl-ethylamino)-1,2-dihydropyridazine-3,6-
dione (104). A solution of 103 (420 mg, 2.01 mmol) in EtOH (20 mL) was treated with TEA 
(0.28 mL, 2.0 mmol) and 2-morpholin-4-ylethylamine (260 mg, 2.00 mmol) at room 
temperature. The reaction mixture was heated at reflux for 18 h at 100 oC, cooled to room 
temperature and concentrated under reduced pressure. The residue was diluted with EtOAc (50 
mL) and washed with water (50 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure to give pure 104 (260 mg, 37%) as a yellow solid: Mp 110-115 oC; IR 
(neat) 3492, 3302, 2947, 2850, 2807, 1617, 1507, 1353, 1293, 1116 cm-1; 1H NMR δ 6.54 (br, 1 
H), 3.85 (t, 2 H, J = 5.8 Hz), 3.69 (t, 4 H, J = 4.6 Hz), 3.59 (s, 3 H), 3.57 (s, 3 H), 2.58 (t, 2 H, J 
= 6.0 Hz), 2.50 (t, 4 H, J = 4.5 Hz); 13C NMR δ 157.1, 153.6, 140.7, 103.4, 66.9 (2C), 57.1, 53.1 
(2C), 40.1, 33.9, 33.8; MS (EI) m/z (relative intensity) 303 (M+, 5), 267 (45), 100 (100); HRMS 
(EI) m/z calcd for C12H19N4O3Cl 302.1146, found 302.1144. 
4-(2-Iodoethyl)-morpholine (105). A solution of 4-(2-chloroethyl)-morpholine 
hydrochloric salt (1.9 g, 10 mmol) in MeOH (10 mL) was treated with NaI (15 g, 0.10 mol). The 
reaction mixture was heated at reflux for 5 d at 100 oC, cooled to room temperature and 
concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and washed 
with saturated NaHCO3 solution (100 mL). The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure to give 105 (800 mg, 36%) as a yellow oil: 1H NMR δ 3.73-
3.70 (m, 4 H), 3.21 (t, 2 H, J = 7.9 Hz), 2.72 (t, J = 7.9 Hz), 2.51-2.48 (m, 4 H); 13C NMR δ 66.9 
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 (2C), 61.1, 53.1 (2C), 1.9; MS (EI) m/z (relative intensity) 241 (M+, 80), 155 (65), 114 (100); 
HRMS (EI) calcd for C6H12NOI 240.9964, found 240.9962. 
2-Amino-3-chlorochromen-4-one (106). Prepared according to the literature:64 1H NMR 
δ 8.04 (2 H, br), 7.93-7.91 (m, 1 H), 7.65-7.60 (m, 1 H), 7.40-7.35 (m, 2 H); 13C NMR δ 169.2, 
161.5, 152.3, 133.1, 125.5, 122.4, 117.1, 92.3; MS (EI) m/z  (relative intensity) 195 (M+, 100), 
167 (20), 121 (45), 91 (40); HRMS (EI) m/z calcd for C9H6NO2Cl 195.0087, found 195.0090. 
3-Chloro-2-(2-morpholin-4-yl-ethylamino)-chromen-4-one (107). A solution of 106 
(190 mg, 1.00 mmol) and 105 (240 mg, 1.00 mmol) in DMF (10 mL) was treated with Cs2CO3 
(1.6 g, 5.0 mmol) and stirred for 3 h at room temperature. The reaction mixture was diluted with 
EtOAc (50 mL) and washed with NaHCO3 solution (50 mL×2). The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by chromatography 
on SiO2 (Hexanes /EtOAc, 2:1) to give 107 (14 mg, 5%) as a pale yellow liquid: IR (neat) 3422, 
2962, 2852, 1636, 1623, 1600, 1450, 1353, 1145, 1113; 1H NMR δ 7.68-7.65 (m, 1 H), 7.53-7.48 
(m, 1 H), 7.43-7.40 (m, 1 H), 7.33-7.26 (m, 1 H), 4.62 (t, 2 H, J = 5.3 Hz), 3.75-3.71 (m, 4 H), 
2.89 (t, 2 H, J = 5.3 Hz), 2.62-2.59 (m, 4 H); 13C NMR δ 154.2, 152.3, 129.5, 123.7, 120.6, 
120.5, 113.2, 112.4, 110.4, 70.6, 67.0 (2C), 57.7, 54.1 (2C); MS (EI) m/z (relative intensity) 241 
([M-HCl]+, 40), 213 (10), 85 (15); HRMS (EI) m/z calcd for C15H16N2O3 (M-HCl) 272.1161, 
found 272.1157. 
2-Benzyloxycarbonylamino-benzoicacid (108). To a solution of anthranilic acid (1.37 
g, 10.0 mmol) in THF (60 mL) was added K2CO3 (2.76 g, 20.0 mmol) in H2O (20 mL) at room 
temperature. The reaction mixture was cooled to 0 °C, treated with CbzCl (1.7 mL, 12 mmol), 
stirred for 2 h at room temperature, washed with Et2O (40 mL) and acidified to pH 1 with 1 N 
aqueous HCl solution. The resulting aqueous solution was extracted with EtOAc (50 mL×2), 
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 dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 108  (1.5 g, 55%) as a white solid: 1H 
NMR δ 11.4 (bs, 1 H), 10.4 (s, 1 H), 8.53 (d, 1 H. J = 8.5 Hz), 8.13 (d, 1 H, J = 8.0 Hz), 7.59 
(dd, 1 H, J = 8.5, 7.2 Hz), 7.50-7.30 (m, 5 H), 7.07 (dd, 1 H, J = 8.0, 7.2 Hz). 
[2-(2-Morpholin-4-yl-ethylcarbamoyl)-phenyl]-carbamic acid benzyl ester (109).  To 
a solution of 108 (1.36 g, 5.01 mmol) in DMF (50 mL) was added TEA (1.4 mL, 10 mmol), 4-
(2-aminoethyl)-morpholine (0.73 mL, 5.5 mmol), HOBt (0.88 g, 6.5 mmol) and EDCI (1.24 g, 
6.51 mmol) at room temperature. The reaction mixture was stirred for 20 h at room temperature, 
diluted with EtOAc (250 mL) and washed with saturated NaHCO3 solution (100 mL×2). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (EtOAc) to give 109 (1.13 g, 59%) as a colorless oil: 
IR (neat) 3324, 2950, 2858, 2822, 1746, 1649, 1582, 1516, 1450 cm-1; 1H NMR δ 10.6 (s, 1 H), 
8.39 (d, 1 H. J = 8.4 Hz), 7.50-7.30 (m, 7 H), 7.04 (dd, 1 H, J = 8.4, 7.4 Hz), 6.88 (bs, 1 H), 5.20 
(s, 2 H), 3.85-3.65 (m, 4 H), 3.55-3.45 (m, 2 H), 2.61-2.53 (m, 2 H), 2.50-2.40 (m, 4 H); 13C 
NMR δ 168.8, 153.7, 139.9, 136.3, 132.6, 128.6 (2C), 128.4 (2C), 128.3 (2C), 126.7, 122.0, 67.1 
(2C), 66.9, 56.7, 53.4 (2C), 36.0; MS (EI) m/z  (relative intensity) 383 (M+, 3). 271 (4), 275 (3); 
HRMS (EI) m/z calcd for C21H25N3O4 383.1845, found 383.1870. 
3-(2-Morpholin-4-yl-ethyl)-1H-quinazoline-2,4-dione (110). To a solution of 109 (720 
mg, 1.88 mmol) in MeOH (188 mL) was added TEA (2.6 mL, 19 mmol) at room temperature. 
The reaction mixture was heated at reflux for 2 d, cooled to room temperature and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(MeOH/CH2Cl2, 1:5) to give 110 (430 mg, 83%) as a white solid: Mp. 205-207 °C (CH2Cl2); IR 
(neat) 3278, 3196, 3048, 2950, 1726, 1649, 1501, 1450 cm-1; 1H NMR δ 10.6 (s, 1 H), 8.09 (d, 1 
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 H. J = 7.9 Hz), 7.61 (dd, 1 H, J = 8.1, 7.9 Hz), 7.22 (dd, 1 H, J = 8.1, 7.5 Hz), 7.09 (d, 1 H, J = 
8.1 Hz), 4.26 (t, 2 H, J = 6.7 Hz), 3.80-3.60 (m, 4 H,), 2.72 (t, 2 H, J = 6.7 Hz), 2.65-2.50 (m, 4 
H); 13C NMR δ 162.5, 152.3, 138.8, 135.1, 128.4, 123.5, 115.0, 114.6, 67.1 (2C), 56.1, 53.9 
(2C), 37.8; MS (EI) m/z  (relative intensity) 275 (M+, 3.5), 232 (1.5), 189 (3.5), 163 (4.5), 100 
(100); HRMS (EI) m/z calcd for C14H17N3O3 275.1270, found 275.1267. 
1-Methyl-3-(2-morpholin-4-yl-ethyl)-1H-quinazoline-2,4-dione (111). To a solution of 
110 (0.10 g, 0.36 mmol) in THF (5 mL) was added NaH (17 mg, 0.72 mmol) at room 
temperature. The reaction mixture was stirred for 1 h, treated with MeI (23 µL, 0.36 mmol) at 
room temperature, stirred for 2 d, quenched with brine (25 mL) and extracted with EtOAc (50 
mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:50) to give 111 (61 mg, 
58%) as a white solid: Mp. 138-140 °C  (CH2Cl2); IR (neat) 2950, 2853, 2811, 1716, 1660, 1598, 
1480 cm-1; 1H NMR δ 8.18 (d, 1 H. J = 7.9 Hz), 7.70-7.60 (m 2 H), 7.27-7.16 (m, 2 H), 4.22 (t, 2 
H, J = 6.9 Hz), 3.80-3.60 (m, 4 H), 3.58 (s, 3 H), 2.64 (t, 2 H, J = 6.9 Hz), 2.60-2.45 (m, 4 H); 
13C NMR δ 161.8, 151.0, 140.6, 135.2, 128.9, 123.0, 115.6, 113.6, 67.1 (2C), 56.0, 53.9 (2C), 
38.8, 30.8; MS (EI) m/z  (relative intensity) 289 (M+, 15), 246 (10), 203 (15); HRMS (EI) m/z 
calcd for C15H19N3O3 289.1426, found 289.1428. 
4-(2-Morpholin-4-yl-ethoxy)-2H-phthalazin-1-one (112). To a solution of 
phthalhydrazide (6.49 g, 40.0 mmol) in DMF (125 mL) was added NaH (960 mg, 40.0 mmol) at 
room temperature. The reaction mixture was stirred for 1 h and treated with 4-(2-iodoethyl)-
morpholine (980 mg, 4.07 mmol) at room temperature. The reaction mixture was stirred for 5 h 
at room temperature, quenched with saturated aqueous NaHCO3 solution (125 mL) and extracted 
with EtOAc (500 mL). The organic layer was dried (MgSO4) and concentrated under reduced 
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 pressure to give crude product (180 mg, 16%). The crude product was recrystallized from Et2O 
to give pure 112 (60 mg, 5%) as a white solid: Mp. 167-169 °C (Et2O); IR (neat) 3170, 3011, 
2909, 2883, 1654, 1593, 1485 cm-1; 1H NMR δ 11.6 (s, 1 H), 8.40-8.33 (m, 1 H), 7.97-7.90 (m, 1 
H), 7.78-7.70 (m, 2 H), 4.47 (t, 2 H, J = 5.5 Hz), 3.74 (t, 4 H, J = 4.3 Hz), 2.88 (t, 2 H, J = 5.5 
Hz), 2.62 (bt, 4 H, J = 4.3 Hz); 13C NMR δ 160.7, 151.0, 133.3, 131.9, 128.9, 126.8, 125.2, 
123.7, 66.9 (2C), 64.7, 57.3, 54.1 (2C); MS (EI) m/z  (relative intensity) 275 (M+, <1), 232 (1.5), 
189 (2), 100 (100); HRMS (EI) m/z calcd for C14H16N3O3 (M-H) 274.1192, found 274.1192. 
2-(2-Morpholin-4-yl-ethyl)-2,3-dihydro-phthalazine-1,4-dione (114). To a solution of 
NaOH (4.0 g, 0.10 mol) in hydrazine-hydrate (20 mL) was added 4-(2-chloroethyl)-
morpholine•HCl salt (1.86 g, 10.0 mmol) at room temperature. The reaction mixture was heated 
at reflux for 3 h, cooled to room temperature, diluted with H2O (30 mL) and extracted with 
chloroform (50 mL×2). The organic layer was dried (MgSO4) and concentrated under reduced 
pressure to give crude 113 (1.02 g, ~70%) as a yellow oil. A solution of crude 113 (1.02 g, 7.02 
mmol) and phthalic anhydride (1.04 g, 7.02 mmol) in xylenes (50 mL) was heated at reflux for 
14 h, cooled to room temperature and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:15) to give crude product (1.49 g, 
77%). The crude product was recrystallized from EtOAc to give pure 114 (640 mg, 33%) as a 
dark white solid: Mp. 167-169 °C (EtOAc); IR (neat) 3468, 2966, 2863, 1614, 1583 cm-1; 1H 
NMR δ 11.7 (bs, 1 H), 8.20-8.14 (m, 1 H), 7.87-7.81 m, 3 H), 4.07 (t, 2 H, J = 6.8 Hz), 3.55-3.40 
(m, 4 H), 2.64 (t, 2 H, J = 6.8 Hz), 2.50-2.35 (m, 4 H); 13C NMR (DMSO-d6) δ 159.1, 151.6, 
131.9, 130.9, 128.6, 126.4, 124.9, 123.5, 65.4 (2C), 56.5, 52.7 (2C), 43.5; MS (EI) m/z  (relative 
intensity) 275 (M+, 2), 257 (2), 189 (3), 175 (3), 162 (3), 133 (55), 100 (100); HRMS (EI) m/z 
calcd for C14H17N3O3 275.1270, found 275.1272. 
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 4-Methoxy-2-(2-morpholin-4-yl-ethyl)-2H-phthalazin-1-one (115).  A solution of 114 
(138 mg, 0.500 mmol) in acetone (5 mL) was treated with K2CO3 (69 mg, 0.50 mmol) and 
dimethyl sulfate (47 µL, 0.50 mmol) at room temperature. The reaction mixture was stirred for 
14 h at room temperature, diluted with EtOAc (50 mL) and washed with brine (25 mL). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (MeOH/CH2Cl2, 1:50 → 1:5) to give 115 (50 mg, 34%) 
as a white solid: Mp. 73-75 °C (CH2Cl2); IR (neat) 2946, 2849, 2815, 1651, 1590, 1340, 1115 
cm-1; 1H NMR δ  m, 1 H), 7.97-7.92 (m, 1 H), 7.87-7.72 (m, 2 H), 4.28 (t, 2 H, J = 6.9 
Hz), 3.97 (s, 3 H), 3.80-3.60 (m, 4 H), 2.82 (t, 2 H, J = 6.9 Hz), 2.65-2.50 (m, 4 H); 13C NMR δ 
158.7, 150.3, 132.7, 131.9, 129.0, 127.2, 124.7, 123.4, 67.1 (2C), 56.4, 54.2, 53.7 (2C), 47.4; MS 
(EI) m/z  (relative intensity) 289 (M+, 1), 271 (4), 203 (5), 177 (7), 113 (70), 100 (100); HRMS 
(EI) m/z calcd for C15H19N3O3 289.1426, found 289.1425. 
7-(2-Morpholin-4-yl-ethyl)-6,7-dihydro-pyrido[2,3-d]pyridazine-5,8-dione (116). A 
solution of (2-morpholin-4-yl-ethyl)-hydrazine (0.75 g, 5.0 mmol) and pyridine dicarboxylic 
anhydride (1.09 g, 7.50 mmol) in toluene (50 mL) was heated at reflux for 16 h, cooled to room 
temperature and concentrated under reduced pressure. The crude residue was washed with Et2O 
and recrystallized from EtOAc to give a ~5:1 mixture of regioisomers (570 mg, 41%). A sample 
of pure major regioisomer 116 was obtained by chromatography on SiO2 (MeOH/CH2Cl2, 1:15 
→ 1:5): Mp. 192-195 °C (CH2Cl2); IR (neat) 3375, 3006, 2950, 2878, 1634, 1567 cm-1; 1H NMR 
(MeOH-d4) δ  (b, 1 H, J = 1.6 Hz), 7.65 (d, 1 H, J = 7.8 Hz), 7.35 (dd, 1 H, J = 7.8, 1.6 
Hz), 4.16 (t, 2 H, J = 5.2 Hz), 3.80-3.60 (m, 4 H), 3.12 (bt, 2 H, J = 5.2 Hz), 3.00-2.80 (m, 4 H); 
13C NMR (MeOH-d4) δ 159.4, 155.1, 154.4, 144.9, 134.8, 128.6, 124.5, 66.1 (2C), 57.1, 53.9 
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 (2C), 46.1; MS (EI) m/z  (relative intensity) 276 (M+, 3), 190 (2); HRMS (EI) m/z calcd for 
C13H16N4O3 276.1222, found 276.1222. 
Caulibugulone A. To a solution of 5-hydroxy-isoquinoline (90%, 0.80 g, 5.0 mmol) in 
EtOH/H2O (20 mL/2 mL) was added PIFA (4.28 g, 12.0 mmol) at room temperature. The 
reaction mixture was stirred for 1 h and treated with CeCl3 (2.4 g, 10 mmol) and methylamine 
(2.0 M in MeOH, 20 mL, 40 mmol) at room temperature.  The reaction mixture was stirred for 
20 h and concentrated under reduced pressure. The crude residue was diluted with EtOAc (250 
mL) and washed with brine (100 mL). The organic layer was dried (MgSO4) and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(Hexanes/EtOAc, 1:1) to give a mixture of caulibugulone A and its regioisomer (0.48 g, 51%, 
~4:1 ratio by 1H NMR). Further separation by chromatography on SiO2 (CH2Cl2/MeOH, 200:1 
→ 100:1) gave caulibugulone A as a red solid: Mp. 228-230 °C (Dec.); IR (neat) 3263, 1685, 
1598, 1501, 1419, 1173, 1075, 830 cm-1; 1H NMR (CDCl3/CD3OD, 1:1) δ 9.14 (s, 1 H), 8.92 (d, 
1 H, J = 4.5 Hz), 7.91 (d, 1 H, J = 4.5 Hz), 5.76 (s, 1 H), 2.92 (s, 3 H); 13C NMR 
(CDCl3/CD3OD, 1:1) δ 181.4 (2C), 156.1, 150.7, 147.8, 140.7, 125.6, 120.0, 100.6, 29.3; MS 
(EI) m/z  (relative intensity) 188 (M+, 100), 173 (30), 159 (14), 131 (20), 105 (21), 82 (64); 
HRMS (EI) m/z calcd for C10H8N2O2 188.0586, found 188.0583. 
Caulibugulone B. To a solution of caulibugulone A (30 mg, 0.16 mmol) in dioxane (4 
mL) was added NBS (29 mg, 0.16 mmol) in dioxane (1 mL) at room temperature. The reaction 
mixture was stirred for 4 h and concentrated under reduced pressure. The crude residue was 
directly purified by chromatography on SiO2 (CH2Cl2 → CH2Cl2/MeOH, 50:1) to give 
caulibugulone B (32 mg, 74%) as a dark red solid: Mp. 182-184 °C (Dec.); IR (neat) 3278, 
1690, 1583, 1542, 1419, 1291 cm-1; 1H NMR (pyridine-d5) δ 9.36 (s, 1 H), 9.00 (d, 1 H. J = 5.0 
 98
 Hz), 8.20 (bs, 1 H, -NH), 7.98 (d, 1 H, J = 4.9 Hz), 3.39 (d, 3 H, J = 5.7 Hz); 13C NMR 
(pyridine-d5) δ 180.1 (2C), 156.1, 148.4 (2C), 138.2, 119.2, 33.0 (2 carbons are missing in 
solvent peaks); MS (EI) m/z  (relative intensity) 266 (M+, 100), 187 (49), 160 (39), 82 (23); 
HRMS (EI) m/z calcd for C10H7BrN2O2 265.9691, found 265.9695. 
Caulibugulone C. To a solution of caulibugulone A (9.4 mg, 0.050 mmol) in MeOH (5 
mL) was added NCS (6.7 mg, 0.050 mmol) at room temperature. The reaction mixture was 
stirred for 20 h and concentrated under reduced pressure. The crude residue was directly purified 
by chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give caulibugulone C (9.1 mg, 82%) as a 
dark red solid: Mp. 219-221 °C (Dec.); IR (neat) 3274, 1689, 1588, 1563, 1417, 1316 cm-1; 1H 
NMR (pyridine-d5) δ 9.35 (s, 1 H), 9.01 (d, 1 H, J = 5.0 Hz), 8.35 (bs, 1 H, -NH), 7.98 (d, 1 H, J 
= 5.0 Hz), 3.38 (d, 3 H, J = 5.6 Hz); 13C NMR (pyridine-d5) δ 180.5 (2C), 156.3, 148.4 (2C), 
146.6, 138.6, 119.2, 32.5 (1 carbon is missing in solvent peaks); MS (EI) m/z  (relative intensity) 
222 (M+, 100), 187 (51), 160 (35), 131 (25); HRMS (EI) m/z calcd for C10H7ClN2O2 222.0196, 
found 222. 0194. 
Caulibugulone D. To a solution of 5-hydroxy-isoquinoline (90%, 200 mg, 1.25 mmol) in 
EtOH/H2O (10 mL/1 mL) was added PIFA (1.07 g, 2.50 mmol) at room temperature. The 
reaction mixture was stirred for 2 h and treated with CeCl3.7H2O (930 mg, 2.50 mmol) and 
ethaolamine (0.60 mL, 10 mmol) at room temperature.  The reaction mixture was stirred for 20 
h, diluted with EtOAc (100 mL) and washed with brine (50 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (EtOAc → CH2Cl2/MeOH, 50:1→ 10:1) to give a mixture of 
caulibugulone D and its regioisomer (68 mg, 25%, ~7:1 ratio by 1H NMR). Further separation by 
chromatography on SiO2 (CH2Cl2/MeOH, 100: 1) gave caulibugulone D as a dark orange solid: 
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 Mp. 189-191 °C (Dec.); IR (neat) 3335, 3168, 2921, 2846, 1680, 1633, 1593, 1562, 1301, 1059 
cm-1; 1H NMR (CDCl3/CD3OD = 1: 1) δ 9.17 (s, 1 H), 8.94 (d, 1 H. J = 4.2 Hz), 7.91 (d, 1 H, J = 
5.0 Hz), 5.86 (s, 1 H), 3.78 (t, 2 H, J = 5.4 Hz), 3.35 (t, 2 H, J = 5.4 Hz); 13C NMR 
(CDCl3/CD3OD, 1:1) δ 181.0, 180.5, 155.4, 149.2, 147.2, 140.0, 125.0, 119.3, 100.5, 59.0, 44.7; 
MS (EI) m/z  (relative intensity) 218 (M+, 22), 200 (23), 187 (100); HRMS (EI) m/z calcd for 
C11H10N2O3 218.0691, found 218.0691. 
Caulibugulone E. To a solution of caulibugulone A (230 mg, 1.22 mmol) in CH2Cl2 (25 
mL) was added Ti(O-iPr)4 (1.7 mL, 6.1 mmol) and ammonia (7N in MeOH, 3.6 mL, 25 mmol) at 
room temperature. The reaction mixture was stirred for 7 d and directly purified by 
chromatography on SiO2 (CH2Cl2/MeOH, 50:1 → 10:1) to give caulibugulone A (34 mg, 15%) 
and caulibugulone E (170 mg, 74%) as an orange solid: Mp. 228-230 °C (Dec.); IR (neat) 3351, 
3210, 1618, 1571, 1545, 1519, 1413, 1365, 1280, 1069 cm-1; 1H NMR (CDCl3) δ 11.1 (bs, 1 H, 
=NH) 9.06 (s, 1 H), 8.89 (d, 1 H. J = 4.9 Hz), 8.00 (d, 1 H, J = 4.9 Hz), 6.80 (bs, 1 H, -NH), 5.78  
(s, 1 H), 3.00 (d, 3 H, J = 5.3 Hz); 13C NMR (DMSO-d6) δ 179.5, 158.3, 153.5, 153.2, 147.1, 
137.3, 123.8, 118,6, 98.4, 29.5; MS (EI) m/z  (relative intensity) 187 (M+, 100), 158 (29), 130 
(57), 103 (28), 76 (29); HRMS (EI) m/z calcd for C10H9N2O 187.0746, found 187.0744. 
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 2. Fragmentation Studies toward the Total Synthesis of Parvistemonine 
2.1. Introduction 
2.1.1. Parvistemonine & Other Stemona Alkaloids 
 
The Stemona alkaloids are a class of structurally relatively complex polycyclic alkaloids 
(Figure 26). They have attracted considerable attention from organic chemists since the structural 
elucidation of tuberostemonine ca. 40 years ago.75 The chemical investigation of Stemonaceae 
plants was initially motivated by their use in the Chinese and Japanese folk medicine as 
insecticides and drugs for the treatment of respiratory diseases such as bronchitis, pertussis, and 
tuberculosis, as well as antihelmintics.75 To date, the structures of ca. 50 Stemona and Croomia 
alkaloids have been elucidated by a combination of crystallographic, spectroscopic and 
degradative techniques. In spite of their highly attractive spectrum of biological effects, synthetic 
studies towards the Stemona alkaloids are still quite limited.75 So far syntheses of stenine,76 
croomine,77 isostemofoline,78 stemoamide,79 stemospironine,80 stemonamide,81 isostemonamide,81 
stemonine,82 tuberostemonine,83 didehydrostemofoline84 and isodehydrostemofoline84 have been 
reported. Thus, a concise and general entry into this structurally challenging and 
pharmaceutically attractive class of natural products appears highly desirable. 
Parvistemonine was isolated from the roots of Stemona parviflora collected in Heinan, 
China.85 It has probably the most unique and interesting functional group array of the Stemona 
alkaloids. A γ-butyrolactone and a fused furanofuranone are attached to the central 
azepinopyrrolidine. In addition to a total of 10 chiral centers, ring systems are connected via 
asymmetric carbons. Parvistemonine represents therefore one of the most challenging and 
unusual synthetic targets in the Stemona family. 
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Figure 26. Stemona alkaloids and parvistemonine 
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 2.1.2. Wipf Group Research on Stemona Alkaloids 
 
The Wipf group has had a long-standing interest in the synthesis of Stemona alkaloids since 
the report of the synthesis of the novel hydroindole 1.86 Hydroindole 1 was synthesized in a 
highly stereoselective manner from very readily available tyrosine (Scheme 31). After some 
optimization of the oxidizing reagent, N-protected tyrosine was cyclized to give spirolactone 2 
by treatment with a slight excess of iodobenzene diacetate. Then, methanolysis of lactone 2 at 
ambient temperature in the presence of NaHCO3 cleanly lead to the hydroindole 1 as the major 
diastereomer. In contrast, methanolysis of lactone 2 at 0 °C provided exclusively dienone 3, 
which was converted to hydroindole 1 in MeOH in the presence of NaHCO3. Hydroindole 1 
could also be obtained directly from N-protected tyrosine by oxidation in the presence of sodium 
bicarbonate. 
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Scheme 31. Synthesis of hydroindole 112 
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 Taking advantage of the novel preparation of hydroindole 1, Wipf, Kim and Goldstein 
reported the first asymmetric total synthesis of (−)-stenine in 1995 (Scheme 32).76(b) This 
synthesis began with the benzoylation and Luche reduction of hydroindole 1 to give equatorial 
alcohol 4 in 89%.  Reduction of the π-allylpalladium complex derived from allylic benzoate 4 at 
the more hindered tertiary carbon was accomplished in 68% yield by the use of catalytic 
tris(dibenzylideneacetone)-dipalladium (0) chloroform complex, triethyl phosphine and 
triethylammonium formate, after considerable optimization of the reaction conditions. Oxidation 
of allylic alcohol 5 with TPAP regenerated the enone, which was deprotonated with KHMDS 
and reacted with triflate to give enone 6 in 46% yield. Luche reduction of enone 6 was followed 
by Eschenmoser-Claisen rearrangement to provide 7 in 77% yield. Functional group 
manipulations at the terminal alkene of 7 and pyrrolidine ring of 8 resulted in 9. 
Iodolactonization of 9 under pH 5.5 conditions, followed by Keck allylation gave lactone 10 in 
77% yield. Methylation of lactone 10 occurred selectively in 87% yield from the sterically more 
accessible face, and subsequent conversion of the allyl to a vinyl group by a Johnson-Lemieux 
oxidation, reduction and Grieco-elimination sequence provided tricyclic 11. Closure of the 
azepine, the last remaining ring of the tetracyclic stenine, was initiated by desilylation of 11 and 
oxidation of the primary alcohol to the acid by sequential treatment with Dess-Martin 
periodinane and sodium chlorite. Without purification, the resulting acid was directly 
hydrogenated and cyclized with FDDP to give amide 12. Conversion of the amide 12 to the 
thioamide with Lawesson’s reagent and desulfirization with Raney nickel finally provided (−)-
stenine. Through this elegant total synthesis, they not only realized the first aymmetric route to 
(−)-stenine, but also showed the potential for pyrrolidine alkaloid synthesis offered by the ready 
availability of hydroindole 1.  
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Scheme 32. Total synthesis of (−)-stenine2(c) 
 105
  
Wipf, Rector and Takahashi reported the first asymmetric total synthesis of (−)-
tuberostemonine in 2002, utilizing hydroindole 1 as a starting material (Scheme 33).83 The 
synthesis began with an improvement of the π-allylpalladium reaction for allyl alcohol 5. 
Silylation of the secondary alcohol, followed by carbamate deprotection, gave amine 13 in 90% 
yield. Cinnamylation of the amine 13, desilylation, TPAP oxidation and a stereoselective allylic 
alkylation sequence provided enone 14, which was converted to the tricyclic compound by a key 
ring closing metathesis reaction with Grubb’s second-generation catalyst. The resulting double 
bond in tricyclic compound was removed via a high-yielding, three-step sequence to give 
tricyclic 15 after transient protection of the enone double bond by conjugate addition-β-
elimination of thiophenol. Ester 16 was obtained as a single diastereomer after Luche reduction 
and TBDMS protection. In preparation for the introduction of the right-side butyrolactone, 
addition of the Weinreb amide, derived from ester 12, to a solution of the lithium anion formed 
from bromo ortho ester 17 and LiDBB provided ketone 18 in excellent yield. The carbonyl group 
was subsequently reduced to give the alcohol in a ~7:1 diasteremeric ratio.  Exposure of this 
mixture of alcohol to TsOH in methanol removed both ortho-ester and silyl enol ether protecting 
groups and also catalyzed cyclization, affording the desired lactone 19. Claisen rearrangement, 
followed by selenolactonization provided 20, which was converted to 21 by Keck-allylation, α-
methylation and isomerization. Cross-metathesis of 21 in the presence of ethane and Ru catalyst 
22 and TsOH, followed by a catalytic hydrogenation over Pd on carbon completed the first total 
synthesis of (−)-tuberostemonine. 
 106
 N
Cbz
CO2Me
H
HO
H 1. TBSCl, Im, DMAP
2. Et3SiH, Pd(OAc)2
TEA, CH2Cl2
N
H
CO2Me
H
TBSO
H
90%
Ph Br1.
K2CO3, tol, 96%
2. TBAF, THF, 96%
3. TPAP, NMO, 88%
4. KHMDS, allyl iodide
66%
N
CO2Me
H
H
O
Ph
1. Grubb's second
CH2Cl2, 92%
2. PhSH, TEA, CH2Cl2
3. (PPh)3RhCl, H2
EtOH/CH2Cl2
4. DBU , CH2Cl2, 81%
N
CO2Me
H
H
O
1. NaBH4
CeCl3.7H2O
2. TBSCl, Im, DMAP
71%
79%
N
CO2Me
H
H
TBSO
1. (Me)(OMe)NH.HCl
MeAlCl2, CH2Cl2, 94%
2.
Br O
O
O
LiDBB, THF, 95%
N
H
H
TBSO O
O
O
O
1. L-selectride
THF, 80%
2. TsOH, MeOH
70%
N
H
H
HO
H
H
O
O
1. H3CC(OMe)2NMe2
heat, 78%
2. PhSeCl, CH3CN/H2O
67%
N
H
H
H
H
O
O
O
O
PhSe
1. AIBN, SnPh3
70%
2. LDA, HMPA, MeI, 76%
3. Grubb's second
allytritylamine, DIEA, tol
heat, 85%
N
H
H
H
H
O
O
O
O
1. TsOH, MesN NMes
Ru
Cl
Cl
O
i-Pr
, 82%
2. Pd/C, H2, MeOH, 97%
N
H
H
H
H
O
O
O
O
(-)-Tuberostemonine
5 13
14
15
16
17 18
19
20
21
22
ethylene,
 
Scheme 33. Total synthesis of (−)-tuberostemonine9
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 2.1.3. Alkoxy Radical Fragmentations  
 
Free radical reactions have become increasingly important in organic synthesis in the last 
two decades.87 Especially carbon-centered radicals are now well studied and widely used.87 In 
contrast, use of oxygen-centered radicals in organic synthesis is still somewhat limited because 
of a relative neglect of this field in comparison with carbon-centered radicals.88 
Alkoxy radicals can react with oxygen, isomerize, or undergo C-C fission as illustrated in 
Scheme 1.88 In general, alkoxy radicals will cleave to give a ketone (or aldehyde) and the most 
stable possible alkyl radical.88 
 
O
O
+
or
CH3
O
O2
O
+ H2O
O
H
C-C Fission Oxidation 1,5-H-Abstraction
 CH2CH2CH3
OH
 
Scheme 34. Reactions of alkoxy radicals88 
 
Alkoxy radicals have been generated by various methods  (Scheme 35).88,89 They can be 
generated by homolytic cleavage of O-X bonds under photolytic or thermal conditions.89 A 
famous example of this process is the Barton reaction.90 Alkoxy radicals can also be generated 
by oxidative cleavage of O-H bonds.88 Another method for generating alkoxy radicals is radical 
transfer to ketone (or aldehyde) functional groups from carbon-centered radicals.91 
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Scheme 35. Methods for generation of alkoxy radicals 
 
Suárez and co-workers introduced photoactivated iodobenzene diacetate /iodine (Suárez 
reagent), a reagent that reliably converts hydroxy-containing substrates (alcohols, carboxylic 
acids, carbohydrates, lactols) into products derived from intermediate oxygen-centered free 
radicals.92 Unlike many other reagent combinations,88,89 conversions using this reagent do not, so 
far, appear to be complicated by consumption of first-formed products. These reactions, for 
alcohols, are assumed to involve intermediate hypohalites (Scheme 36).93 
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Scheme 36. Generation of alkoxy radicals by the Suárez reagent92 
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 The oxidative cleavage of alkoxy radicals attached to fused bicyclic systems may result 
in the formation of medium-sized rings. For example, the oxidative fragmentation of hydroindole 
1 may lead to either the formation of a 9-membered ring via cleavage of the C3a-C7a bond or the 
formation of a pyrrolidine ring via cleavage of the C3a-C4 bond (Figure 27). We envisioned that 
the formation of a 9-membered ring from hydroindole 1 could be utilized in the total synthesis of 
tuberostemonone,94 whereas the formation of pyrrolidine ring could be utilized in the total 
synthesis of parvistemonine.95 
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Figure 27. Oxidative cleavage of hydroindole 1 
 
 
 
In this context, new methodology for the ring expansion of 4-hydroxyindoles such as 23 
to azanonanes was recently reported by our group in an effort toward the total synthesis of 
tuberostemonone (Scheme 37).94 We reported that treatment of 23 with iodine and iodobenzene 
diacetate (Suárez conditions) resulted in the formation of azonane 27 presumably via 
intermediate 25, where the radical is stabilized by the adjacent nitrogen atom.  
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Scheme 37. The ring expansion of 4-hydroxyhydroindole 23 
 
We need to direct the oxidative cleavage to afford products arising from C3-C4 bond 
fragmentation of 4-hydroxyindole 1 for a synthesis of parvistemonine (Figure 27). However, 
such a cleavage in a hydroindole system proved to be difficult without a proper directing group 
because of the radical stabilization effect of the nitrogen atom in 4-hydroxyindole 1, which 
facilitates cleavage of the C3a-C7a bond. Thus, we tried to develop a strategy for specific C3-C4 
bond fragmentation of 4-hydroxyindole 1, overcoming the radical stabilization effect of the 
nitrogen atom. 
The Suárez group had reported a new protocol for the synthesis of nitriles by β-
fragmentation of alkoxy radicals derived from β-hydroxy azides in the presence of  
(diacetoxyiodo)benzene (DIB) and iodine.96 In particular, this reagent was applied to the 
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 synthesis of chiral nitriles by the β-fragmentation of anomeric alkoxy radicals from 2-azido-2-
deoxysugars as shown in Scheme 38. For example, azidosugar 28 was treated with Suarez 
reagent in dichloromethane solution to provide nitrile 32. The proposed mechanism deserves 
some more comment. The C(2) radical initially formed must be oxidized by the reagent to a 
carbocation in order for the nitrile group to be formed after loss of molecular nitrogen.97 
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Scheme 38. Radical cleavage of a β-hydroxy azide 
 
 
Based on this result, we hypothesized that the C(3a)-C(4) cleavage of the hydroindole 
framework would be feasible via an azido fragmentation reaction. Treatment of hydroindole 33 
with PhI(OAc)2/I2 led indeed to oxidative fragmentation of the β-hydroxy azide moiety and 
resulted in the exclusive formation of keto nitrile 38 via radical cleavage of the lateral C-C bond 
(Scheme 39).95 The formation of 38 may be explained by an oxidative fragmentation as proposed 
by the Suárez group.  Although the transannular cleavage intermediate 35 and the lateral C-C 
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 bond cleavage intermediate 36 may both be accessible from the initial alkoxy radical 34, rapid 
and irreversible oxidation of 36 to 37 followed by elimination of N2 provided ketonitrile 38.   
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Scheme 39. Radical cleavage of a β-hydroxy azide21
 
However, ionic mechanisms cannot be excluded as alternatives and Scheme 40 shows 
one possible example for an ionic mechanism. 
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Scheme 40. An alternative ionic mechanism  
 
 
2.2. Strategy and Goals 
2.2.1. Initial Synthetic Scheme for Parvistemonine 
 
Scheme 41 outlines briefly our retrosynthetic approach toward parvistemonine. In this 
scheme, the key reaction is the application of the azido alcohol fragmentation that we have 
recently reported95 and which is discussed in the previous chapter. Starting from L-tyrosine via 
bicyclic 40, we will obtain the fragmentation product 39.  Intramolecular Michael addition to the 
α,β-unsaturated nitrile function of 39, followed by acid-mediated cyclization of the remaining 
secondary alcohol into the nitrile group and hydrolysis of the resulting imidate should furnish the 
novel A/B-ring system of the target molecule. The natural configuration of the A/B-ring system 
appears to be thermodynamically favored based upon our modeling studies.98 Therefore, two of 
the five stereocenters in the A/B-ring will rely on equilibrating conditions.  
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Scheme 41. Retrosynthetic analysis of parvistemonine 
 
Our synthesis will commence with 186  (Scheme 42). First, protection of the hydroxy 
group of 1 with TMSCl, followed by epoxidation and TMS enol ether formation will provide 41. 
Treatment of 41 with a Grignard reagent and catalytic CuI will give the secondary alcohol 
resulting from an anti-selective SN2’ substitution99 and mesylation and elimination will 
regenerate the enone functionality in 42. Luche reduction of 42, followed by mesylation and a 
second SN2’-substitution with a vinyl cuprate reagent should furnish diene 43. Bis-epoxidation of 
43 with MCPBA, followed by azidolysis with lithium azidohydridoisobutylaluminate100 will 
provide azido alcohol 44. In this sequence, epoxidation should occur mostly from the β-face of 
the bicycle (the stereoselectivity of the concomitant epoxidation of the side chain alkene is not 
important for the synthesis) and azide will preferentially open the terminally unsubstituted 
epoxide. 
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Scheme 42. Planned total synthesis of parvistemonine 
 
Next, the addition of  (R)-[BnOCH(CH3)]2CuLi101 to epoxide 44 and benzylation of  the 
resulting alcohol will give 45 (Scheme 43). Although it is difficult to predict what the 
regioselectivity of the addition step will be, inspection of models allows rationalization for either 
regioisomeric an attack based on the fact that the six-membered ring of the bicycle should be in a 
boat conformation. The major isomer is believed to be formed by an attack distant to the tertiary 
alcohol due to electrostatic repulsions.102 In case the incorrect regioisomer is favored, we will 
attempt dihydroxylation of the endocyclic alkene, selective triflation of the sterically more 
accessible C(5) alcohol and a direct SN2 displacement. Preparation of fully functionalized 46 sets 
the stage for the crucial fragmentation step. Since the nitrile side chain in the model study95 fell 
two carbons short of what is needed for parvistemonine, we will attempt a novel vinylogous 
azido alcohol fragmentation. Vinyl azide 46 will be generated by mesylation/elimination103 and 
 116
 TMS-ether deprotection of 45. The α,β-unsaturated nitrile 49 will be obtained via 47 and 48 by 
treatment of 46 with hypervalent iodine reagent and iodine. 
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Scheme 43. Planned total synthesis of parvistemonine 
 
Relatively mild tosyl hydrazone reduction104 of 49, and selective removal of the benzyl 
protective groups in the presence of the alkene with Pd(OAc)2/Et3SiH105 will generate triol 50 
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 which is expected to close via intramolecular Michael and nitrile additions followed by 
hydrolysis of the intermediate imidate to the  desired tetrahydrofuranyl tetrahydrofuran 51 
(Scheme 44).106 Azepine ring closure of 51 will provide the advanced intermediate 52. Treatment 
of 52 by the standard sequence with organolithium reagent 53 that we have used for 
tuberostemonine and tuberostemonone preparations will lead to the remaining ring. The selective 
conversion of the methyl ester moiety in 53 to the hydroxamate as well as the subsequent 
reaction with the organolithium reagent in the presence of a lactone might stir some controversy.  
However, we believe that the steric shielding and the electronic deactivation around the lactone 
are sufficient to protect it from these transformations.  
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Scheme 44. Planned total synthesis of parvistemonine 
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 2.2.2.    Vinylogous Alkoxy Azido Radical Fragmentation Reaction 
 
The proposed synthetic scheme for parvistemonine requires a vinylogous alkoxy azido 
radical fragmentation reaction as a key step. Though alkoxy azido fragmentation reactions were 
reported as discussed earlier, the vinylogous version of this reaction is novel. Thus, before 
embarking on this preparation of the fully functionalized system, we decided to study the 
vinylogous azido alcohol fragmentation in a simplified model system to check the feasibility of 
this reaction. Our initial strategy was to synthesize hydroxy vinyl azide 54 from hydroindole 1 as 
a substrate for the fragmentation.  We were going to try the vinylogous azido alcohol 
fragmentation of 54 with PhI(OAc)2/I2 to hopefully generate the desired α,β-unsaturated  nitrile 
57 ().   
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Scheme 45. Model study for fragmentation 
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 Although 54 was chosen as the first substrate for a model study, the synthesis of 54 was 
still challenging because of the introduction of the isopropenyl group and the subsequent 
manipulations toward the vinyl azide. Therefore, compound 58 was also selected as a second 
substrate (Scheme 46). It is advantageous to use 58 as a substrate for the fragmentation because 
isopulegol, the starting material for 58, has an isopropenyl group already located in the right 
position next to the alcohol group.  
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Scheme 46. Simplified model study for fragmentation 
 
We also envisioned that it would be worthwhile to pursue an even more readily available 
substrate because we could test the feasibility of the fragmentation reaction more quickly. In 
addition, the synthetic methods for this study could be used in the second model system. 
Therefore, we decided to synthesize 62 starting from isopulegol and test the vinylogous alkoxy 
azido fragmentation (Scheme 46). 
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Scheme 47. Third model study for fragmentation 
 
These model studies might not solve all outstanding issues even if we succeeded in 
obtaining the desired products via fragmentation reactions. First of all, we cannot pursue any 
further elaboration of the resulting α,β-unsaturated nitriles.  Next, we cannot be absolutely sure 
of the success of a fragmentation in the total synthesis of parvistemonine because radical 
fragmentation reactions are usually very substrate dependent.107 Therefore, the applicability of 
this reaction toward the total synthesis of parvistemonine was still going to remain questionable. 
In spite of these problems, model studies can be justified because of the novelty of the 
vinylogous azido alcohol fragmentation for generating α,β-unsaturated nitriles in an 
unprecedented manner.  
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 2.3. Results and Discussion 
2.3.1. Fragmentation Model Studies 
 
As discussed in Section 2.2, we initially wanted to synthesize hydroxy vinyl azide 54 for a 
model study of the vinylogous alkoxy azido fragmentation. Exposure of Cbz-tyrosine to 
PhI(OAc)2 in the presence of sodium bicarbonate and sodium carbonate gave 1 in low to 
moderate yield (Scheme 47).  This reaction worked more successfully on small scale, but poorly 
on large scale (> 10 g). Nonetheless, alcohol 3 was protected as a TMS-ether with TMSCl to 
give 66. Unfortunately, many attempts for a 1,4-addition of the isopropenyl group to 66 did not 
give the desired product 67.  
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Scheme 48. Attempted synthesis of the first model system 
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 While we were not quite sure why we were unable to obtain the desired 1,4-addition 
product at this point, we decided to proceed to the second model study and revisit this first model 
system later. We found subsequently that the use of a free hydroxy group in hydroindole 1 was 
critical for the success of the conjugated reaction. For the second model study, we selected 77 as 
the target substrate for the fragmentation reaction and we thought that 78 would be readily 
prepared from the known compound 72108 (Scheme 48). For the synthesis of 78, we first 
prepared ketone 70 according to literature procedures.109 Then, isopulegol (technical, ~70%) was 
subjected to Jones oxidation and the resulting ketone 71 was reacted with 70 in the presence of 
LDA to give 72. Treatment of 72 with Ba(OH)2 at 0 oC provided 73. The structure of 73 was 
confirmed by comparison of NMR data with the literature.108 Reduction of 73 with NaBH4 in 
EtOH gave diol 74 as a single diastereomer. Though the stereochemistry of the secondary 
alcohol of 74 was not important, it was tentatively assigned as α based on the previous reports 
and NMR analysis.110 The secondary alcohol group in 74 was then selectively methylated with 
excess MeI to give methyl ether 75. Epoxidation of 75 with MCPBA provided 76 as a single 
diastereomer in good yield (the stereochemistry was not determined). The epoxide was subjected 
to azidolysis with NaN3 in the presence of NH4Cl to give hydroxy azide 77 along with a 
regioisomer, which was generated by attack of azide at the more hindered carbon. Other 
conditions for azidolysis with various catalysts proved to be unpractical.111 In addition, after 
considerable attempts for dehydration, we found that only trace amounts of the desired vinyl 
azide 78 as an inseparable mixture with other isomers could be obtained from the reaction of 77 
with TsCl in the presence of KOH. In most other cases, the undesired alkene 80 was obtained as 
the major isomer. These results may be explained by insufficient acidity of the α-position of the 
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 azide, the thermodynamic instability of the desired vinyl azide or steric effects. In other to avoid 
these problems, we decided to change the strategy and generate the vinyl azide at an early stage.  
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Scheme 49. Attempted preparation of the second model system 
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 Though we had considered several possible literature transformations,111 we could only 
test some reactions for the synthesis of the vinyl azide due to the potential danger in the use of 
low boiling azides (Scheme 50).112 
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Scheme 50. Some possible transformations for the synthesis of vinyl azides 
 
Two routes were examined for the synthesis of the vinyl azide (Scheme 51). One method 
was to use the same protocol as in the second model study to synthesize a vinyl azide in at a 
relatively early stage and to separate the desired vinyl azide from other regioisomers. This 
approach was thought to be only feasible if the generation of vinyl azide would be preferred due 
to reduced steric hindrance and the separation would be easy. An alternative method was to use a 
Peterson-type olefination in order to achieve much better regioselectivity, while a relatively long 
reaction sequence would be required.  
 125
 1)  Hydroxy Azide
R R
O
mCPBA NaN3 R
N3
OH
dehydration R
N3
advantage: common and known method problem: regioselectivity of dehydration step
2)  Peterson-Type Olefination
R
or OsO4, NaIO4
R
O
or Ph3P=CHI
CHI3, CrCl2 R
I
t-BuLi, TMSCl R
TMS
mCPBA
R
TMS
ONaN3
R
TMS
N3
H+R
N3
advantage: easy control of regioselectivity problem: a long reaction sequence
OH
O3
 
Scheme 51. Alternative methods for vinyl azide preparation 
 
After significant experimentation pursuing these two routes, we could identify a suitable 
method to generate the desired hydroxy vinyl azide in a satisfactory sequence (Scheme 52). 
Treatment of (±)-isopulegol with MCPBA gave epoxide 81 as ~1:1 mixture of diastereomers in 
good yield. Epoxide 81 was then subjected to azidolysis with NaN3 to give azide 82, which could 
be isolated as a predominantly single isomer along with a trace of a minor isomer. Since the yield 
was moderate, one of the two diastereomers of epoxide 81 might have been less reactive or 
decomposed preferentially. Selective protection of the secondary hydroxy group in azido alcohol 
82 as the MOM ether with MOMCl gave 83. Treatment of 83 with SOCl2 and pyridine114 
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 followed by treatment with concentrated HCl gave the desired hydroxy vinyl azide 84 along with 
other regioisomers. Fortunately, in this case, the separation of 88 was possible by 
chromatography on SiO2. 
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Scheme 52. Synthesis of hydroxy vinyl azide 84 
 
Alternatively, vinyl azide 84 was synthesized according to Scheme 53. In this route, 
isopulegol was first protected with MOMCl to give MOM ether 85. Then, MOM-protected 
isopulegol 85 was transformed into epoxide 86 (~1:1 diastereomeric ratio) by epoxidation with 
MCPBA. Azidolysis of 86 with NaN3 gave 83 which also underwent dehydration and 
deprotection as described previously. Compared with the previous route described in Scheme 52, 
this route was better because overall yield of this route was 23%, whereas that of the previous 
route was 8%. 
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Scheme 53. Alternative route for the synthesis of hydroxy vinyl azide 84 
 
With the desired hydroxy vinyl azide 84 in hand, we wanted to synthesize the tertiary 
alcohol substrate 88 to test the fragmentation reaction (Scheme 54). First, Dess-Martin reaction 
of 84 gave 87 in 81% yield and Grignard reaction of 87 with MeMgBr gave 88 in good 
diastereoselectivity, presumably due to preferential α-attack of the Grignard reagent.114 Now, the 
stage was set for attempting the first vinylogous azido alcohol fragmentation. The initial attempt 
for this reaction was made using excess PhI(OAc)2 and iodine, but failed to generate the desired 
product 89. A second attempt was made using 1.5 equiv. of PhI(OAc)2 and 1.5 equiv. of iodine 
and gave the desired product 89 in 49% yield. The third attempt used 1.5 equiv. of PhI(OAc)2 
and 1.5 equiv. of iodine and gave the desired product 89 in 69% yield. Further separation and 
NMR analysis showed that 71 was obtained as a 6:1 E/Z mixture, and the double bond geometry 
was determined by the comparison of the 1H NMR spectrum with a closely related compound.115 
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Scheme 54. The first successful fragmentation reactions  
 
Encouraged by these results, we moved to a bicyclic system to test the generality of this 
novel fragmentation process. Treatment of 87 with 70 in the presence of LDA, followed by 
treatment with 1N HCl gave diketone 91 (Scheme 55). Diketone 91 was then cyclized to give 
bicyclic 92 by an aldol type reaction with Ba(OH)2. Reduction of 92 with NaBH4 and CeCl3 
furnished diol 93 and the secondary alcohol of 93 was selectively methylated with MeI in the 
presence of NaH to give the desired product 94.  
  
 129
 N3
O TMS
O
N3
H
HO
N3
OO
H
MeI, NaH, THF
Ba(OH)2.8H2O
N3
H
HO
N3
H
HO
O
LDA, then1)
2) 1 N HCl, 2 h
26 %
EtOH, 0 oC, 1.5 h
NaBH4, CeCl3
THF/MeOH rt, 6 h
2 h, 0 oC
37%
97%
75%
87 91 92
93
70
94
HO MeO
 
Scheme 55. Synthesis of bicyclic hydroxy vinyl azide 94 
 
Exposure of 94 to Suárez conditions  (1.2 equiv. of PhI(OAc)2 and 1.2 equiv. of iodine at 
room temperature for 3 h) gave the desired fragmented product in 51% yield (Scheme 56). In this 
case, two E/Z isomers were formed in almost equal amounts. The configuration of the vinyl 
azide seemed to lack control. Therefore, another procedure with 1.2 equiv. of PhI(OAc)2 and 1.2 
equiv. of iodine under elevated reaction temperature and longer reaction time was used and 
showed improved selectivity for the E-isomer but produced a lower yield along with inseparable 
side products. Based on these results, we might conclude that the E/Z-selectivity of the 
fragmentation is controlled by thermodynamic factors and an isomerization process during the 
fragmentation leads to the more stable E-configuration of the α,β-unsaturated nitrile. 
 
 130
 1.2 eq. PhI(OAc)2
1.2 eq. PhI(OAc)2
H
O
CN
H
H
O
CN
CH2Cl2, rt, 3 h
~ 1 : 1.551% 95
1.2 eq. I2
E : Z =
CH2Cl2, 50 oC, 6 h
<26%
94
95
1.2 eq. I2
E major
   inseparable
   side products+
MeO
MeO
N3
H
HO
94
MeO
 
Scheme 56. Further fragmentation reactions 
 
The mechanism of our fragmentation reactions can be proposed as shown in Figure 28 
based on the previous reports.95,96 However, the actual mechanism for the fragmentation is still 
unclear and ionic mechanisms for these conversions cannot be excluded as discussed in Section 
2.1.3. 
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Figure 28. Proposed mechanism of fragmentation reactions of 88 
 
 131
 2.3.2.   Fragmentation Reactions in Hydroindole Systems 
 
After accomplishing two model studies successfully, we decided to revisit hydroindole 
systems. To this end, we synthesized hydroxy vinyl azide 103 from common intermediate 1 in 
several steps (Scheme 57).  
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Scheme 57. Synthesis of hydroxy vinyl azide 103 
 
 
The 1,4-conjugate addition reaction of hydroindole 1 with vinyl magnesium bromide in the 
presence of copper iodide provided a 1:1.2 mixture of diastereomers in 40% yield. This time, the 
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 1,4-conjugate addition of the vinyl group was achieved by using a free hydroxy group instead of 
using the TMS-protected alcohol. The addition product was reacted with MOMCl to give 
separable diastereomers, and purification by chromatography on Si2O provided pure ketone 
96.117 Ketone 96 was reduced with NaBH4 to furnish alcohol 97, which was O-methylated to give 
98. Epoxidation of 98, followed by the azidolysis of 99 gave azido alcohol 100, which was 
reacted with methane sulfonyl chloride to give mesylate 101. Elimination of mesylate 101 turned 
out to be a very sluggish reaction, so only small amounts of vinyl azide 102 could be obtained by 
the reaction of 101 with DBU in benzene under reflux conditions. Since more vigorous reaction 
conditions led to rapid decomposition of 101, we repeated the elimination reaction under the 
same conditions several times to get sufficient material. Vinyl azide 102 was converted to the 
desired hydroxy vinyl azide 103 by the removal of the MOM group of 102 with HCl. With the 
desired vinyl azide 103 in hand, we tried the fragmentation reaction under several reaction 
conditions. However, we could not obtain products of a vinylogous azido alcohol fragmentation 
(Scheme 58). In most cases, we just isolated the undesired product 104 derived from the 
iodoetherification of hydroxy vinyl azide substrates or starting material (Table 10). 
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Scheme 58. Attempts for fragmentation of 103 
 
Table 10. Attempted conditions for fragmentation of 103. 
Entry Reagents Temperature Solvent Results 
1 PhI(OAc)2 (1.2 equiv.) 
I2 (1.2 equiv.) 
Room temp. CH2Cl2 (0.03 M) 104 (77%) 
2 a PhI(OAc)2 (1.2 equiv.) 
I2 (1 equiv.) 
Room temp. CH2Cl2 (0.04 M) 104 (57%) 
3 I2 (1.2 equiv.) Room temp. CH2Cl2 (0.03 M) 104 b
4 PhI(OAc)2 (1.2 equiv.) 
I2 (1 equiv.), AcOH 
Room temp. CH2Cl2 (0.04 M) 104 (71%) 
5 PhI(OAc)2 (2 equiv.) Room temp. CH2Cl2 (0.02 M) No reaction (S. M.) 
6 Pb(OAc)4 (2 eqiuv.) Room temp. CH2Cl2 (0.03 M) No reaction (S. M.) 
7 Pb(OAc)4 (2 eqiuv.) Reflux CH2Cl2 (0.02 M) No reaction (S. M.) 
8 PhI(OAc)2 (2 equiv.) 
ICl (1 equiv.) 
Room temp. CH2Cl2 (0.04 M) 104 (53%) 
a. Reagents were mixed and stirred for 30 min before addition of substrate. 
b. Yield was not determined. 
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 In the hope that small changes in the structure of substrate would result in a dramatic 
effect on the fragmentation reaction, we decided to synthesize additional hydroindole substrates 
using similar chemistry to the synthesis of 103 (Scheme 59).  First, we synthesized hydroxy 
vinyl azide 106 in several steps starting from 105, a diastereomer of 96, using the same sequence 
as described in the synthesis of 103. Then, hydroxy vinyl azides 108 and 109 were similarly 
prepared from 107, which was the product of the 1,4-addition of 1 with isopropenyl magnesium 
bromide under Kharash conditions.  However, to our great disappointment, we could not obtain 
any desired product from the reaction of hydroxy vinyl azides 106, 108 and 109 with 
iodine/iodobenzene diacetate or other reagents. Mostly, the major products formed were derived 
from iodo-etherification as shown in Scheme 58.   
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Scheme 59. Synthesis of other hydroxy vinyl azides in the hydroindole system 
 135
 Based on these observations, we prepared another hydroxy vinyl azide substrate, which 
was thought to avoid the iodo-etherification reaction due to the decreased reactivity of the vinyl 
functionality. Hydroxy vinyl azide 115 was obtained in several steps from the known amide 
11094 (Scheme 60). Iodolactonization of 110, followed by reduction of iodide 111 with n-
Bu3SnH provided lactone 112, which was converted to vinyl mesylate 113 by formylation and 
subsequent mesylation.118 Displacement with azide gave vinyl azide 114,119   and deprotection of 
the TMS group of 114 afforded the desired substrate 115.  
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Scheme 60. Synthesis of hydroxy vinyl azide 115 
 
Initially, we envisioned that the conjugation of the double bond by the lactone 
functionality in 115 and the resulting conformational change might prohibit the iodo-
etherification of 115, but we were also concerned about the possibility of a conjugate addition-
elimination reaction. Indeed, treatment of 115 with PhI(OAc)2 and I2 provided the addition-
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 elimination product 116 as a major product along with inseparable by-products (Scheme 61). It is 
possible that iodine acted as catalyst for this addition-elimination reaction. 
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Scheme 61. Addition-elimination reaction of 115 
 
However, the reaction of 115 with pre-mixed and pre-irradiated PhI(OAc)2 and I2 
afforded the fragmented product 117 presumably via prompt quenching of the radical 
intermediate with the acetoxy radical (Scheme 62). Even though we obtained the fragmented 
product 117 with the correct C,C-bond cleavage, further manipulation of 117 seemed to be 
difficult because of the presence of several sensitive functionalities. Therefore, we chose another 
substrate for the desired fragmentation, which could allow further conversions. 
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Scheme 62. A regioselective oxidative fragmentation of 115 
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 2.3.3. Alternative Regioselective Fragmentation Reactions 
 
The β-effect of silicon120 involves the stabilization of a positive charge β to silicon by 
overlap of the carbon-silicon σ-bond with the vacant p-orbital of the adjacent carbocation as 
shown in Figure 29.121 This effect has been widely utilized in organic synthesis.  
 
Me3Si Me
H R
NIS
+ Me
R
I
Me3Si
H
rotate by 60 o
+ Me
RH
I
Me3Si
I
I Me
RH
hyperconjugative stabilization of β-cation  
Figure 29.  β-Effect of silicon in the iododesilylation121 
 
We envisioned that a radical β to silicon might be stabilized by an adjacent silicon atom 
in a similar way. Recently, the Posner group utilized this β-effect of silicon in the ring expansion 
of n-sized conjugated cycloalkenones into homoallylic n+3 lactones as shown in Scheme 63.122 
They prepared γ-lactols 120 by nucleophilic 1,4-addition of LiSiMe3 to 2-cyclohexenone 118, 
followed by mild and rapid α-alkylation of the corresponding cycloalkanone enolates using 
diverse epoxides and BF3•OEt2. Treatment of 120 with PhI(OAc)2 and I2 provided lactone 121 
presumably via radical intermediates 122 and 123. In this case, the formation of 120 can be 
attributed to the β-effect of silicon.  
 138
 1. LiSiMe3, HMPA
2. TEA, TMSCl
OSiMe3
SiMe3
118 119
1. MeLi, THF
2. R
O
BF3.OEt2
PhI(OAc)2, I2
CH2Cl2
O
O
R
HO
SiMe3
O
R
HO
SiMe3
O
O R
84-91%
O
R
O
SiMe3
O
R
SiMe3
O
120
121
120
O
O R
122 123 121  
Scheme 63. Ring expansion of cycloalkenones into lactones by fragmentation122 
 
Thus, we envisioned that the introduction of a TMS-methylene functional group at C(4) 
of hydroindole 1 might induce a directing effect to stabilize the radical intermediate 125, 
presumably due to the β-effect of silicon, and result in the formation of the desired 
pyrrolidinones 126 or 127 as shown in Scheme 64.  
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Scheme 64. β-Effect of silicon in the fragmentation of hydroindole 124 
 
With this concept in mind, we synthesized silane 128 by the stereoselective conjugate 
addition of hydroindole 1 with TMSCH2MgBr under Kharash conditions (Scheme 65).123 Acetal 
129 was also synthesized by the treatment of 128 with ethylene glycol under mild acidic 
conditions. Fragmentation of compounds 128 and 129 with iodine and iodobenzenediacetate led 
indeed to the desired pyrrolidinones 130 and 131.124 
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Scheme 65. Regioselective oxidative fragmentation of 128 and 129 
 
  After the successful regioselective fragmentation of 128 and 129, we prepared a more 
highly substituted substrate with a TMS-methlyene side chain to probe the generality of the 
reaction. Especially, we wanted to investigate the effect of an additional side chain at C(7) in the 
fragmentation reaction. For this purpose, we synthesized alcohol 136 from 128 in 5 steps 
(Scheme 66). Ketone 128 was deprotonated with LHMDS and reacted with allyl iodide to give 
132 as a single diastereomer125 in 76% yield  (90% based on recovered starting material). 
Compound 132 was acetalized with ethylene glycol in 84% yield, and 133 was subjected to a 
Johnson-Lemieux-reaction126 to provide aldehyde 134 in 85% yield. This aldehyde was reduced 
to the primary alcohol 135, which was protected with TBSCl to provide 136 in 98% yield.  
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Scheme 66. Preparation of 136 
 
With the desired substrate 136 in hand, we tried the fragmentation reaction of 136 with 
iodine and iodobenzene-diacetate (Scheme 67). Interestingly but unfortunately, we obtained the 
internally fragmented product 138127 as a major product in 23% yield along with the desired 
product 137128 in 10% and starting material in 9% yield. Though we are not sure about the 
reasons for the reactivity difference between 129 and 136, this result suggested that the 
introduction of an alkyl chain at the C(7a) position could affect the fragmentation reaction. 
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Scheme 67. Fragmentation reaction of 136 
 
The result of the fragmentation reaction of 136 inspired the preparation of another 
substrate, which could avoid the undesired regioselectivity in the fragmentation. We envisioned 
that in tricyclic ring compounds access of the acetoxy group to the C(7a) position would be 
prevented by severe steric hindrance, thus overcoming the radical stabilizing effect at C(7a) by 
the additional side chain. In this context, we synthesized the tricycles 142 and 143 in several 
steps from 133, which was described in the synthesis of 136 (Scheme 68). The Cbz group of 
aceetal 133 was selectively removed to give amine 139 in 85% in the presence of the terminal 
alkene using the conditions105 from the synthesis of (−)-tuberostemonine.83 The free secondary 
amine of 139 was acylated with acryloyl chloride to provide diene 140, which was subjected to 
ring closing metathesis with the second generation Grubb’s catalyst129 to give tricyclic 141 in an 
excellent 94% yield. The hydrogenation of 141 reduced the internal double bond to furnish 142 
in 89% yield and deacetalization of 142 provided 143 in 96% yield.  
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Scheme 68. Synthesis of tricyclic compounds 142 and 143 
 
With the desired tricyclic compounds 142 and 143 in hand, we explored the 
fragmentation reactions using iodine and iodobenzene diacetate (Scheme 69). We observed that 
tricyclic 142 was stable under the standard reaction conditions (using 3 equiv. of iodine and 3 
equiv. of iodobenzene diacetate at ambient temperature in dichloromethane solution), and most 
of the starting material was recovered after 1-day reaction time. Trials under more vigorous 
conditions such as reflux in toluene or dichloroethane solution led to extensive decomposition of 
142 instead of controlled fragmentation. The tricyclic ketone 143, in contrast, provided the 
desired fragmented product 145130 in 25% yield. It is noteworthy that there was no evidence for 
the formation of the undesired internally fragmented product during this reaction consistent with 
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 our original strategy.  After some attempts to optimize the fragmentation of 143, we realized that 
the low yield of this reaction resulted from the instability of the product 145. Although the 
reaction yield was not satisfactory, we did succeed in obtaining the desired product in the 
fragmentation reaction of the tricyclic derivative. Hence, we hope that this reaction can be 
applied in the synthesis of parvistemonine or other pyrrolidine alkaloids. 
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Scheme 69. Fragmentation reactions of tricyclic compounds 142 and 143 
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 2.4. Conclusion 
Two model studies for a novel vinylogous azido alkoxy radical fragmentation reaction 
were successfully completed as described in Section 2.3.1. Although these model studies were 
still limited in terms of generality and applicability, they established the feasibility of the 
vinylogous azido alkoxy radical fragmentation reaction. This new fragmentation reaction is of 
fundamental mechanistic interest and also provides a new approach for the preparation of 
acrylamides, which are versatile intermediates in organic synthesis.   
Attempts for a vinylogous azido alkoxy radical fragmentation in hydroindole systems 
were not successful mainly due to competing side reactions such as iodo-etherification and 
conjugate addition-elimination as stated in Section 2.3.2. Though it is not entirely clear why 
these side reactions were preferred over the desired fragmentations in hydroindoles, our findings 
illustrate that fragmentation reactions are highly substrate dependent. Thus, it is very difficult to 
make general predictions. 
The introduction of a TMS-methylene group at the C(3) position in hydroindole systems 
directed the fragmentation to give the desired bond cleavage products, even though undesired 
side reactions or low reactivity was a problem. Since fragmentation reactions are very substrate-
dependent, it is not yet clear if this fragmentation approach is feasible for the total synthesis of 
parvistemonine. However, the results in Section 2.3.3 are promising and we hope that this 
approach will bear fruit in the near future. Scheme 70 shows one possible approach to 
parvistemonine using the TMS-methylene group fragmentation strategy. 
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Scheme 70. A possible scheme for the completion of the synthesis of parvistemonine 
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 2.5. Experimental Section 
 
General Methods. All moisture-sensitive reactions were performed under an atmosphere 
of dry nitrogen and all glassware was dried in an oven prior to use. THF and ether were dried by 
distillation over Na/benzophenone and CH2Cl2 was dried by distillation over CaH2 or filtered 
through a solvent filtration system. Pure isopulegol was obtained by chromatography on SiO2 of 
technical grade isopulegol from Acros. Unless otherwise stated, all commercially available 
materials were used without purification. IR spectra were recorded neat using NaCl cells. NMR 
spectra were obtained at 300MHz/75MHz (1H/13C NMR) in CDCl3 unless noted otherwise. High 
and low resolution mass spectra were determined by introduction with a direct insertion probe 
into a VG-70-70 HF spectrometer operating in the electron ionization (EI) mode.  
 
(2S,3aR,7aR)-3a-Hydroxy-6-oxo-2,3,3a,6,7,7a-hexahydroindole-1,2-dicarboxylic acid 
1-benzyl ester 2-methyl ester (1). Prepared according to literature procedures:86 1H NMR 
(mixture of rotamers) δ 7.45-7.20 (m, 5 H), 6.84, 6.80 (2d, 1 H, J = 10.3 Hz), 6.03, 6.02 (2d, 1 H, 
J = 10.4 Hz), 5.23, 5.11 and 5.11, 5.02 (2AB, 2 H, J = 12.1 Hz), 4.60-4.40 (m, 2 H), 3.87, 3.57 
(2s, 3 H), 3.33, 3.12 (2dd, 1 H, J = 16.4, 6.0 Hz), 2.70-2.50 (m, 1 H), 2.4-2.1 (m, 2 H). 
(2S,3aR,7aR)-6-Oxo-3a-trimethylsilanyloxy-2,3,3a,6,7,7a-hexahydroindole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (66). Prepared according to literature 
procedures:94 1H NMR (mixture of rotamers) δ 7.40-7.30 (m, 5 H), 6.76, 6.74  (2d, 1 H, J = 10.3 
Hz), 6.03, 6.00 (2d, 1 H, J = 10.4 Hz), 5.23, 5.18 and 5.19, 5.08 (2AB, 2 H, J = 12.2 Hz), 4.66-
4.35 (m, 2 H), 3.74, 3.59 (2s, 3 H), 3.33, 3.12 (2dd, 1 H, J = 16.4, 6.0 Hz), 2.55-2.26 (m, 3 H), 
0.13, 0.11 (2s, 9 H). 
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   3-Trimethylsilanylbut-3-en-2-ol (69). Prepared according to literature procedures:109 1H 
NMR δ 5.81 (dd, 1 H, J = 2.4, 1.5 Hz), 5.39 (dd, 1 H, J = 2.4, 1.0 Hz), 4.49 (q, 1 H, J = 6.0 Hz), 
1.45 (br, 1 H, -OH), 1.30 (d, 3 H, J = 6.5 Hz), 0.15 (s, 9 H). 
  3-Trimethylsilanylbut-3-en-2-one (70). Prepared according to literature procedures:109 
1H NMR δ 6.50 (d, 1 H, J = 1.0 Hz), 6.17 (d, 1 H, J = 1.0 Hz), 2.29 (s, 3 H), 0.15 (s, 9 H). 
(2S*,3R*,6S*)-6-Isopropenyl-3-methyl-2-(3-oxobutyl)-cyclohexanone (72). Prepared 
according to literature procedures:108 1H NMR δ 4.89 (s, 1 H), 4.66 (s, 1 H), 2.97 (dd, 1 H, J = 
13.0, 5.1 Hz), 2.63-2.50 (m, 1 H), 2.40-2.25 (m, 1 H), 2.09 (s, 3 H), 2.06-1.53 (m, 8 H), 1.72 (s, 3 
H), 1.06 (d, 3 H, J = 6.5 Hz); 13C NMR δ 211.3, 209.2, 143.5, 112.6, 58.4, 56.6, 41.3, 40.0, 34.5, 
31.7, 29.9, 21.6, 20.7, 20.2. 
(4aS*,5R*,8S*,8aS*)-8a-Hydroxy-8-isopropenyl-5-methyloctahydronaphthalen-2-
one (73). Prepared according to a literature procedure:108 1H NMR δ 4.90 (s, 1 H), 4.73 (s, 1 H), 
2.45-2.20 (m, 4 H), 2.11-2.02 (m, 2 H), 1.88-1.62  (m, 3 H), 1.76 (s, 3 H), 1.60-1.15 (m, 4 H), 
0.92 (d, 3 H, J = 6.5 Hz); 13C NMR δ 211.1, 146.9, 113.2, 75.9, 54.7, 53.4, 50.0, 41.3, 35.4, 32.0, 
27.5, 25.9, 25.1, 20.3. 
(2R*,4aS*,5R*,8S*,8aS*)-8-Isopropenyl-5-methyloctahydronaphthalene-2,8a-diol 
(74). A solution of 73 (18 mg, 0.080 mmol) in EtOH (1 mL) was treated with NaBH4 (5.0 mg, 
0.13 mmol) and stirred for 2 h at 0 oC. The reaction mixture was quenched with saturated NH4Cl 
solution, diluted with EtOAc (25mL) and washed with brine (25 mL). The organic layer was 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 74 (14 mg, 78%) as a white solid: Mp 
105-106 oC (CH2Cl2); IR (neat) 3430, 2943, 2927, 2863, 2844, 1620, 1454 cm-1; 1H NMR δ 4.90 
(s, 1 H), 4.75 (s, 1 H), 3.97-3.86 (m, 1 H), 2.10-1.90 (m, 3 H), 1.82  (s, 3 H), 1.80-1.72 (m, 3 H), 
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 1.50-1.31 (m, 4 H), 1.30-1.00 (m, 4 H), 0.88 (d, 3 H, J = 6.5 Hz); 13C NMR δ 148.1, 112.3, 73.4, 
67.8, 54.7, 50.7, 46.9, 35.8, 35.7, 31.6, 27.4, 25.2, 23.8, 20.3; MS (EI) m/z  (relative intensity) 
224 (M+, 5), 206 (24), 188 (18), 123 (100); HRMS (EI) m/z calcd for C14H24O2 224.1776, found 
224.1780. 
  (1R*,4S*,4aS*,6R*,8aS*)-4-Isopropenyl-6-methoxy-1-methyloctahydronaphthalen-
4a-ol (75). A solution of 74 (15 mg, 0.067 mmol) in THF (1 mL) was treated with NaH (60% in 
mineral oil, 6.0 mg, 0.15 mmol) and MeI (10 µL, 0.16 mmol) at room temperature. The reaction 
mixture was stirred for 20 h at room temperature, quenched with saturated aqueous NH4Cl 
solution, diluted with EtOAc (50 mL) and washed with of brine (25 mL). The organic layer was 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 75 (13 mg, 81%) as a white solid: Mp 
100-102 oC; IR (neat) 3536, 2951, 2921, 2878, 1635, 1456, 1369 cm-1; 1H NMR δ 4.90 (s, 1 H), 
4.75 (s, 1 H), 3.48-3.40 (m, 1 H), 3.34 (s, 3 H), 2.20-1.90 (m, 3 H), 1.82  (s, 3 H), 1.82-1.65 (m, 
3 H), 1.50-1.35 (m, 3 H), 1.40-1.20 (m, 1 H), 1.18-1.02 (m, 3 H), 0.88 (d, 3 H, J = 6.5 Hz); 13C 
NMR δ 148.2, 112.3, 76.5, 73.2, 56.0, 54.7, 51.0, 43.7, 35.7, 31.8, 31.7, 27.5, 25.3, 23.7, 20.3; 
MS (EI) m/z  (relative intensity) 238 (M+, 6), 220 (18), 188 (22), 123 (100); HRMS (EI) m/z 
calcd for C15H26O2 238.1933, found 238.1934. 
(1R*,4S*,4aS*,6R*,8aR*)-6-Methoxy-1-methyl-4-(2-methyloxiranyl)-
octahydronaphthalen-4a-ol (76). A solution of 75 (14 mg, 0.060 mmol) in CH2Cl2 (1 mL) was 
treated with mCPBA (~70%, 40 mg, ~0.16 mmol) at room temperature. The reaction mixture 
was stirred for 1 h at room temperature, diluted with EtOAc (50 mL) and washed with saturated 
NaHCO3 (25 mL) and saturated aqueous Na2S2O3 solution (25 mL). The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by chromatography 
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 on SiO2 (Hexanes/EtOAc, 5:1) to give 76 (14 mg, 93%) as a white solid: Mp 92-96 °C; IR (neat) 
3505, 2953, 2924, 2851, 1444, 1371, 1093 cm-1; 1H NMR δ 3.57-3.49 (m, 1 H), 3.39 (s, 3 H), 
2.67 (d, 1 H, J = 4.5 Hz), 2.62 (d, 1 H, J = 4.5 Hz), 2.47-2.43 (m, 1 H), 2.25-2.15 (m, 1 H), 2.03 
(bs, 1 H, OH), 1.76-1.60 (m, 4 H), 1.38 (s, 3 H), 1.35-1.00 (m, 7 H), 0.81 (d, 3 H, J = 6.5 Hz); 
13C NMR δ 76.0, 73.8, 59.4, 55.9, 55.1, 51.7, 51.1, 43.0, 35.2, 31.5 (2C), 24.5, 23.0, 22.2, 20.0; 
MS (EI) m/z  (relative intensity) 254 (M+, <1), 236 (6), 205 (12), 123 (25), 108 (100); HRMS 
(EI) m/z calcd for C15H26O3 254.1882, found 254.1882. 
(1R*,4S*,4aS*,6R*,8aS*)-4-(2-Azido-1-hydroxy-1-methylethyl)-6-methoxy-1-
methyloctahydronaphthalen-4a-ol (77). A solution of 76 (156 mg, 0.610 mmol) in MeOH (5 
mL) and H2O (2 mL) was treated with NaN3 (397mg, 6.11 mmol) and NH4Cl (326 mg, 6.09 
mmol) at room temperature. The reaction mixture was heated at reflux for 1 d at 90 oC, cooled to 
room temperature and concentrated under reduced pressure. The residue was diluted with EtOAc 
(30 mL) and washed with H2O (25 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
5:1) to give a regioisomer (45 mg, 25%) and 77 (65 mg, 36%) as a white solid: Mp 102-106 oC; 
IR (neat) 3404, 2925, 2862, 2109, 1451, 1380, 1296, 1157, 1089 cm-1; 1H NMR δ 3.57 (d, 1 H, J 
= 12.0 Hz), 3.52-3.42 (m, 1 H), 3.37 (s, 3 H), 3.32 (d, 1 H, J = 12.0 Hz), 2.90-2.80 (m, 1 H), 
2.20-2.10 (m, 1 H), 1.90-1.45 (m, 6 H), 1.40 (s, 3 H), 1.30-1.00 (m, 5 H), 0.87 (d, 3 H, J = 6.4 
Hz); 13C NMR δ 76.5, 76.3, 75.8, 60.6, 55.8, 53.4, 51.6, 44.5, 35.7, 31.5, 31.3, 29.3, 23.6, 23.5, 
20.3; MS (EI) m/z  (relative intensity) 297 (M+, <1), 275 (<1), 108 (100); HRMS (EI) m/z calcd 
for C15H27N3O3 297.2052, found 297.2050. 
(1R*,4aS*,6R*,8aR*)-4-(2-Azido-1-methylethylidene)-6-methoxy-1-
methyloctahydronaphthalen-4a-ol. (80). A solution of 77 (17 mg, 0.057 mmol) in CH2Cl2 (1 
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 mL) was treated with Ms2O (50 mg, 0.28 mmol) and TEA (0.040 mL, 0.28 mmol). The reaction 
mixture was stirred for 1 h at room temperature and directly purified by chromatography on SiO2 
(Hexanes/EtOAc, 10:1) to give undesired 80 (7.0 mg, 40%) as the major product: 1H NMR δ 3.8-
3.7 (m, 1 H), 3.55 (d, 1 H, J = 12.5 Hz), 3.43 (d, 1 H, J = 12.4 Hz), 3.39 (s, 3 H), 3.32 (d, 1 H, J 
= 12.0 Hz), 2.25-2.12 (m, 1 H), 1.9-0.9 (m, 11 H), 1.75 (s, 3 H), 0.89 (d, 3 H, J = 6.5 Hz). 
(1R*,2S*,5R*)-5-Methyl-2-(2-methyloxiranyl)-cyclohexanol (81).  A solution of pure 
(±)-isopulegol (1.5 g, 10 mmol) in CH2Cl2 (20 mL) was treated with mCPBA (~70 %, 3.4 g, ~ 14 
mmol). The reaction mixture was stirred for 1 h at room temperature, diluted with EtOAc (100 
mL) and washed with saturated NaHCO3 solution (50 mL×2) and saturated aqueous Na2S2O3 
solution (50 mL×2). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by chromatography on SiO2 (Hexanes /EtOAc, 2:1) to give 81 
(1.2 g, 71 %) as a colorless oil (~1:1 diastereomeric ratio): IR (neat) 3428, 2918, 2863, 1642, 
1457 cm-1; 1H NMR δ 3.63 (dt, 0.5 H, J = 4.4, 10.4 Hz), 3.40 (bs, 0.5 H, -OH), 3.24 (dt, 0.5 H, J 
= 4.2, 10.4 Hz), 2.90 (bs, 0.5 H, -OH), 2.85 (d, 0.5 H, J = 4.1 Hz), 2.61 (d, 0.5 H, J = 4.2 Hz), 
2.53 (d, 0.5 H, J = 4.7 Hz), 2.48 (d, 0.5 H, J = 4.7 Hz), 2.00-1.75 (m, 2 H), 1.70-1.50 (m, 2 H), 
1.49-0.99 (m, 3 H), 1.30 (s, 1.5 H), 1.26 (s, 1.5 H), 0.98-0.90 (m, 1 H), 0.87 (d, 3 H, J = 6.5 Hz); 
13C NMR δ 71.3, 70.5, 60.2, 59.2, 52.8, 52.6, 51.2, 49.3, 43.6, 43.0, 33.9, 31.2, 31.0, 27.7, 27.6, 
22.1, 20.5, 17.0; MS (EI) m/z  (relative intensity) 152 ([M−H2O]+, 40), 123 (40), 109 (33), 95 
(48), 84 (100); HRMS (EI) m/z calcd for C10H16O (M−H2O) 152.1201, found 152.1198. 
(1R*,2S*,5R*)-2-(2-Azido-1-hydroxy-1-methylethyl)-5-methylcyclohexanol (82). A 
solution of 63 (850 mg, 4.99 mmol) in H2O (5 mL) and MeOH (15 mL) was treated with NaN3 
(1.6 g, 25 mmol) at room temperature. The reaction mixture was heated at reflux for 20 h, cooled 
to room temperature, diluted with EtOAc (50 mL) and washed with H2O (25 mL). The organic 
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 layer was dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (Hexanes /EtOAc, 2:1) to give 82 (560 mg, 56%) as a pale brown oil 
containing a trace of a minor diastereomer. Major diastereomer: IR (neat) 3296, 2912, 2866, 
2094, 1595 cm-1; 1H NMR δ 5.18 (br, 1 H, -OH), 4.63 (br, 1 H, -OH), 3.69 (dt, 1 H, J = 4.2, 10.4 
Hz), 3.19 (d, 1 H, J = 12.7 Hz), 3.08 (d, 1 H, J = 12.6 Hz), 1.95-1.80 (m, 1 H), 1.70-1.30 (m, 3 
H), 1.12 (s, 3 H), 1.20-0.95 (m, 3 H), 0.85 (d, 3 H, J = 6.4 Hz); 13C NMR δ 77.0, 72.1, 59.4, 
48.2, 44.6, 34.1, 31.2, 26.4, 22.0, 20.7; MS (EI) m/z  (relative intensity) 214 ([M+H]+, 2), 157 
(90), 139 (95), 95 (100); HRMS (EI) m/z calcd for C10H20N3O2 (M+H) 214.1556, found 
214.1554. 
(1R*,2S*,5R*)-2-(2-Azido-1-hydroxy-1-methyl-ethyl)-1-(2-methoxymethoxy)-5-
methyl-cyclohexanol (83). A solution of 82 (280 mg, 1.31 mmol) in CH2Cl2 (10 mL) was 
treated with MOMCl (0.20 mL, 2.6 mmol) and i-PrNEt2 (0.45 mL, 2.6 mmol) at 0 oC. The 
reaction mixture was stirred for 17 h at room temperature and diluted with CH2Cl2 (50 mL). The 
solution was washed with brine (25 mL) and the organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
(Hexanes /EtOAc, 5:1) to give 83 (200 mg, 61%) as a colorless oil: IR (neat) 3469, 2952, 2927, 
2096, 1463 cm-1; 1H NMR δ 5.04 (bs, 1 H, -OH), 4.89 (d, 1 H, J = 7.1 Hz), 4.64 (d, 1 H, J = 7.1 
Hz), 3.77 (dt, 1 H, J = 4.0, 10.6 Hz), 3.45 (s, 3 H), 3.25 (d, 1 H, J = 12.6 Hz), 3.03 (d, 1 H, J = 
12.6 Hz), 2.25-2.15 (m, 1 H), 1.90-1.80 (m, 1 H), 1.75-1.55 (m, 2 H), 1.50-1.30 (m, 1 H), 1.18 (s, 
3 H), 1.20-1.00 (m, 3 H), 0.96 (d, 3 H, J = 6.5 Hz); 13C NMR δ 94.3, 78.7, 76.4, 59.2, 56.7, 47.5, 
40.4, 34.1, 31.2, 26.8, 22.1, 21.1; MS (EI) m/z  (relative intensity) 258 ([M+H]+, 8), 212 (12); 
HRMS (EI) m/z calcd for C12H24N3O3 (M+H) 258.1818, found 258.1806. 
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 (1R*,2S*,5R*)-2-(2-Azido-1-methylvinyl)-5-methylcyclohexanol (84).  A solution of 
83 (1.3 g, 5.0 mmol) in CH2Cl2 (10 mL) was treated with pyridine (2.0 mL, 25 mmol) and SOCl2 
(0.90 mL, 13 mmol) at 0 oC. The reaction mixture was stirred for 30 min at room temperature 
and diluted with CH2Cl2 (50 mL). The solution was washed with brine (25 mL) and the organic 
layer was dried (Na2SO4) and concentrated under reduced pressure. The residue was diluted with 
MeOH (10 mL) and treated with concentrated HCl (2 mL). The reaction was stirred for 3 h and 
concentrated. The residue was diluted with EtOAc (50 mL) and washed with water (25 mL).  
The organic layer was dried (Na2SO4) and concentrated under reduced pressure. The residue was 
purified by chromatography on SiO2 (Hexanes /EtOAc, 10:1) to give 84 (0.32 g, 33%) as a 
colorless oil: IR (neat) 3379, 2925, 2862, 2103, 1655, 1452, 1273, 1025 cm-1; 1H NMR δ 6.08 (s, 
1 H), 3.43 (dt, 1 H, J = 3.8, 10.1 Hz), 2.05-1.90 (m, 1 H), 1.93 (bs, 1 H, -OH), 1.80-1.25 (m, 6 
H), 1.55 (s, 3 H), 0.98-0.94 (m, 1 H), 0.90 (d, 3 H, J = 6.4 Hz); 13C NMR δ 128.3, 122.7, 70.1, 
52.0, 43.1, 34.2, 31.5, 29.6, 22.2, 11.3; MS (EI) m/z  (relative intensity) 195 (M+, 5), 169 (7), 96 
(100); HRMS (EI) m/z calcd for C10H17N3O 195.1372, found 195.1363. 
(1S*,2R*,4R*)-1-Isopropenyl-2-methoxymethoxy-4-methylcyclohexane (85). A 
solution of pure isopulegol (7.1 g, 46 mmol) in CH2Cl2   (100 mL) was treated with MOMCl (5.2 
mL, 69 mmol) and i-PrNEt2 (12 mL, 69 mmol) at 0 oC. The reaction mixture was stirred for 16 h 
at room temperature and diluted with CH2Cl2 (200 mL). The solution was washed with brine 
(200 mL) and the organic layer was dried (Na2SO4) and concentrated under reduced pressure to 
give 85 (8.2 g, 90%) as a colorless oil: IR (neat) 3077, 2923, 1651, 1461, 1382, 1212, 1156, 
1105, 1034, 915 cm-1; 1H NMR δ 4.76 (s, 1 H), 4.75 (s, 1 H), 4.68 (d, 1 H, J = 7.0 Hz), 4.51 (d, 1 
H, J = 7.0 Hz), 3.44 (dt, 1 H, J = 4.3, 10.6 Hz), 3.30 (s, 3 H), 2.10-1.90 (m, 2 H), 1.70 (s, 3 H), 
1.65-1.20 (m, 5 H), 0.99-0.95 (m, 1 H), 0.87 (d, 3 H, J = 6.5 Hz); 13C NMR δ 147.7, 111.4, 95.0, 
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 77.4, 55.3, 52.0, 41.4, 34.3, 31.6, 30.9, 22.3, 19.8; MS (EI) m/z  (relative intensity) 198 (M+, 
2.5), 183 (3), 167 (63), 123 (100); HRMS (EI) m/z calcd for C12H22O2 198.1620, found 
198.1616. 
(1R*,2R*,4R*)-1-Methyloxirane-2-methoxymethoxy-4-methylcyclohexane (86). A 
solution of 85 (9.60 g, 48.4 mmol) in CH2Cl2 (100 mL) was treated with mCPBA (~70 %, 16.7 
g, ~67.7 mmol). The reaction mixture was stirred for 1 h at room temperature, diluted with 
EtOAC (500 mL) and washed with saturated aqueous NaHCO3 solution (125 mL×2) and 
saturated aqueous Na2S2O3 solution (125 mL×2). The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure to give 86 (9.60 g, 93%) as a colorless oil (~1:1 
diastereomeric ratio): IR (neat) 3036,2915, 2826, 1448, 1386, 1222, 1154, 1108, 1046 cm-1; 1H 
NMR δ 4.69 (d, 0.5 H, J = 7.0 Hz), 4.61 (d, 0.5 H, J = 7.0 Hz), 4.50 (d, 0.5 H, J= 6.9 Hz), 4.42 
(d, 0.5 H, J = 6.7 Hz), 3.47-3.30 (m, 1 H), 3.30 (s, 1.5 H), 3.22 (s, 1.5 H), 2.60-2.58 (m, 0.5 H), 
2.55-2.51 (m, 0.5 H), 2.40-2.30 (m, 1 H), 2.05-1.90 (m, 1 H), 1.80-1.70 (m, 0.5 H), 1.60-1.45 (m, 
1.5 H), 1.40-1.20  (m, 2 H), 1.20 (s, 1.5 H), 1.12 (s, 1.5 H), 1.20-0.80 (m, 2 H), 0.79 (d, 3 H, J = 
6.6 Hz); 13C NMR δ 94.6, 94.5, 76.7, 58.1, 57.5, 56.4, 55.6, 55.4, 51.5, 50.6, 49.6, 40.8, 40.7, 
33.9, 33.7, 31.3, 31.2, 28.0, 26.3, 22.1, 17.8, 16.3; MS (EI) m/z  (relative intensity) 214 (M+, <1), 
183 (20), 169 (93); HRMS (EI) m/z calcd for C12H22O3 214.1569 , found 214.1564. 
(2S*,5R*)-2-(2-Azido-1-methylvinyl)-5-methylcyclohexanone (87). A solution of 84 
(0.87 g, 4.5 mmol) in CH2Cl2 (25 mL) was treated with Dess-Martin periodinane (3.2 g, 9.0 
mmol). The reaction mixture was stirred for 20 h at room temperature, diluted with EtOAC (100 
mL) and washed with saturated aqueous NaHCO3 (50 mL) and saturated aqueous Na2S2O3 
solution (50 mL). The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 10:1) to give 
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 87 (0.70 g, 81%) as a pale yellow oil: IR (neat) 2952, 2922, 2860, 2106, 1719, 1655, 1463, 1380, 
1284 cm-1; 1H NMR δ 5.97 (s, 1 H), 2.87 (dd, 1 H, J = 12.8, 5.0 Hz), 2.43-2.37 (m, 1 H), 2.06 –
1.72 (m, 5 H), 1.61 (s, 3 H), 1.49-1.35 (m, 1 H), 1.03 (d, 3 H, J = 6.1 Hz); 13C NMR δ 209.8, 
125.9, 123.1, 56.0, 50.5, 35.2, 33.9, 31.2, 22.4, 13.9; MS (EI) m/z  (relative intensity) 193 (M+, 
1), 94 (65), 84 (100); HRMS (EI) m/z calcd for C10H15N3O 193.1215, found 193.1224. 
  (1S*,2S*,4R*)-2-(2-Azido-1-methyl-vinyl)-1,5-dimethyl-cyclohexanol (88). A solution 
of 87 (120 mg, 0.621 mmol) in THF (5 mL) was treated with MeMgBr (3.0 M in THF, 0.31 mL, 
0.93 mmol) at 0 oC under an N2 atmosphere. The reaction mixture was stirred for 3 h at 0 oC, 
quenched with saturated aqueous NH4Cl solution (5 mL), diluted with EtOAc (25 mL) and 
washed with water (10 mL). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 10:1) 
to give 70 (65 mg, 50%) as a pale yellow oil: IR (neat) 3492, 2950, 2920, 2865, 2103, 1647, 
1449, 1384, 1290 cm-1; 1H NMR δ 6.05 (s, 1 H), 1.81-1.71 (m, 4 H), 1.70 (s, 3 H), 1.65-1.62 (m, 
1 H), 1.46-1.40 (m, 1 H), 1.14 (s, 3 H), 1.08-1.00 (m, 2 H), 0.89 (d, 3 H, J = 6.2 Hz); 13C NMR δ 
129.8, 122.5, 71.9, 52.2, 49.4, 35.0, 29.8, 28.0, 27.7, 22.3, 15.9; MS (EI) m/z  (relative intensity) 
209 (M+, 8), 161 (40), 146 (70), 108 (80), 96  (100); HRMS (EI) m/z calcd for C11H19N3O 
209.1528, found 209.1532. 
2,6-Dimethyl-8-oxonon-2-enenitrile (89). A solution of 88 (63 mg, 0.30 mmol) in 
CH2Cl2 (10 mL) was treated with PhI(OAc)2 (0.12 g, 0.36 mmol) and I2 (91 mg, 0.36 mmol) at 
room temperature.  The reaction mixture was stirred for 3 h at room temperature, diluted with 
EtOAC (50 mL) and washed with saturated aqueous NaHCO3 solution (25 mL) and saturated 
aqueous Na2S2O3 solution (25 mL). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
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 5:1) to give 89 (37 mg, 69%) as a pale yellow oil (~6:1, E/Z isomers). Major isomer: IR (neat) 
2959, 2922, 2873, 2214, 1704, 1637, 1432, 1460, 1368, 1161 cm-1; 1H NMR δ 6.31 (dt, 1 H, J = 
7.5, 1.3 Hz), 2.40 (dd, 1 H, J = 16.5, 6.1 Hz), 2.28 (dd, 1 H, J = 16.5, 7.3 Hz), 2.2-2.1 (m, 2 H), 
2.13 (s, 3 H), 2.10-1.95 (m, 1 H), 1.85 (s, 3 H), 1.50-1.35 (m, 1 H), 1.30-1.20 (m, 1 H), 0.91 (d, 3 
H, J = 6.7 Hz); 13C NMR δ 208.3, 148.1, 120.7, 109.4, 50.9, 35.1, 30.7, 28.8, 26.2, 19.6, 14.9; 
MS (EI) m/z  (relative intensity) 179 (M+, 6), 164 (10), 122 (90), 95 (100); HRMS (EI) m/z calcd 
for C11H17NO 179.1310, found 179.1315. 
(2S*,3R*,6S*)-6-(2-Azido-1-methylvinyl)-3-methyl-2-(3-oxobutyl)-cyclohexanone 
(91). According to the procedure described for the synthesis of 72, 91 (350 mg, 26%) was 
prepared from 87 (1.0 g, 5.2 mmol) and 70 (1.1 g, 7.7 mmol) as a pale yellow oil: IR (neat) 2952, 
2931, 2866, 2100, 1707, 1652, 1441, 1364, 1281 cm-1; 1H NMR δ 5.95 (s, 1 H), 2.92 (dd, 1 H, J 
= 13.0, 5.1 Hz), 2.6-2.5 (m, 1H), 2.45-2.30 (m, 1 H), 2.11 (s, 3 H), 2.15-1.50 (m, 8 H), 1.60 (s, 3 
H), 1.08 (d, 3 H, J = 5.8 Hz); 13C NMR δ 211.1, 209.2, 125.9, 122.9, 56.7, 56.6, 41.3, 39.8, 34.5, 
31.6, 30.0, 20.7, 20.2, 14.2; MS (EI) m/z  (relative intensity) 235 ([M−N2]+, 21), 201 (40), 158 
(65), 109 (100); HRMS (EI) m/z calcd for C14H21NO (M−N2) 2351572, found 235.1561. 
(4aS*,5R*,8S*,8aS*)-8a-Hydroxy-8-(2-azido-1-methylvinyl)-5-methyl-
octahydronaphthalene-2-one (92). According to the procedure described for the synthesis of 
73, 92 (340 mg, 97%) was prepared from 91 (350 mg, 1.33 mmol) as a pale yellow oil: IR (neat) 
3472, 2956, 2931, 2872, 2103, 1722, 1642, 1287 cm-1; 1H NMR δ 6.02 (s, 1 H), 2.50-2.20 (m, 3 
H), 2.15-1.75 (m, 6 H), 1.65 (s, 3 H), 1.60-1.10 (m, 4 H), 0.94 (d, 3 H, J = 6.4 Hz); 13C NMR δ 
210.9, 128.3, 123.8, 76.9, 54.1, 53.3, 50.5, 41.4, 35.5, 32.2, 27.4, 26.0, 20.3, 16.3; MS (EI) m/z  
(relative intensity) 263  (M+, 0.5), 235 (2); HRMS (EI) m/z calcd for C14H21N3O2 263.1634, 
found 263.1642. 
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 (2R*,4aS*,5R*,8S*,8aS*)-8-(2-Azido-1-methylvinyl)-5-methyloctahydro-
naphthalene-2,8a-diol (93). CeCl3•7H2O (300 mg, 0.805 mmol) was added to a solution of 92 
(190 mg, 0.722 mmol) in THF (5 mL) and MeOH (5 mL) at room temperature. The reaction 
mixture was stirred at room temperature for 15 min, cooled to 0 oC, reacted with NaBH4 (30 mg, 
0.79 mmol), stirred for 30 min, diluted with EtOAc (25 mL) and washed with brine (25 mL). The 
organic layer was dried (Na2SO4) and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 93 (70 mg, 37%) as a 
pale yellow solid: Mp 107-111 °C (CH2Cl2); IR (neat) 3394, 2928, 2872, 2106, 1652, 1454, 
1380, 1284 cm-1; 1H NMR δ 6.02 (s, 1 H), 3.95-3.85 (m, 1 H), 2.05-1.92 (m, 2H), 1.88-1.70 (m, 
4 H), 1.67 (s, 3 H), 1.60 (br, 1 H, -OH), 1.45-1.30 (m, 2 H), 1.30 (m, 3 H), 1.15-1.00 (m, 2 H), 
0.88 (d, 3 H, J = 6.7 Hz); 13C NMR δ 129.2, 122.7, 74.2, 67.6, 53.8, 50.7, 46.3, 35.5, 35.4, 31.6, 
26.9, 23.6, 20.1, 15.8; MS (EI) m/z  (relative intensity) 265 (M+, 0.5), 237 (2), 219 (40), 123 
(40), 96 (100); HRMS (EI) m/z calcd for C14H23N3O2 265.1790, found 263.1801. 
(1R*,4S*,4aS*,6R*,8aS*)-4-(2-Azido-1-methylvinyl)-6-methoxy-1-
methyloctahydronaphthalen-4a-ol (94). A solution of 93 (62 mg, 0.23 mmol) in THF (5 mL) 
was treated with 60% NaH (96 mg, 1.2 mmol) and MeI (0.15 mL, 1.2 mmol). The reaction 
mixture was stirred for 6 h at room temperature and quenched with saturated aqueous NH4Cl 
solution (5 mL), diluted with EtOAc (50 mL) and washed with brine (25 mL). The organic layer 
was dried (Na2SO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 94 (48 mg, 75%) as a pale yellow solid: 
Mp 106-109 °C; IR (neat) 3487, 2928, 2869, 2100, 1648, 1448, 1380, 1290, 1101 cm-1; 1H NMR 
δ 6.00 (s, 1 H), 3.45-3.35 (m, 1 H), 3.34 (s, 3 H), 2.20-2.10 (m, 1 H), 2.01 (ddd, 1 H, J = 13.0, 
4.2, 2.2 Hz), 1.86-1.70 (m, 4 H), 1.66 (s, 3 H), 1.45-0.97 (m, 7 H), 0.88 (d, 3 H, J = 6.4 Hz); 13C 
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 NMR δ 129.1, 122.7, 76.2, 74.0, 56.0, 53.8, 51.0, 43.3, 35.4, 31.6 (2C), 27.0, 23.4, 20.1, 15.8; 
MS (EI) m/z  (relative intensity) 279 (M+, 2), 251 (3), 236 (2), 123 (75), 96 (100); HRMS (EI) 
m/z calcd for C15H25N3O2 279.1947, found 279.1942. 
6-{(1S*,4R*)-4-Methoxy-2-oxo-cyclohexyl)}-2-methyl-hept-2-enenitrile (95). To a 
solution of 94 (42 mg, 0.15 mmol) in CH2Cl2 (5 mL) was added PhI(OAc)2 (58 mg, 0.18 mmol) 
and I2 (46 mg, 0.18 mmol) at room temperature. The reaction mixture was stirred for 3 h at room 
temperature, diluted with EtOAc (25 mL) and washed with saturated aqueous Na2S2O3 solution 
(10 mL) and saturated aqueous NaHCO3 solution (10 mL). The aqueous layer was extracted with 
EtOAc (25 mL). The combined organic layers were dried (Na2SO4) and concentrated. The crude 
residue was purified by chromatography on SiO2 (Hexanes/EA, 10:1) to give 95 (19 mg, 51%) as 
a pale yellow oil (~1:1.5, E/Z mixture): IR (neat) 2925, 2878, 2217, 1713, 1456, 1373, 1237, 
1101 cm-1; 1H NMR δ 6.33 (t, 0.4 H, J = 7.3 Hz), 6.14 (t, 0.6 H, J = 7.5 Hz), 3.50-3.35 (m, 1 H), 
3.35 (s, 3 H), 2.80 (dd, 1 H, J = 13.2, 2.7 Hz), 2.40-1.95 (m, 6 H), 1.92 (s, 1.8 H), 1.86 (s, 1.2 H), 
1.70-1.55 (m, 2 H), 1.50-1.20 (m, 3 H), 0.87 (d, 1.8 H, J = 6.5 Hz), 0.86 (d, 1.2 H, J = 6.5 Hz); 
13C NMR δ 209.6, 209.4, 148.2, 120.8, 118.2, 109.5, 78.9, 56.2, 54.5, 54.2, 48.2, 33.8, 35.6, 
30.7, 29.5, 30.3, 22.4, 22.2, 20.1, 15.9, 14.9; MS (EI) m/z  (relative intensity) 249 (M+, <1), 234 
(1), 217 (1), 96 (90); HRMS (EI) m/z calcd for C15H23NO2 249.1729, found 249.1732. 
(2S,3aR,4R,7aR)-3a-Methoxymethoxy-6-oxo-4-vinyl-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (96). To a solution of hydroindole 1 (1.43 g, 
4.14 mmol) and CuI (237 mg, 1.24 mmol) in THF (40 mL) was added vinylmagnesium bromide 
(1.0 M in THF, 8.3 mL) at –20 °C. The reaction mixture was warmed to room temperature for 3 
h, quenched with saturated aqueous NH4Cl solution (50 mL) and extracted with EtOAc (200 
mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
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 residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give conjugate 
addition product (700 mg, 45%) as a white foam. The conjugate addition product (700 mg, 1.87 
mmol) was then dissolved in CH2Cl2 (10 mL) and treated with MOMCl (0.43 mL, 5.7 mmol) 
and diisopropylethyl amine (0.99 mL, 5.7 mmol) at room temperature. The reaction mixture was 
stirred for 5 d at room temperature, diluted with EtOAc (50 mL) and washed with brine (25 mL). 
The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 96 (195 mg, 
25%) as a white foam and its diastereomer 105 (225 mg, 29%) along with 263 mg of recovered 
starting material. 96: [α]D −15.0 (c 1.0, CH2Cl2); IR (neat) 2955, 2904, 1752, 1711, 1414, 1347, 
1219, 1025 cm-1; 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.00-5.80 (m, 1 H), 5.25-
4.95 (m, 4 H), 4.80-4.65 (m, 2 H), 4.65-4.35 (m, 2 H), 3.70, 3.55 (2s, 3 H), 3.36, 3.35 (2s, 3 H), 
3.30-3.10 (m, 1 H), 3.00-2.70 (m, 2 H), 2.60-2.20 (m. 4 H); 1H NMR (DMSO-d6 at 373 °K) δ 
7.50-7.30 (m, 5 H), 6.10-5.90 (m, 1 H), 5.30-5.15 (m, 4 H), 4.90-4.75 (m, 2 H), 4.65-4.50 (m, 2 
H), 3.70 (s, 3 H), 3.40 (s, 3 H), 3.45-3.30 (m, 1 H), 3.10-2.95 (m, 1 H), 2.85-2.65 (m, 2 H), 2.65-
2.35 (m, 2 H), 2.18 (d, 1 H, J = 14.3 Hz); 13C NMR (mixture of rotamers) δ 207.7, 206.9, 172.0, 
171.3, 154.7, 154.6, 136.2, 135.5, 128.7, 128.5, 128.3, 128.2, 117.5, 117.4, 91.8, 91.6, 85.6, 85.1, 
67.7, 67.3, 60.9, 60.0, 58.0, 57.8, 56.5, 52.4, 52.2, 44.7, 43.2, 41.6, 41.1, 36.2, 35.1; MS (EI) m/z  
(relative intensity) 355 ([M− C2H6O2]+, 0.25), 252 (15), 91 (100); HRMS (EI) m/z calcd for 
C20H21NO5 (M−C2H6O2) 355.1420, found 355.1424.  
(2S,3aR,4R,6R,7aR)-6-Hydroxy-3a-methoxymethoxy-4-vinyl-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (97). A solution of 96 (720 mg, 1.72 mmol) in 
THF-MeOH  (1:1, 20 mL) was treated with CeCl3•7H2O (640 mg, 1.72 mmol) and NaBH4 (196 
mg, 5.11 mmol) at 0 °C. The reaction mixture was stirred for 1 h at room temperature, diluted 
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 with EtOAc (150 mL) and washed with brine (100 mL). The organic layer was dried (MgSO4) 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (Hexanes/EtOAc, 1:2) to give 97 (606 mg, 84%) as a white foam: [α]D −19.7 (c 1.0, 
CH2Cl2); IR (neat) 3411, 2955, 1762, 1685, 1634, 1414, 1347, 1199, 1020 cm-1; 1H NMR 
(mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.05-5.95 (m, 1 H), 5.25-5.00 (m, 4 H), 4.79, 4.77 
(2d, 1 H, J = 17.7 Hz), 4.60, 4.58 (2d, 1 H, J = 17.7 Hz) 4.43, 4.37 (2d, 1 H, J = 9.7 Hz), 4.40-
4.25 (m, 1 H), 3.80-3.60 (m, 1 H), 3.69, 3.56 (2s, 3 H), 3.37, 3.35 (2s, 3 H), 2.90-2.30 (m, 4 H), 
2.15-1.90 (m, 2 H), 1.40-1.20 (m, 1 H), 1.15-1.10 (m, 1 H); 1H NMR (DMSO-d6, 373 °K) δ 
7.50-7.30 (m, 5 H), 6.02-5.90 (m, 1 H), 5.25-5.05 (m, 4 H), 4.75 (d, 1 H, J = 6.9 Hz), 4.64 (d, 1 
H, J = 6.9 Hz) 4.45 (d, 1 H, J = 10.0 Hz), 4.33 (bs, 1 H, -OH), 4.27 (dd, 1 H, J = 10.5, 4.3 Hz), 
3.70-3.55 (m, 1 H), 3.62 (s, 3 H), 3.33 (s, 3 H), 2.90-2.70 (m, 1 H), 2.65-2.40 (m, 2 H), 2.00-1.80 
(m, 2 H), 1.35 (dd, 1 H, J = 24.2, 12.1 Hz), 1.14 (dd, 1 H, J = 23.1, 11.8 Hz); 13C NMR (mixture 
of rotamers) δ 171.9, 171.3, 154.7, 154.3, 137.0, 136.8, 136.6, 136.5, 128.6, 128.5, 128.2, 128.0, 
116.1, 116.0, 91.2, 85.3, 84.5, 67.3, 67.2, 66.6, 66.4, 58.6, 58.5, 56.9, 56.8 , 56.4, 56.3, 52.2, 
52.0, 40.7, 40.6, 39.8, 39.3, 36.9, 36.5, 36.2, 35.0; MS (EI) m/z  (relative intensity) 419 (M+, 
0.01), 387 (0.1), 357 (8), 254 (7), 224 (8), 91 (100); HRMS (EI) m/z calcd for C22H29NO7  
419.1944, found 419.1938. 
(2S,3aR,4R,6R,7aR)-6-Methoxy-3a-methoxymethoxy-4-vinyl-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (98). A solution of 97 (434 mg, 1.03 mmol) in 
CH2Cl2 (10 mL) was treated with MeOTf (0.35 mL, 3.1 mmol) and 2,6-dibutyl-4-dimethyl-
pyridine (637 mg, 3.10 mmol) at room temperature. The reaction mixture was stirred for 20 h at 
room temperature, diluted with EtOAc (50 mL) and washed with brine (50 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue was 
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 purified by chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 98 (430 mg, 96%) as a white 
foam: [α]D −7.8 (c 1.0, CH2Cl2); IR (neat) 2950, 2822, 1762, 1705, 1403, 1358, 1209, 1086 cm-1; 
1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.05-5.95 (m, 1 H), 5.25-5.00 (m, 4 H), 
4.81, 4.78 (2d, 1 H, J = 17.5 Hz), 4.60, 4.56 (2d, 1 H, J = 17.5 Hz) 4.43, 4.37 (2d, 1 H, J = 9.7 
Hz), 4.40-4.25 (m, 1 H), 3.69, 3.56 (2s, 3 H), 3.37, 3.36 (2s, 3 H), 3.34, 3.28 (2s, 3 H), 3.30-3.10 
(m, 1 H), 3.00-2.55 (m, 2 H), 2.45-2.30 (m. 1 H), 2.15-2.00 (m, 2 H), 1.35-1.20 (m, 1 H), 1.10-
0.90 (m, 1 H); 1H NMR (DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 6.05-5.90 (m, 1 H), 5.30-5.05 
(m, 4 H), 4.77 (d, 1 H, J = 7.0 Hz), 4.66 (d, 1 H, J = 6.8 Hz) 4.46 (d, 1 H, J = 9.9 Hz), 4.27 (dd, 1 
H, J = 10.8, 6.3 Hz), 3.70-3.50 (m, 1 H), 3.62 (s, 3 H), 3.34 (s, 3 H), 3.29 (s, 3 H), 2.85-2.70 (m, 
1 H), 2.65-2.40 (m, 2 H), 2.05-1.85 (m, 2 H), 1.31 (dd, 1 H, J = 23.5, 11.9 Hz), 1.14 (dd, 1 H, J = 
23.5, 11.9 Hz); 13C NMR (mixture of rotamers) δ 171.9, 171.3, 154.6, 154.2, 137.0, 136.8, 136.7, 
136.6, 128.6, 128.5, 128.2, 128.0, 116.0, 115.9, 91.3, 85.5, 84.6, 75.3, 67.3, 67.0, 58.5, 58.4, 
56.9, 56.8, 56.4, 56. 3, 56.2, 52.2, 52.0, 40.8, 40.7, 36.5, 36.2, 35.5, 35.0, 33.8, 33.4; MS (EI) m/z  
(relative intensity) 433 (M+, 0.1), 371 (0.2), 236 (12), 146 (5), 91 (100); HRMS (EI) m/z calcd 
for C23H31NO7 433.2100, found 433.2121. 
(2S,3aR,4R,6R,7aR)-6-Methoxy-3a-methoxymethoxy-4-oxiranyl-octahydro-indole-
1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (99). A solution of 98 (505 mg, 1.16 
mmol) in CH2Cl2 (11 mL) was treated with mCPBA (70%, 1.15 g, 4.66 mmol) at room 
temperature. The reaction mixture was stirred for 18 h at room temperature, diluted with EtOAc 
(100 mL) and washed with saturated aqueous NaHCO3 solution (2×50 mL) and saturated 
aqueous Na2S2O3 solution (2×50 mL). The organic layer was dried (MgSO4) and concentrated 
under reduced pressure to give 99 (518 mg, 99%, ~1:1 inseparable mixture of diastereomers) as a 
white foam: [α]D −24.1 (c 1.0, CH2Cl2); IR (neat) 2950, 1759, 1703, 1407, 1347, 1207, 1084, 
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 1025 cm-1; 1H NMR (mixture of rotamers and diastereomers) δ 7.45-7.25 (m, 5 H), 5.30-5.00 (m, 
2 H), 4.85-4.70 (m, 1 H), 4.70-4.20 (m, 3 H), 3.70, 3.57 (2s, 3 H), 3.39, 3.37, 3.34, 3.33 (4s, 3 
H), 3.30, 3.24 (2s, 3 H), 3.20-3.05 (m, 2 H), 2.95-2.00 (m, 6 H), 1.95-1.80 (m, 1 H), 1.20-0.80 
(m, 2 H); 1H NMR (DMSO-d6, 373 °K, mixture of diastereomers) δ 7.50-7.30 (m, 5 H), 5.25-
5.05 (m, 2 H), 4.85-4.65 (m, 2 H), 4.60-4.45 (m, 1 H), 4.40-4.20 (m, 1 H), 3.64 (s, 3 H), 3.36, 
3.34 (2s, 3 H), 3.27 (s, 3 H), 3.15-3.00 (m, 1 H), 2.80-2.50 (m, 5 H), 2.35-2.05 (m, 2 H), 2.00-
1.80 (m, 1 H), 1.50-1.05 (m, 2 H); 13C NMR (mixture of rotamers and diastereomers) δ 171.8, 
171.1, 154.6, 154.1, 136.5 (1C), 128.6, 128.5, 128.2, 128.1, 128.0 (5C), 91.5, 91.4 (1C), 85.2, 
84.8, 84.4, 83.9 (1C), 75.1 (1C), 67.6, 67.3, 67.2 (1C), 58.7, 58.5, 58.4 (1C), 57.1, 57.0 (1C), 
56.4 (1C), 56.3, 55.8 (1C), 52.2, 52.0 (1C), 51.7 (1C), 45.0, 44.8, 44.0 (1C), 39.0, 38.8, 38.4 
(1C), 36.7, 36.3 (1C), 35.7, 35.5, 35.3, 35.1 (1C), 29.7, 29.4, 29.3 (1C); MS (EI) m/z  (relative 
intensity) 390 ([M−CO2CH3]+, 1.2), 346 (1.6), 328 (1.3), 300 (45), 91 (100); HRMS (EI) m/z 
calcd for C21H28NO6 (M−CO2CH3) 390.1917, found 390.1926. 
(2S,3aR,4R,6R,7aR)-4-(2-Azido-1-hydroxy-ethyl)-6-methoxy-3a-methoxymethoxy-
octahydro-indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (100). A solution of 99 
(510 mg, 1.13 mmol) in DMF (5.5 mL) was treated with NaN3 (735 mg, 11.3 mmol) and NH4Cl 
(604 mg, 11.3 mmol) at room temperature. The reaction mixture was heated at reflux for 18 h, 
cooled to room temperature, diluted with EtOAc (100 mL) and washed with saturated aqueous 
NaHCO3 solution (2×50 mL). The organic layer was dried (MgSO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
1:1) to give 100 (490 mg, 88%, ~1:1 mixture of diastereomers) as a white foam: [α]D −14.0 (c 
0.5, CH2Cl2); IR (neat) 3460, 2951, 2827, 2101 (N3), 1759, 1704 cm-1; 1H NMR (mixture of 
rotamers and diastereomers) δ 7.45-7.25 (m, 5 H), 5.30-5.00 (m, 2 H), 5.00-4.75 (m, 1 H), 4.60-
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 4.30 (m, 3 H), 4.25-4.10 (m, 1 H), 3.90-3.10 (m, 3 H), 3.71, 3.70, 3.59, 3.57 (4s, 3 H), 3.47, 3.27, 
3.26 (3s, 3 H), 3.33, 3.32 (2s, 3 H), 2.95-2.20 (m, 4 H), 2.10-1.80 (m, 2 H), 1.55-1.35, 1.10-0.80 
(m, 2 H); 13C NMR (mixture of rotamers and diastereomers) δ 172.2, 171.6, 171.5, 170.9, 154.5, 
154.3, 154.0, 136.6, 136.5, 136.3, 128.6-127.8, 92.0, 91.1, 86.8, 85.8, 85.3, 84.5, 75.6, 74.7, 
74.6, 73.8, 73.7, 67.6, 67.4, 67.3, 67.1, 58.7, 58.5, 58.0, 57.8, 57.1, 57.0, 56.4, 56.2, 54.3, 54.2, 
52.3, 52.1, 40.3, 40.2, 40.0, 37.0, 36.3, 36.0, 35.8, 35.4, 35.0, 34.9, 32.0, 31.7, 28.1, 27.9; MS 
(EI) m/z  (relative intensity) 402 ([M−C7H7]+, 0.5), 371 (1.5), 344 (5), 300 (7.5), 91 (100); 
HRMS (EI) m/z calcd for C16H26N4O8 (M−C7H7) 402.1750, found 402.1749. 
(2S,3aR,4R,6R,7aR)-4-(2-Azido-1-methanesulfonyloxy-ethyl)-6-methoxy-3a-
methoxymethoxy-octahydro-indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
(101). A solution of 100 (485 mg, 0.985 mmol) in CH2Cl2 (5 mL) was treated with MsCl (564 
mg, 4.92 mmol) and pyridine (0.80 mL, 9.9 mmol) at room temperature. The reaction mixture 
was stirred for 2 d at room temperature, diluted with EtOAc (50 mL) and washed with brine (25 
mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 101 (531 mg, 
94%, ~1:1 mixture of diastereomers) as a white foam: [α]D −28.7 (c 1.0, CH2Cl2); IR (neat) 
2951, 2107 (N3), 1759, 1701, 1413 cm-1; 1H NMR (mixture of rotamers and diastereomers) δ 
7.45-7.25 (m, 5 H), 5.30-4.90 (m, 3 H), 4.85-4.70 (m, 1 H), 4.70-4.15 (m, 3 H), 3.90-3.10 (m, 3 
H), 3.72, 3.71, 3.59, 3.58 (4s, 3 H), 3.36, 3.34 (2s, 3 H), 3.33, 3.27, 3.26 (3s, 3 H), 3.11 (s, 3 H), 
3.00-2.00 (m, 5 H), 1.50-1.20 (m, 1 H), 1.10-0.90 (m, 1 H); 13C NMR (mixture of rotamers and 
diastereomers) δ 171.6, 171.5, 170.9, 154.3, 154.1, 154.0, 136.5, 128.6, 128.5, 128.2, 128.0, 
127.9, 91.6, 91.3, 84.5, 84.2, 83.8, 83.3, 82.1, 81.6, 75.2, 75.0, 67.4, 67.3, 58,9, 58.5, 57.2, 57.0, 
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 56.6, 56.4, 53.9, 53.6, 53.4, 52.3, 52.1, 41.1, 40.9, 40.4, 40.1, 39.5, 39.1, 37.2, 36.2, 36.0, 35.8, 
35.3, 35.2, 34.6, 31.7, 31.0, 29.4, 29.0. 
(2S,3aR,4R,6R,7aR)-4-(2-Azidovinyl)-6-methoxy-3a-methoxymethoxy-octahydro-
indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (102). A solution of 101 (0.29 g, 
0.51 mmol) in benzene (10 mL) was treated with DBU (0.38 mL, 2.5 mmol) at room 
temperature. The reaction mixture was heated at reflux for 20 h, cooled to room temperature, 
diluted with EtOAc (50 mL) and washed with brine (25 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 102 (42 mg, 17%, ~2:1 E/Z mixture of 
isomers) as a white foam and 198 mg of recovered 101 (68%). 102: 1H NMR (mixture of 
rotamers and E/Z isomers) δ 7.45-7.25 (m, 5 H), 6.24 (d, 0.33 H, J = 7.5 Hz), 5.94 (d, 0.67 H, J = 
13.7 Hz), 5.43 (dd, 0.67 H, J = 13.7,7.0 Hz), 5.30-5.00 (m, 2 H), 4.90-4.20 (m, 4.33 H), 3.40-
3.05 (m, 1 H), 3.72, 3.58 (2s, 3 H), 3.37, 3.34 (2s, 3 H), 3.27 (s, 3 H), 3.00-2.30 (m, 3 H), 2.20-
1.90 (m, 2 H), 1.30-1.10 (m, 1 H), 1.05-0.80 (m, 1 H); 13C NMR (mixture of rotamers and E/Z 
isomers) δ 171.8, 171.2, 154.7, 154.5, 154.1, 136.7, 136.6, 136.5, 128.6-128.0 (6C), 118.7, 
118.6, 91.5, 91.3, 85.6, 85.1, 84.8, 84.1, 75.1, 75.0, 67.4, 67.2, 58.2, 58.1, 56.7, 56.4, 56.3, 56.2, 
52.2, 52.1, 38.5, 36.4, 36.2, 35.5, 35.0, 34.8, 34.3. 
(2S,3aR,4R,6R,7aR)-4-(2-Azidovinyl)-6-methoxy-3a-hydroxy-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (103). A solution of 102 (92 mg, 0.19 mmol) 
in MeOH (2 mL) was treated with concentrated HCl (0.2 mL) at 0 °C. The reaction mixture was 
stirred for 2 h, diluted with EtOAc (20 mL) and washed with H2O (10 mL). The organic layer 
was dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 103 (75 mg, 90%, ~2:1 E/Z mixture) as a 
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 white foam: 13C NMR (mixture of rotamers and E/Z isomers) δ 175.6, 175.4, 175.2, 175.0, 
154.7, 153.7, 136.3, 136.1, 136.0, 128.7-127.9 (6C), 118.7, 118.6, 118.5, 118.4, 80.2, 80.1, 79.3, 
79.2, 75.3, 67.6, 65.4, 65.2, 57.1, 56.4, 56.3, 53.3, 53.2, 52.9, 52.8, 41.2, 41.1, 36.3, 35.3, 34.2, 
33.7. Further separation by chromatography on SiO2 (Hexanes/EtOAc, 2:1) provided pure E and 
Z isomer. (E)-isomer: 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.00 (d, 1 H, J = 
13.4 Hz), 5.39, 5.37 (2dd, 1 H, J = 13.6, 7.4 Hz), 5.35-4.98 (m, 2 H), 4.57 (s, 1 H, -OH), 4.40-
4.30 (m, 1 H), 3.92, 3.87 (2dd, 1 H, J = 11.6, 6.3 Hz), 3.84-3.54 (s, 3 H), 3.36, 3.32 (2s, 3 H), 
3.40-3.20 (m, 1 H), 2.80-2.30 (m, 3 H), 2.15-2.00 (m, 1 H), 1.85-1.70 (m, 1 H), 1.35-1.15 (m, 1 
H), 1.10-0.85 (m, 1 H); (Z)-isomer: 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.30 
(d, 1 H, J = 7.5 Hz), 5.25-4.98 (m, 2 H), 4.80-4.65 (m, 1 H), 4.45-4.30 (m, 1 H), 4.14 (s, 1 H, -
OH), 3.92, 3.87 (2dd, 1 H, J = 11.5, 6.1 Hz), 3.81, 3.53 (2s, 3 H), 3.36, 3.32 (2s, 3 H), 3.40-3.20 
(m, 1 H), 3.10-2.90 (m, 1 H), 2.80-2.40 (m, 2 H), 2.05-1.95 (m, 1 H), 1.87, 1.83 (2d, 1 H, J = 5.3 
Hz), 1.35-1.15 (m, 1 H), 1.10-0.85 (m, 1 H). 
2-Azido-3-iodo-5-methoxyoctahydro-1-oxa-7-aza-cyclopenta[d]indene-7,8-
dicarboxylic acid 7-benzyl ester 8-methyl ester (104). To a solution of 103 (~2:1 E/Z mixture 
of isomers, 75 mg, 0.17 mmol) in CH2Cl2 (5 mL) was added iodobenzene diacetate (67 mg, 0.21 
mmol) and iodine (53 mg, 0.21 mmol) at room temperature. The reaction mixture was stirred for 
3 h at room temperature, diluted with EtOAc (25 mL) and washed with saturated aqueous 
NaHCO3 solution (10 mL) and saturated aqueous Na2S2O3 solution (10 mL). The organic layer 
was dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 104 (75 mg, 77%, ~3:1 mixture of 
diastereomers) as a white foam. Further separation by chromatography on SiO2 
(Hexanes/EtOAc, 4:1) provided pure major diastereomer: IR (neat) 2950, 2107 (N3), 1758, 1704, 
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 1414, 1351, 1210, 1094 cm-1; 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 5.72 (d, 1 H, 
J = 6.1 Hz), 5.30-5.00 (m, 2 H), 4.59, 4.52 (2d, 1 H, J = 9.5 Hz), 4.10, 4.00 (2dd, 1 H, J = 9.1, 
6.7 Hz), 3.81, 3.65 (2s, 3 H), 3.65-3.55 (m, 1 H), 3.45-3.30 (m, 1 H), 3.34, 3.28 (2s, 3 H), 2.80-
2.45 (m, 2 H), 2.45-2.30 (m, 1 H), 2.28-1.90 (m, 2 H), 1.35-1.10 (m, 2 H); 13C NMR (mixture of 
rotamers) δ 171.9, 171.4, 154.3, 153.9, 136.4, 128.7-128.1, 100.4, 88.7, 87.9, 67.6, 67.3, 60.7, 
60.3, 57.8, 56.8, 56.6, 52.9, 52.7, 50.8, 36.6, 35.2, 34.1, 32.8, 28.8, 28.3, 23.1; MS (EI) m/z  
(relative intensity) 557 ([M+1]+, 0.2), 497 (15), 91 (100); HRMS (EI) m/z calcd for C21H26N4O6I 
(M+H) 557.0897, found 557.0924. 
(2S,3aR,4R,7aR)-3a-Methoxymethoxy-6-oxo-4-vinyl-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (105). Obtained as a diastereomer in the 
synthesis of 96. 105: [α]D −46.6 (c 1.0, CH2Cl2); IR (neat) 3062, 2955, 1747, 1705, 1639, 1414, 
1342, 1214, 1020 cm-1; 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.00-5.80 (m, 1 H), 
5.25-4.90 (m, 4 H), 4.80-4.65 (m, 2 H), 4.40-4.25 (m, 2 H), 3.70, 3.44 (2s, 3 H), 3.32 (s, 3 H), 
3.05-2.85, 2.75-2.50 (m, 4 H), 2.45-2.20 (m. 3 H); 1H NMR (DMSO-d6 at 373 °K) δ 7.50-7.30 
(m, 5 H), 6.10-5.95 (m, 1 H), 5.35-5.10 (m, 4 H), 4.85-4.70 (m, 2 H), 4.57 (dd, 1 H, J = 8.5, 5.3 
Hz), 4.35 (dd, 1 H, J = 7.0, 6.8 Hz) 3.69  (s, 3 H), 3.38 (s, 3 H), 3.45-3.30 (m, 1 H), 3.10-2.80 
(m, 2 H), 2.70-2.50 (m, 3 H), 2.50-2.30 (m, 2 H); 13C NMR (mixture of rotamers) δ 208.5, 208.3, 
172.4, 171.0, 155.1, 154.4, 136.0, 135.9, 135.7, 128.7, 128.6, 128.5, 128.3, 128.0, 118.4, 91.8, 
83.3, 82.2, 67.9, 67.3, 61.4, 60.5, 58.4, 58.2, 56.2, 52.5, 52.3, 46.2, 45.8, 42.8, 41.2, 41.0, 35.1, 
34.9; MS (EI) m/z  (relative intensity) 417 (M+,  3), 386 (15), 355 (42), 312 (33), 252 (67), 91 
(100); HRMS (EI) m/z calcd for C20H21NO5 (M−O2C2H6) 386.1604, found 386.1617. 
(2S,3aR,4S,6S,7aR)-4-(2-Azido-vinyl)-6-methoxy-3a-hydroxy-octahydro-indole-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (106). Prepared as an inseparable ~2:1 mixture 
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 of E/Z isomers in several steps from 105 by the same sequence as described for the synthesis of 
103. 106: 1H NMR (mixture of rotamers and E/Z isomers) δ 7.45-7.25 (m, 5 H), 6.28, 6.26 (2d, 
0.3 H, J = 7.6 Hz), 5.95, 5.93 (2d, 0.7 H, J = 13.6 Hz), 5.70-5.50 (m, 0.7 H), 5.30-4.95 (m, 2.3 
H), 4.45-4.25 (m, 1 H), 4.10-3.95 (m, 1 H), 3.80, 3.53 (2s, 3 H), 3.60-3.40 (m, 1 H), 3.35, 3.17 
(2s, 3 H), 2.90-2.70, 2.45-2.10 (2m, 3 H), 2.00-1.40 (m, 4 H).  
(2S,3aR,4RS,7aR)-3a-Hydroxy-4-isopropenyl-6-oxooctahydroindole-1,2-dicarboxylic 
acid 1-benzyl ester 2-methyl ester (107). To a solution of 1 (4.58 g, 13.3 mmol) in THF (50 
mL) was added CuI (758 mg, 3.98 mmol) and isopropenyl magnesium bromide (0.5M in THF, 
53 mL) at –20 °C. The reaction mixture was warmed to room temperature for 2 h, quenched with 
saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (250 mL). The organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 107 as an inseparable ~1:1 mixture of 
diastereomers (2.44 g, 47%):  1H NMR (mixture of rotamers and diastereomers) δ 7.40-7.15 (m, 
5 H), 5.20-4.60 (m, 4 H), 4.50-4.30 (m, 1 H), 4.17, 3.86 (2bs, 1 H, -OH), 4.20-3.90 (m, 1 H), 
3.63, 3.61, 3.43, 3.24 (4s, 3 H), 3.20-2.70 (m, 2 H), 2.60-1.85 (m, 5 H), 1.74 (s, 3 H); 13C NMR 
(mixture of rotamers and diastereomers) δ 209.3, 207.9, 207.3, 174.5, 174.2, 173.6, 173.5, 154.9, 
154.6, 154.5, 154.2, 144.1, 143.9, 142.9, 136.2, 136.0, 128.6, 128.5, 128.2, 128.0, 115.0, 114.3, 
113.9, 80.5, 80.4, 79.6, 79.4, 67.6, 67.4, 67.2, 66.5, 66.2, 64.9, 64.2, 59.5, 59.3, 57.8, 57.7, 53.0, 
52.7, 52.6, 52.5, 47.6, 47.0, 44.9, 44.0, 43.1, 42.3, 42.0, 41.9, 41.3, 40.6, 36.1, 34.8, 23.8, 23.6, 
23.0; MS (EI) m/z  (relative intensity) 387 (M+, 3), 369 (2), 328 (12), 284 (30), 91 (100); HRMS 
(EI) m/z calcd for C21H25NO6 387.1682, found 387.1673. 
(2S,3aR,4R,6R,7aR)-4-(2-Azido-1-methyl-vinyl)-3a-hydroxy-6-methoxy-octahydro-
indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (108). Prepared in several steps 
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 from 107 by a similar sequence as described in the synthesis of 103. 108: IR (neat) 3444, 2952, 
2104, 1705, 1650, 1413, 1351 cm-1; 1H NMR (mixture of rotamers) δ 7.40-7.20 (m, 5 H), 6.10 
(bs, 1 H), 5.25-4.95 (m, 2 H), 4.50-4.30 (m, 1 H), 4.20-3.75 (m, 2 H), 3.82, 3.53 (2s, 3 H), 3.50-
3.20 (m, 1 H), 3.37, 3.32 (2s, 3 H), 2.90-2.70, 2.60-2.40 (2m, 3 H), 2.05-1.70 (m, 2 H), 1.65 (s, 3 
H), 1.50-1.30 (m, 1 H), 1.05-0.80 (m, 1 H); 13C NMR (mixture of rotamers) δ 175.4, 175.2, 
154.8, 153.8, 136.3, 136.0, 128.7, 128.6, 128.3, 128.1, 126.0, 124.2, 80.3, 79.4, 75.9, 67.6, 66.1, 
65.9, 57.4, 57.1, 56.4, 56.3, 53.3, 52.9, 45.7, 45.6, 36.5, 36.0, 35.5, 34.9, 33.6, 33.1, 14.8, 14.6; 
MS (EI) m/z  (relative intensity) 444 (M+, <1), 426 (<1), 385 (10), 91 (100); HRMS (EI) m/z 
calcd for C22H28N4O6 444.2009, found 444.2019. 
(2S,3aR,4S,6S,7aR)-4-(2-Azido-1-methylvinyl)-3a-hydroxy-6-methoxy-octahydro-
indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (109). Prepared in several steps 
from 107 by a similar sequence described for the synthesis of 106. 109: IR (neat) 3451, 3033, 
2951, 2826, 2100, 1701 cm-1; 1H NMR (mixture of rotamers) δ 7.45-7.25 (m, 5 H), 6.11 (s, 1 H), 
5.30-4.90 (m, 2 H), 4.50-4.35 (m, 1 H), 4.00-3.85 (m, 1 H), 3.76, 3.47 (2s, 3 H), 3.60-3.45 (m, 1 
H), 3.36, 3.15 (s, 3 H), 3.35-3.25, 3.10-3.05 (2m, 1 H), 2.70-2.55 (m, 1 H), 2.38 (dd, 1 H, J = 8.9, 
6.0 Hz), 2.25-1.65 (m, 4 H), 1.76 (s, 3 H); 13C NMR (mixture of rotamers) δ 174.9, 174.2, 155.3, 
154.1, 136.3, 128.6, 128.3, 128.2, 128.1, 127.4, 127.3, 122.7, 122.4, 82.0, 79.9, 74.9, 67.5, 67.1, 
64.6, 64.1, 58.9, 58.6, 56.1, 55.9, 52.8, 52.3, 40.2, 38.6, 38.2, 30.6, 30.2, 29.7, 29.3, 18.3; MS 
(EI) m/z  (relative intensity) 444 (M+, <1), 426 (<1), 385 (3), 91 (100); HRMS (EI) m/z calcd for 
C22H28N4O6 444.2009, found 444.2020. 
(2S,3aR,4R,7aS)-4-Dimethylcarbamoylmethyl-3a-(trimethylsilanyloxy)-2,3,3a,4,7,7a-
hexahydroindole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (110). Prepared 
according to literature procedures:94 1H NMR (mixture of rotamers) δ 7.40-7.20 (m, 5 H), 5.80-
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 5.60 (m, 2 H), 5.20-4.85 (m, 2 H), 4.45-4.30 (m, 1 H), 3.95-3.80 (m, 1 H), 3.65, 3.44 (2s, 3 H), 
2.94, 2.93 (2s, 3 H), 2.88 (s, 3 H), 2.80-2.00 (m, 7 H), 0.04 (s, 9 H); 13C NMR (mixture of 
rotamers) δ 172.4, 171.6, 171.5, 171.3, 155.0, 154.3, 136.4, 136.2, 132.1, 131.0, 128.3, 128.2, 
127.9, 127.8, 124.7, 124.6, 84.0, 82.0, 67.0, 66.6, 63.5, 58.2, 51.8, 51.7, 41.2, 40.7, 40.1, 39.5, 
37.0, 35.3, 33.5, 29.6, 2.2. 
(1aR,3aS,4S,5aR,7S,8aR)-4-Iodo-2-oxo-8a-(trimethylsilanyloxy)-decahydro-3-oxa-6-
aza-as-indacene-6,7-dicarboxylic acid 6-benzyl ester 7-methyl ester (111). To a solution of 
110 (520 mg, 1.07 mmol) in pH-6 phosphate buffer (5 mL) and THF (5 mL) was added I2 (1.36 
g, 5.34 mmol) at room temperature. The reaction mixture was stirred for 2 h at room temperature 
and quenched with saturated aqueous Na2S2O3 solution until the purple color disappeared.  The 
reaction mixture was diluted with EtOAc (50 mL) and washed with brine (25 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure.  The crude residue was 
purified by column chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 111 (470 mg, 74%) 
as a white foam: [α]D −8.1 (c 1.0, CH2Cl2); IR (neat) 3027, 2950, 2894, 1782, 1752, 1708, 1414, 
1260 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.55-7.30 (m, 5 H), 5.20, 5.14 (AB, 2 H, J = 12.3 Hz), 
5.06 (dd, 1 H, J = 8.4, 8.3 Hz), 4.55-4.45 (m, 1 H), 4.39 (dd, 1 H, J = 8.4, 8.3 Hz), 4.08 (dd, 1 H, 
J = 8.2, 8.0 Hz), 3.68 (bs. 3 H), 3.20-3.00 (m, 1 H), 2.95-2.75 (m, 2 H), 2.70-2.45 (m, 2 H), 2.25-
2.00 (m, 2 H), 0.23 (s, 9 H); 13C NMR (mixture of rotamers) δ 174.3, 172.1, 171.8, 154.4, 153.6, 
135.6, 135.5, 128.6, 128.5, 128.4, 128.3, 128.0, 86.6, 86.4, 80.6, 80.0, 68.0, 67.4, 62.1, 61.7, 
58.5, 58.1, 52.6, 52.3, 40.9, 40.8, 39.2, 38.9, 38.3, 37.8, 31.1, 31.0, 19.5, 1.7; MS (EI) m/z  
(relative intensity) 587 (M+, <1), 572 (1), 528 (3), 484 (4), 416 (4); HRMS (EI) m/z calcd for 
C23H30NO7SiI 587.0836, found 587.0846. 
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 (1aR,3aS,4S,5aR,7S,8aR)-2-Oxo-8a-(trimethylsilanyloxy)-decahydro-3-oxa-6-aza-as-
indacene-6,7-dicarboxylic acid 6-benzyl ester 7-methyl ester (112). To a solution of 111 (460 
mg, 0.78 mmol) in dry benzene (15 mL) was added AIBN (26 mg, 0.016 mmol) and n-Bu3SnH 
(0.25 mL, 0.94 mmol) at room temperature.  The reaction mixture was heated at reflux for 1 h, 
cooled to room temperature and concentrated under reduced pressure. The crude residue was 
washed with hexanes and purified by column chromatography on SiO2 (Hexanes/EtOAc, 2:1) to 
give 112 (340 mg, 95%) as a white foam: [α]D −32.0 (c 1.0, CH2Cl2); IR (neat) 3032, 2950, 
2899, 1772, 1752, 1711, 1414, 1127 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.45-7.30 (m, 5 H), 
5.14, 5.08 (AB, 2 H, J = 12.5 Hz), 4.67 (dd, 1 H, J = 12.5, 6.2 Hz), 4.36 (appt, 1 H, J = 8.2 Hz), 
3.86 (dd, 1 H, J = 6.2, 5.8 Hz), 3.63 (s, 3 H), 2.75-2.35 (m, 4 H), 2.30-2.10 (m, 1 H), 2.00-1.70 
(m, 4 H), 0.16 (s, 9 H); 13C NMR (mixture of rotamers) δ 176.6, 176.4, 172.6, 172.4, 155.2, 
153.9, 135.9, 128.6, 128.5, 128.4, 79.9, 78.9, 78.2, 78.0, 67.8, 67.2, 61.2, 61.0, 58.4, 58.1, 52.5, 
52.2, 40.2, 40.1, 39.9, 39.2, 32.4, 32.2, 21.7, 20.2, 1.8; MS (EI) m/z  (relative intensity) 461 (M+, 
1), 446 (3), 358 (3), 220 (85), 91 (100); HRMS (EI) m/z calcd for C23H31NO7Si 461.1870, found 
461.1882.  
(1aR,3aS,5aR,7S,8aR)-1-Methanesulfonyloxymethylene-2-oxo-8a-(trimethyl-
silanyloxy)-decahydro-3-oxa-6-aza-as-indacene-6,7-dicarboxylic acid 6-benzyl ester 7-
methyl ester (113). To a solution of 112 (1.40 g, 3.03 mmol) in THF (20 mL) was added 
LHMDS (1.0M in hexanes, 4.3 mL) at −78 °C. The reaction mixture was stirred for 30 min, 
treated with ethyl formate (2.3 mL, 28 mmol) at −78 °C, stirred for 1 h at −78 °C, quenched with 
saturated aqueous NH4Cl solution and warmed to room temperature. The reaction mixture was 
diluted with EtOAc (100 mL) and washed with brine (50 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was dissolved in CH2Cl2 
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 (20 mL) and treated with TEA (2.0 mL, excess) and MsCl (1.0 mL, excess). The reaction 
mixture was stirred for 1 h at room temperature, diluted with EtOAc (100 mL) and washed with 
brine (50 mL) and 1N NaOH. The organic layer was dried (MgSO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
1:1) to give 113 (1.38 g, 80%) as a white foam: [α]D +9.9 (c 1.0, CH2Cl2); IR (neat) 3027, 2960, 
2893, 1754, 1696 cm-1; 1H NMR (mixture of rotamers) δ 7.80, 7.79 (2s, 1 H), 7.40-7.20 (m, 5 
H), 5.20-4.80 (m, 2 H), 4.70-4.45 (m, 1 H), 4.40-4.10 (m, 1 H), 3.95-3.75 (m, 1 H), 3.77, 3.43 
(2s. 3 H), 3.24, 3.22 (2s, 3 H), 3.05-2.95 (m, 1 H), 2.70-2.20 (m, 2 H), 2.20-1.50 (m, 4 H), 0.14, 
0.09 (2s, 9 H); 13C NMR (mixture of rotamers) δ 172.6, 172.4, 169.8, 155.2, 153.9, 141.4, 135.8, 
128.6, 128.5, 117.9, 117.5, 81.4, 80.5, 77.2, 77.0, 67.9, 67.4, 61.5, 61.1, 58.6, 58.3, 52.7, 52.4, 
42.6, 42.3, 39.8, 38.9, 23.0, 21.8, 21.4, 21.2, 2.2; MS (EI) m/z  (relative intensity); 567 (M+, 1), 
488 (4), 444 (18), 91 (100); HRMS (EI) m/z calcd for  C25H33NO10SiS 567.1594, found 
567.1612. 
(1aR,3aS,5aR,7S,8aR)-1-azidomethylene-2-oxo-8a-(trimethyl-silanyloxy)-decahydro-
3-oxa-6-aza-as-indacene-6,7-dicarboxylic acid 6-benzyl ester 7-methyl ester (114). A 
solution of 113 (0.18 g, 0.32 mmol) in EtOH (3 mL) was treated with NaN3 (0.21 g, 3.2 mmol) at 
room temperature. The reaction mixture was stirred for 14 h at room temperature, diluted with 
EtOAc (30 mL) and washed with saturated aqueous NaHCO3 solution (20 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 114 (114 mg, 70%) as a white 
foam: [α]D +12.0 (c 0.5, CH2Cl2); IR (neat) 3032, 2945, 2899, 2100 (N3), 1752, 1706, 1640, 
1413 cm-1; 1H NMR (mixture of rotamers) δ 7.50 (s, 1 H), 7.45-7.25 (m, 5 H), 5.25-4.85 (m, 2 
H), 4.55-4.35 (m, 1 H), 4.33-4.25 (m, 1 H), 3.90-3.70 (m, 1 H), 3.77, 3.42 (2s. 3 H), 2.90-2.70 
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 (m, 2 H), 2.55-2.25 (m, 1 H), 2.20-1.80 (m, 3 H), 1.80-1.70, 1.60-1.40 (2m, 1 H), 0.07 (s, 9 H); 
13C NMR (mixture of rotamers) δ 172.9, 172.7, 170.7, 155.2, 153.9, 136.0, 135.9, 135.4, 135.0, 
128.7, 128.6, 128.5, 128.4, 128.2, 118.7, 118.4, 81.7, 80.9, 76.9, 76.7, 67.8, 67.3, 61.7, 61.4, 
58.8, 58.4, 52.6, 52.3, 42.7, 42.6, 39.8, 39.2, 23.1, 21.8, 21.6, 1.8; MS (EI) m/z  (relative 
intensity); 486 ([M−N2]+, 3), 471 (13), 427 (10); HRMS (EI) m/z calcd for  C24H30N2O7Si 
(M−N2) 486.1822, found 486.1823. 
(1aR,3aS,5aR,7S,8aR)-1-azidomethylene-2-oxo-8a-(hydroxy)-decahydro-3-oxa-6-
aza-as-indacene-6,7-dicarboxylic acid 6-benzyl ester 7-methyl ester (115). To a solution of 
114 (0.25 g, 0.49 mmol) in THF (20 mL) was added HF-pyridine complex (4 mL, excess) at 
room temperature. The reaction mixture was stirred for 20 h at room temperature, diluted with 
EtOAc (200 mL) and washed with saturated aqueous NaHCO3 solution (100 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (Hexanes/EtOAc, 1:2) to give 115 (200 mg, 93%) as a white 
foam: [α]D −7.5 (c 1.0, CH2Cl2); IR (neat) 3421, 3063, 2955, 2890, 2110 (N3), 1747, 1700, 1650, 
1414 cm-1; 1H NMR (mixture of rotamers) δ 7.60 (s, 1 H), 7.45-7.25 (m, 5 H), 5.20-4.90 (m, 2 
H), 4.70-4.50 (m, 1 H), 4.40-4.25 (m, 1 H), 4.00-3.80 (m, 1 H), 3.72, 3.47 (2bs. 3 H), 3.20-3.00 
(m, 1 H), 2.75-2.55 (m, 1 H), 2.40-2.10 (m, 1 H), 2.10-1.80 (m, 3 H), 1.70-1.45 (m, 1 H); 13C 
NMR (mixture of rotamers) δ 173.0, 172.9, 171.4, 171.2, 155.1, 154.2, 137.5, 137.4, 135.9, 
128.4, 128.2, 115.8, 115.7, 79.4, 78.5, 76.9, 76.7, 67.5, 67.1, 63.0, 62.4, 58.3, 58.1, 52.5, 52.3, 
42.6, 42.2, 41.5, 23.2, 22.4, 22.0; MS (EI) m/z  (relative intensity); 414 ([M−N2]+, 35), 355 (4), 
311 (7), 279 (35), 221 (33), 91 9(100); HRMS (EI) m/z calcd for C21H22NO7 (M−N2) 414.1427,  
found 414.1431. 
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 (3aR,4R,6aR,8S,9aR)-7-((benzoyloxy)carbonyl)-8-(methoxycarbonyl)-
3a,4,5,6,6a,7,8,9-octahydro-dihydrofuro[3,4,c]furan-1(3H)-one-indole (116). To a solution of 
115 (22 mg, 0.050 mmol) in CH2Cl2 (1 mL) was added PhI(OAc)2 (40 mg, 0.13 mmol) and I2 
(25 mg, 0.10 mmol) at room temperature. The reaction mixture was heated at reflux for 14 h, 
cooled to room temperature and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (Hexanes/EtOAc, 1:1) to give 116 (10 mg, 50%) as a white 
foam: IR (neat) (no -N3 and no -OH) 2919, 2848, 1793, 1706, 1409, 1342, 1112 cm-1; 1H NMR 
(mixture of rotamers) δ 7.90 (s, 1 H), 7.50-7.20 (m, 5 H), 5.30-5.00 (m, 2 H), 4.73, 4.65  (2d, 1 
H, J = 8.7 Hz), 4.40-4.25 (m, 1 H), 3.80-3.50 (m, 1 H), 3.79, 3.63 (2s. 3 H), 3.30-3.05 (m, 1 H), 
2.70-2.25 (m, 4 H), 2.15-1.85 (m, 2 H); 13C NMR (mixture of rotamers) δ 172.2, 172.0, 164.7, 
163.0, 162.5, 154.8, 136.2, 135.9, 128.8, 128.7, 128.4, 128.3, 128.0, 112.4, 109.9, 96.3, 96.2, 
91.2, 90.3, 77.4, 69.7, 69.0, 67.9, 67.8, 60.2, 60.0, 53.1, 52.9, 40.0, 38.9, 32.8, 32.5, 29.6, 28.8. 
5-[2-(3-Acetoxy-4-azidomethylene-5-oxo-tetrahydro-furan-2-yl)-ethyl]-4-oxo-
pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (117). A solution of 
PhI(OAc)2  (612 mg, 1.90 mmol) and I2 (247 mg, 0.970 mmol) in CH2Cl2 (3 mL) was irradiated 
at reflux for 20 min with a halogen lamp. To this solution was added 115 (86 mg, 0.19 mmol) in 
CH2Cl2 (1 mL). The reaction mixture was irradiated at reflux for 30 min, cooled to room 
temperature, diluted with EtOAc (50 mL) and washed with saturated aqueous Na2S2O3 solution 
(25 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure.  The 
crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 117 (40 
mg, 41%) as a white foam: [α]D  −16.4 (c 0.5, CH2Cl2); IR (neat) 3037, 2955, 2924, 2848, 2120 
(N3), 1757, 1706, 1413 cm-1; 1H NMR (mixture of rotamers) δ 7.51 (s, 1 H), 7.40-7.20 (m, 5 H), 
6.62 (s, 1 H), 5.35-5.00 (m, 2.5 H), 4.90-4.70 (m, 1.5 H), 4.15-4.05 (m, 1 H), 3.76, 3.51 (2s. 3 
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 H), 3.00-2.80 (m, 1 H), 2.65-2.45 (m, 1 H), 2.20 (s, 3 H), 2.20-1.80 (m, 3 H), 1.75-1.40 (m, 1 H); 
13C NMR (mixture of rotamers) δ 209.5, 209.1, 172.3, 169.9, 169.4, 155.0, 152.1, 152.4, 135.7, 
130.0, 128.7, 128.6, 128.4, 81.2, 81.0, 77.6, 68.3, 67.8, 62.0, 61.6, 56.0, 52.9, 52.7, 40.3, 39.8, 
29.0, 27.8, 27.2, 27.0, 20.8; MS (EI) m/z  (relative intensity) 472 ([M−N2]+, 4.5), 444 (1.5), 430 
(4.5); HRMS (EI) m/z calcd for C23H24N2O9 (M−N2) 472.1482, found 472.1489. 
(2S,3aR,4S,7aR)-3a-Hydroxy-6-oxo-4-(trimethylsilanylmethyl)-octahydro-indole-
1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (128). To a solution of Mg (0.43 g, 18 
mmol) in Et2O (35 mL) was added TMSCH2Br (2.50 mL, 17.5 mmol) at room temperature. The 
solution was stirred for 1 h until it became homogeneous and added to the slurry of 1 (1.2 g, 3.5 
mmol) and CuI (0.67 g, 3.3 mmol) in THF (40 mL) at −20 oC. The reaction mixture was slowly 
warmed to room temperature, stirred for 2 h, quenched with saturated aqueous NH4Cl solution 
(100 mL), diluted with EtOAc (500 mL) and washed with brine (200 mL). The organic layer was 
dried (MgSO4) and concentrated under reduced pressure.  The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 128 (950 mg, 63%) as a white foam: [α]D  
−22.4 (c 1.0, CH2Cl2); IR (neat) 3400, 3068, 2950, 2899, 1680, 1414, 1352 cm-1; 1H NMR 
(DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 5.15, 5.10 (AB, 2 H, J = 14.0 Hz), 4.70-4.30 (m, 2 H), 
4.15 (dd, 1 H, J = 6.4, 6.3 Hz), 3.66 (s, 3 H), 2.88 (dd, 1 H, J = 14.6, 6.6 Hz), 2.70-2.40 (m, 2 H), 
2.35-2.10 (m, 3 H), 2.03-1.98 (m, 1 H), 1,17 (d, 1 H, J = 14.6 Hz), 0.37 (dd, 1 H, J = 14.0, 9.7 
Hz), 0.08 (s, 9 H); 13C NMR (mixture of rotamers) δ 207.7, 206.9, 175.6, 175.4, 154.6, 153.9, 
135.9, 128.7, 128.6, 128.4, 128.1, 81.2, 80.5, 67.9, 67.7, 66.6, 66.1, 57.4, 53.3, 52.9, 45.3, 44.3, 
37.7, 37.5, 34.7, 33.5, 18.8, 18.5, −0.7; MS (EI) m/z  (relative intensity) 433 (M+, <1), 418 (3), 
330 (30), 91 (100); HRMS (EI) m/z calcd for C21H28NO6Si (M−CH3) 418.1686, found 418.1669. 
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 (2S,3aR,4S,7aR)-3a-Hydroxy-6-(ethylene)-dioxo-4-(trimethylsilanylmethyl)-
octahydro-indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (129). A solution of 128 
(43 mg, 0.10 mmol), ethylene glycol (56 µL, 1.0 mmol) and p-toluenesulfonic acid monohydrate 
(1.9 mg, 0.010 mmol) in benzene (2 mL) was heated at reflux for 14 h. The reaction mixture was 
cooled room temperature, diluted with EtOAc (50 mL) and washed with saturated aqueous 
NaHCO3 solution (25 mL). The organic layer was dried (MgSO4) and concentrated under 
reduced pressure.  The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 
2:1) to give 129 (35 mg, 73%) as a white foam: [α]D  −5.7 (c 1.0, CH2Cl2); IR (neat) 3457, 3032, 
2945, 2894, 1696, 1414, 1362 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 5.15, 
5.08  (AB, 2 H, J = 12.3 Hz), 4.42 (d, 1 H, J = 10.1 Hz), 4.30-4.10 (m, 1 H), 4.05-3.80 (m, 5 H), 
3.65 (bs, 3 H), 2.60-2.40 (m, 1 H), 2.40-2.20 (m, 1 H), 2.20-2.05 (m, 1 H), 1.88 (d, 1 H, J = 13.5 
Hz), 1.75-1.60 (m, 1 H), 1.50-1.30 (m, 2 H), 1.08 (dd, 1 H, J = 14.5, 3.3 Hz), 0.29 (dd, 1 H, J = 
14.4, 10.8 Hz), 0.07 (s, 9 H); 13C NMR (mixture of rotamers) δ 175.5, 175.3, 154.9, 153.9, 
136.6, 136.2, 128.6, 128.3, 128.1, 127.7, 107.1, 81.2, 80.3, 67.5, 67.4, 65.3, 65.1, 64.8, 64.7, 
64.5, 64.4, 57.1, 56.9, 53.2, 52.8, 39.9, 39.6, 38.4, 37.7, 36.4, 36.3, 34.7, 33.6, 17.7, -0.5; MS 
(EI) m/z  (relative intensity) 477 (M+, 3), 462 (42), 418 (90), 374 (100); HRMS (EI) m/z calcd for 
C24H35NO7Si 477.2183, found 477.2172. 
(2S,5R)-5-[4-Acetoxy-2-oxo-5-(trimethylsilanyl)-pentyl]-4-oxopyrrolidine-1,2-
dicarboxylic acid 1-benzyl ester 2-methyl ester (130). To a solution of 128 (0.91 g, 2.1 mmol) 
in CH2Cl2 was added PhI(OAc)2  (2.0 g, 6.2 mmol) and I2 (1.6 g, 6.3 mmol) at room temperature. 
The reaction mixture was heated at reflux for 12 h, cooled to room temperature, diluted with 
EtOAc (200 mL) and washed with saturated aqueous Na2S2O3 solution (100 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure.  The crude residue was 
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 purified by chromatography on SiO2 (Hexanes/EtOAc, 4:1) to give 130 (540 mg, 54%) as a white 
foam: [α]D  -52.3 (c 2.0, CH2Cl2); IR (neat) 3032, 2955, 2893, 1767, 1737, 1716, 1408, 1352, 
1245 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 5.30-5.10 (m, 3 H), 4.72 (dd. 1 H, 
J = 10.1, 3.9 Hz), 4.18 (dd, 1 H, J = 4.3, 3.8 Hz), 3.62 (s, 3 H), 3.53-3.20 (m, 1 H), 3.26 (dd, 1 H, 
J =18, 10 Hz), 3.06 (dd, 1 H, J = 18, 3.4 Hz), 2.80-2.50 (m, 3 H), 1.96 (s, 3H), 0.99 (d, 2 H, J = 
6.8 Hz), 0.07 (s, 9 H); 13C NMR (DMSO-d6, 373 oK) δ 208.0, 204.2, 171.5, 168.6, 153.5, 135.6, 
127.7 (2C), 127.3, 127.1 (2C), 68.0, 66.3, 58.0, 55.7, 51.4, 48.6, 43.9, 38.8, 22.4, 20.1 −1.7 (3C); 
MS (EI) m/z  (relative intensity) 431 ([M−AcOH]+, 80), 372 (70), 296 (90), 91(100); HRMS (EI) 
m/z calcd for C22H29NO6Si (M−C4H4O2) 431.1764, found 431.1764. 
(2S,5R)-5-[4-Acetoxy-2-((ethylene)-dioxo)-5-(trimethylsilanyl)-pentyl]-4-oxo-
pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (131). To a solution of 129 
(0.21 g, 0.44 mmol) in CH2Cl2 (10 mL) was added PhI(OAc)2  (0.42 g, 1.3 mmol) and I2 (0.33 g, 
1.3 mmol) at room temperature. The reaction mixture was stirred for 14 h at room temperature, 
diluted with EtOAc (100 mL) and washed with saturated aqueous Na2S2O3 solution (50 mL). 
The organic layer was dried (MgSO4) and concentrated under reduced pressure.  The crude 
residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 3:1) to give 131 (115 mg, 
50%) as a colorless oil. [α]D  -53.7 (c 1.0, CH2Cl2); IR (neat) 3032, 2960, 2889, 1757, 1731, 
1711, 1413, 1352, 1250 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 5.30-5.10 (m, 3 
H), 4.75-4.60 (m. 1 H), 4.10-3.60 (m, 5 H), 3.65 (s, 3 H), 3.13 (dd, 1 H, J =18.4, 10.1 Hz), 2.65-
2.50 (m, 2 H), 2.30-2.15 (m, 1 H), 2.10-1.90 (m, 1 H), 1.95 (s, 3 H), 1.90-1.75 (m, 1 H), 1.00-
0.90 (m, 2 H), 0.05 (s, 9 H); 13C NMR (mixture of rotamers) δ 209.2, 208.9, 172.8, 170.6, 170.4, 
154.6, 136.0, 128.8, 128.5, 128.1, 109.1, 68.6, 68.3, 68.1, 67.6, 64.5, 64.3, 60.6, 59.9, 56.4, 52.8, 
52.6, 45.4, 45.2, 40.1, 39.7, 38.6, 37.8, 24.7, 21.8, -0.7; MS (EI) m/z  (relative intensity) 476 
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 ([M-OAc]+, 37), 432 (10), 362 (100); HRMS (EI) m/z calcd for  C24H34NO7Si (M−C2H3O2), 
476.2105, found 476. 2083. 
(2S,3aR,4S,7R)-7-Allyl-3a-hydroxy-6-oxo-4-(trimethylsilanylmethyl)-
octahydroindole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (132). To a solution of 
128 (4.82 g, 11.1 mmol) in THF (100 mL) was added LHMDS (1.0 M in THF, 27.8 mL) at –78 
°C.  The reaction mixture was stirred for 1 h at –78 °C, treated with allyl iodide (5.08 mL, 55.6 
mmol), slowly warmed to –20 °C for 3 h, quenched with saturated aqueous NH4Cl solution (100 
mL) and diluted with brine (200 mL). The reaction mixture was extracted with EtOAc (300 
mL×2), dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified 
by chromatography on SiO2 (Hexanes/EtOAc, 3:1) to give recovered 128 (750 mg, 16%) and 
132 (3.98 g, 76%) as a white foam: [α]D −17.4 (c 1.0, CH2Cl2); IR (neat) 3437, 2952, 2898, 
1716, 1409, 1345, 1248, 1226 cm-1; 1H NMR (DMSO-d6, 373 °K) δ 7.50-7.30 (m, 5 H), 5.90-
5.60 (m, 1 H), 5.12 (bs, 2 H), 5.20-4.85 (m, 2 H), 4.65 (d, 1 H, J = 9.6 Hz), 4.01 (d, 2 H, J = 4.0 
Hz), 3.65 (bs, 3 H), 2.80-2.05 (m, 7 H), 1.94 (d, 1 H, J = 9.4 Hz), 1.20 (dd, 1 H, J = 14.6, 2.9 
Hz), 0.34 (dd, 1 H, J = 14.4, 10.1 Hz), 0.08 (s, 9 H); 13C NMR (mixture of rotamers) δ 208.8, 
208.0, 175.9, 175.7, 154.9, 154.3, 135.8, 135.6, 135.5, 128.7, 128.6, 128.4, 116.9, 116.7, 81.6, 
80.8, 71.3, 71.2, 68.2, 67.8, 57.3, 55.8, 55.5, 53.4, 52.9, 45.3, 44.9, 37.4, 37.0, 35.0, 34.0, 33.0, 
32.1, 18.8, 18.7, −0.6 (3C); MS (EI) m/z  (relative intensity) 473 (M+, 9), 414 (25), 370 (44), 338 
(28), 320 (30); HRMS (EI) m/z calcd for C25H35NO6Si 473.2234, found 473.2229. 
(2S,3aR,4S,7R)-7-Allyl-3a-Hydroxy-6-(ethylene)-dioxo-4-(trimethylsilanylmethyl)-
octahydroindole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (133). A solution of 132 
(2.90 g, 6.12 mmol), p-TsOH⋅H2O (116 mg, 6.10 mmol) and ethylene glycol (3.41 mL, 61.2 
mmol) in benzene (120 mL) was heated at reflux for 20 h, cooled to room temperature, diluted 
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 with EtOAc (500 mL) and washed with saturated aqueous NaHCO3 solution (250 mL). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 133 (2.66 g, 84%) as a 
white foam: [α]D −12.5 (c 1.0, CH2Cl2); IR (neat) 3453, 2952, 2892, 1710, 1411, 1351, 1247, 
1220 cm-1; 1H NMR (mixture of rotamers) δ 7.40-7.20 (m, 5 H), 5.90-5.60 (m, 1 H), 5.15-4.65 
(m, 4 H),  4.40-3.80 (m, 7 H), 3.78, 3.37 (2s, 3 H), 2.45-2.25 (m, 2 H), 2.25-2.05 (m, 2 H), 1.80-
1.70 (m, 2 H), 1.60-1.45 (m, 1 H), 1.25-1.00 (m, 2 H), 0.16 (dd, 1 H, J = 13.4, 12.2 Hz), 0.00 (s, 
9 H); 13C NMR (mixture of rotamers) δ 175.6, 175.5, 155.1, 154.4, 138.9, 138.4, 135.8, 128.3, 
128.1, 128.0, 113.2, 113.0, 108.9, 108.8, 81.2, 80.4, 70.0, 67.5, 64.9, 64.8, 64.3, 56.7, 56.5, 53.0, 
52.5, 49.4, 48.5, 39.5, 39.4, 35.3, 35.0, 33.8, 30.3, 17.3, −0.7; MS (EI) m/z  (relative intensity) 
517 (M+, 12), 414 (11), 364 (28), 338 (28), 243 (85), 91 (100), HRMS (EI) m/z calcd for 
C27H39NO7Si 517.2496, found 517.2471. 
(2S,3aR,4S,7R)-3a-Hydroxy-7-(2-oxoethyl)-6-(ethylene)-dioxo-4-
(trimethylsilanylmethyl)-octahydro-indole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl 
ester (134). To a solution of 133 (0.20 g, 0.39 mmol) in H2O-dioxane (1:3, 4 mL) was added 
OsO4 (2.5% in BuOH, 0.2 mL), NaIO4 (410 mg, 1.93 mmol) and 2,6-lutidine (90 µl, 0.78 mmol) 
at room temperature. The reaction mixture was stirred for 4 h at room temperature, diluted with 
EtOAc (50 mL) and washed with brine (25 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(Hexanes/EtOAc, 2:1) to give 134 (0.17 g, 85%) as a white solid: Mp 152-155 °C (CH2Cl2); [α]D 
−10.0 (c 1.0, CH2Cl2); IR (neat) 3453, 2966, 2884, 1716, 1696, 1409, 1352, 1214 cm-1; 1H NMR 
(mixture of rotamers) δ 9.71, 9.36 (2s, 1 H), 7.50-7.30 (m, 5 H), 5.24, 5.08 and 5.15, 4.98 (2AB, 
2 H, J = 12.0 Hz), 4.88, 4.56 (2s, 1 H, -OH), 4.44, 4.18 (2d, 1 H, J = 9.9 Hz), 4.15-3.70 (m, 5 H), 
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 3.90, 3.76 (2s, 3 H), 2.85-2.45 (m, 2 H), 2.40-2.05 (m, 3 H), 1.95-1.80  (m, 2 H), 1.35-1.10 (m, 2 
H), 0.27 (dd, 1 H, J = 14.0, 10.8 Hz), 0.08 (s, 9 H); 1H NMR (DMSO-d6 at 373 °K) δ 9.68 (bs, 1 
H), 7.50-7.30 (m, 5 H), 5.25-5.00 (m, 2 H), 4.49 (d, 1 H, J = 9.8 Hz), 4.10-3.90 (m, 2 H), 3.96 (s, 
3 H), 3.85-3.55 (m, 4 H), 2.71 (dd, 1 H, J = 14.1, 10.3 Hz), 2.60 (dd, 1 H, J = 3.8, 1.9 Hz), 2.50-
2.30 (m, 2 H), 2.25-2.05 (m, 1 H), 1.95-1.80 (m, 1 H), 1.84 (dd, 1 H, J = 13.8, 4.5 Hz), 1.37 (t, 1 
H, J = 13.6 Hz),  1.12 (dd, 1 H, J = 14.5, 3.7 Hz), 0.36 (dd, 1 H, J = 14.5, 10.6 Hz), 0.12 (s, 9 H);  
13C NMR (mixture of rotamers) δ 201.1, 200.2,  175.7, 154.9, 154.7, 135.7, 135.6, 128.7, 128.6, 
128.5, 128.4, 128.3, 108.2, 108.0, 81.3, 80.5, 69.5, 69.0, 67.9, 69.8, 65.1, 65.0, 64.3, 64.0, 57.1, 
56.7, 53.3, 52.8, 44.6, 44.2, 41.4, 40.9, 38.6, 35.5, 35.3, 34.8, 33.8, 17.4, 0.6; MS (EI) m/z  
(relative intensity) 519 (M+, 0.5), 504 (2), 416 (13), 185 (25), 91 (100), 73 (32); HRMS (EI) m/z 
calcd for C26H37NO8Si 519.2288, found 519.2300. 
(2S,3aR,4S,7R,7aR)-3a-Hydroxy-7-(2-hydroxyethyl)-6-(ethylene)-dioxo-4-(trimethyl-
silanylmethyl)-octahydroindole-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (135). 
To a solution of 134 (840 mg, 1.62 mmol) in THF-MeOH (1:1, 30 mL) was added NaBH4 (306 
mg, 8.08 mmol) at 0 °C.  The reaction mixture was stirred at 0 °C for 1 h, quenched with brine 
(100 mL) and extracted with EtOAc (250 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(Hexanes/EtOAc, 1:4) to give 135 (780 mg, 93%) as a white foam: [α]D −8.3 (c 1.0, CH2Cl2); IR 
(neat) 3411, 2945, 2879, 1726, 1690, 1408, 1357, 1219 cm-1; 1H NMR (mixture of rotamers) δ 
7.50-7.30 (m, 5 H), 5.26, 4.97 and 5.08, 4.98 (2AB, 2 H, J = 12.1 Hz), 4.70, 4.30 (2bs, 1 H, -
OH), 4.29, 4.13 (2d, 1 H, J = 9.4 Hz), 4.10-3.85 (m, 5 H), 3.80, 3.38 (2s, 3 H), 3.60-3.50 (m, 1 
H), 3.35-3.20 (m, 1 H), 2.50-1.90 (m, 3 H), 1.85-1.50  (m, 4 H), 1.20-1.05 (m, 2 H), 0.16 (dd, 1 
H, J = 14.2, 11.5 Hz), 0.00 (s, 9 H); 13C NMR (mixture of rotamers) δ 175.8, 175.7 (1C), 155.4, 
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 155.0 (1C), 136.0, 135.8 (1C), 128.8, 128.6, 128.5, 128.4 (5C), 109.0, 108.9 (1C), 81.3, 80.5 
(1C), 70.4, 70.1 (1C), 67.8, 67.7 (1C), 64.8, 64.4, 64.3 (2C), 62.2, 62.1 (1C), 56.9, 56.8 (1C), 
53.2, 52.7 (1C), 46.7, 45.8 (1C), 38.7 (1C), 35.4, 35.2 (1C), 35.0, 33.9 (1C), 29.2, 29.0 (1C), 17.3 
(1C), −0.6 (3C); MS (EI) m/z  (relative intensity) 503 ([M−H2O], <1), 368 (9), 324 (10), 185 
(20), 91 (100); HRMS (EI) m/z calcd for C26H37NO7Si (M−H2O) 503.2339, found 503.2318. 
(2S,3aR,4S,7R,7aR)-3a-Hydroxy-7-(2-tert-butyldimethylsilyloxyethyl)-6-(ethylene)-
dioxo-4-(trimethylsilanylmethyl)-octahydroindole-1,2-dicarboxylic acid 1-benzyl ester 2-
methyl ester (136). To a solution of 135 (150 mg, 0.288 mmol) in CH2Cl2 was added TBSCl (65 
mg, 0.43 mmol), imidazole (29 mg, 0.43 mmol) and DMAP (3.7 mg, 0.030 mmol) at 0 °C. The 
reaction mixture was stirred for 30 min, diluted with EtOAc (50 mL) and washed with H2O (25 
mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 4:1) to give 136 (180 mg, 
98%) as a white foam: [α]D −2.3 (c 1.0, CH2Cl2); IR (neat) 3446, 2955, 2878, 2845, 1721, 1705, 
1408, 1250, 1221, 1081 cm-1; 1H NMR (mixture of rotamers) δ 7.50-7.30 (m, 5 H), 5.14, 4.98 
(AB, 1.2 H, J = 11.9 Hz) 5.14  (s, 0.8 H), 4.74, 4.41 (2bs, 1 H, -OH), 4.30, 4.29 (2d, 1 H, J = 9.3 
Hz), 4.15-3.85 (m, 5 H), 3.84, 3.37 (2s, 3 H), 3.70-3.40 (m, 2 H), 2.55-2.35 (m, 1 H), 2.25-1.50  
(m, 6 H), 1.20-1.05 (m, 2 H), 0.93-0.89 (3s, 9 H), 0.19 (m, 1 H), 0.10-0.01 (3s, 15 H); 1H NMR 
(DMSO-d6 at 373 °K) δ 7.50-7.30 (m, 5 H), 5.30-5.00 (m, 2 H), 4.40-4.25 (m, 2 H), 4.15-3.85 
(m, 5 H), 3.80-3.50 (m, 4 H), 2.95 (bs, 1 H), 2.70-2.55 (m, 1 H), 2.20-2.00 (m, 1 H), 1.95-1.70  
(m, 5 H), 1.28 (t, 1 H, J =13.6 Hz),  1.11 (dd, 1 H, J = 14.4, 3.4 Hz), 0.98 (s, 9 H), 0.32 (dd, 1 H, 
J = 14.5, 10.6 Hz), 0.11 (s, 15 H); 13C NMR (mixture of rotamers) δ 175.8, 155.4, 154.9, 136.0, 
135.9, 128.5, 128.4, 128.3, 128.1, 109.6, 109.3, 81.3, 80.5, 70.4, 70.3, 67.7, 65.1, 64.9, 64.4, 
63.0, 62.7, 56.9, 56.7, 53.2, 45.3, 44.7, 39.2, 39.1, 35.4, 35.2, 29.5, 29.3, 26.1, 25.8, 18.4, 17.4, 
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 −0.6, −3.4, −5.1; MS (ESI) m/z  (relative intensity) 658 ([M+Na]+, 100), (2), 486 (50); HRMS 
(ESI) m/z calcd for C32H53NO8SiNa (M+Na) 658.3207, found 658.3237. 
5-[1-{2-[2-Acetoxy-3-(trimethylsilanyl)-propyl]-[1,3]dioxolan-2-yl}-3-(tert-
butyldimethyl-silanyloxy)-propyl]-4-oxo-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-
methyl ester (137) and 7-Acetoxy-6-[2-(tert-butyldimethylsilanyloxy)-ethyl]-11-oxo-12-
(trimethylsilanylmethyl)-1,4-dioxa-8-aza-spiro[4.8]tridecane-8,9-dicarboxylic acid 8-benzyl 
ester 9-methyl ester (138). To a solution of 136 (150 mg, 0.236 mmol) in CH2Cl2 (5 mL) was 
added iodobenzene diacetate (0.23 g, 0.71 mmol) and iodine (0.18 g, 0.71 mmol) at room 
temperature. The reaction mixture was stirred for 18 h at room temperature, diluted with EtOAc 
(50 mL) and washed with saturated aqueous Na2S2O3 solution (25 mL). The organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 5:1) to give 138 (38 mg, 23%) and 137 (17 mg, 10%) 
along with recovered 136 (13 mg, 9%). 137: [α]D −21.0 (c 0.5, CH2Cl2); IR (neat) 2958, 2927, 
2887, 2850, 1754, 1640, 1410, 1349, 1250, 1097 cm-1; 1H NMR (mixture of rotamers) δ 7.50-
7.25 (m, 5 H), 5.40-5.00 (m, 3 H), 4.70-4.50 (m, 1 H), 4.23 (bs, 1 H), 4.00-3.40 (m, 9 H), 3.20-
2.95, 2.75-2.65 (2m, 2 H), 2.50-2.30 (m, 1 H), 2.20-1.60 (m, 4H), 1.96 (s, 3 H), 0.90 (s, 9 H), 
1.00-0.80 (m, 2 H), 0.08 (s, 6 H), -0.03 (s, 9 H); 13C NMR (mixture of rotamers) δ 209.7, 209.3, 
172.8, 170.3, 154.1, 136.0, 128.6, 111.2, 68.0, 67.9, 67.4, 65.5, 64.2, 62.4, 62.1, 58.0, 56.2, 52.4, 
42.5, 40.7, 30.4, 30.2, 26.1, 24.8, 21.7, 21.4, 18.4, 1.1, -0.8, -5.2; MS (ESI) m/z  (relative 
intensity) 716 ([M+Na], 100), 634 (72), 520 (40); HRMS (ESI) m/z calcd for C34H55NO10NaSi2 
(M+Na) 716.3262 , found 716.3294. 138: [α]D −33.0 (c 1.0, CH2Cl2); IR (neat) 2958, 2926, 
2893, 2857, 1751, 1703, 1424, 1315, 1247, 1098 cm-1; 1H NMR (rotamers) δ 7.50-7.30 (m, 5 H), 
6.78, 6.69 (2d, 1 H, J = 10.1 Hz) 5.34, 5.12 and 5.24, 5.14 (2AB, 2 H, J = 12.4 Hz), 4.25-4.05, 
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 4.00-3.80 (2m, 3 H), 3.75-3.45 (m, 3 H), 3.65, 3.36 (2s, 3 H), 3.45-3.20 (m, 1 H), 3.00 (d, 1 H, J 
= 12.3 Hz), 2.85-2.65 (m, 1 H), 1.99, 1.90 (2s, 3 H), 1.85-1.60 (m, 4 H), 1.50-1.30 (m. 1 H), 
1.15-1.05 (m, 1 H), 0.89 (s, 9 H). 0.65-0.50 (m, 1 H), 0.05 (s, 6 H), -0.04 (s, 9 H); 13C NMR 
(mixture of rotamers) δ 216.4, 170.5, 170.4, 169.0, 168.5, 154.6, 136.3, 135.7, 128.9, 128.6, 
128.5, 128.4, 128.2, 128.1, 110.4, 110.2, 78.9, 68.1, 64.8, 64.7, 62.6, 55.0, 52.8, 52.6, 46.3, 44.0, 
43.7, 42.7, 40.6, 39.7, 30.8, 30.6, 26.1, 20.9, 20.8, 18.4, 17.5, 1.12, -0.9, -5.1; MS (ESI) m/z  
(relative intensity) 716 ([M+Na], 48), 634 (100), 590 (20); HRMS (ESI) m/z calcd for 
C34H55NO10NaSi2 (M+Na) 716.3262 , found 716.3263.  
(2S,3aR,4S,7R,7aR)-7-Allyl-3a-hydroxy-6-(ethylene)-dioxo-4-(trimethyl-
silanylmethyl)-octahydro-indole-2-carboxylic acid 2-methyl ester (139). A solution of Et3SiH 
(1.77 mL, 11.1 mmol), Pd(OAc)2 (99 mg, 0.44 mmol) and TEA (0.12 mL, 0.88 mmol) in CH2Cl2 
(20 mL) was stirred for 30 min at room temperature. To this solution was added 133 (2.30 g, 
4.44 mmol) in CH2Cl2 (20 mL). The reaction mixture was stirred for 20 h at room temperature, 
quenched with saturated aqueous NaHCO3 solution (100 mL), stirred for 3 h and extracted with 
CH2Cl2 (250 mL×2). The organic layer was dried (MgSO4) and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (Hexanes/EtOAc, 2:1 → 
1:2) to give 139 (1.44 g, 85%) as a white solid: Mp. 113-116 °C (CH2Cl2); [α]D +13.1 (c 1.0, 
CH2Cl2); IR (neat) 3480, 2955, 2888, 1736, 1634, 1434, 1250, 1209 cm-1; 1H NMR δ 6.00-5.80 
(m, 1 H), 5.00 (dd, 1 H, J = 17.0, 1.5 Hz), 4.90 (d, I H, J = 10.0 Hz), 4.05-3.80 (m, 5 H), 3.72 (s, 
3 H), 2.91 (d, 1 H, J = 11.0 Hz), 2.85-2.70 (m, 1 H), 2.60-2.40 (m, 1 H), 2.35-2.15 (m, 3 H), 
2.10-1.95 (m, 1 H), 1.82 (dd, 1 H, J = 14.1, 1.6 Hz), 1.74 (dd, 1 H, J = 13.8, 4.3 Hz), 1.60-1.40 
(m, 1 H), 1.16 (t, 1 H, J = 13.5 Hz), 1.06 (dd, 1 H, J = 14.5, 2.7 Hz), 0.23 (dd, 1 H, J = 14.4, 11.5 
Hz), 0.00 (s, 9 H); 13C NMR δ 176.7, 139.1, 114.6, 109.6, 82.8, 70.5, 65.1, 64.3, 56.2, 52.5, 47.5, 
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 39.7, 36.3, 35.7, 31.8, 17.8, -0.6 (3C); MS (EI) m/z  (relative intensity) 383 (M+, 3), 324 (60), 73 
(100), HRMS (EI) m/z calcd for C19H33NO5Si 383.2128, found 383.2120. 
(2S,3aR,4S,7R),7aR)-1-Acryloyl-7-allyl-3a-hydroxy-6-(ethylene)-dioxo-4-
(trimethylsilanylmethyl)-octahydroindole-2-carboxylic acid methyl ester (140). To a solution 
of 139 (1.44 g, 3.75 mmol) in CH2Cl2 (40 mL) was added TEA (2.61 mL, 18.8 mmol) and acroyl 
chloride (0.61 mL, 7.5 mmol) at 0 °C. The reaction mixture was stirred for 30 min at 0 °C, 
quenched with brine (100 mL) and extracted with EtOAc (250 mL). The organic layer was dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 2:1) to give 140 (1.46 g, 89%) as a white foam: [α]D 
+11.6 (c 1.0, CH2Cl2); IR (neat) 3436, 2950, 2893, 1710, 1650, 1613, 1429, 1362, 1214 cm-1; 1H 
NMR δ 6.50 (dd, 1 H, J = 16.7, 9.9 Hz), 6.37 (dd, 1 H, J = 16.7, 2.1 Hz), 5.80-5.60 (m, 2 H), 
4.85 (dd, 1 H, J = 8.4, 1.5 Hz), 4.81 (s, 1 H), 4.74 (s, 1 H), 4.33 (dd, 1 H, J = 10.2, 1.3 Hz), 4.20-
3.85 (m, 5 H), 3.81 (s, 3 H), 2.41 (dd, 1 H, J = 14.6, 10.3 Hz), 2.30-2.10 (m, 2 H), 2.05-1.95 (m, 
1 H), 1.85-1.70 (m, 2 H), 1.65-1.50 (m, 1 H), 1.18 (t, 1 H, J = 13.8 Hz), 1.09 (dd, 1 H, J = 14.3, 
3.0 Hz), 0.18 (dd, 1 H, J = 14.3, 11.1 Hz), 0.00 (s, 9 H); 13C NMR δ 175.6, 165.6, 137.8, 129.1, 
127.9, 114.2, 108.9, 81.6, 70.5, 65.1, 64.4, 56.8, 53.1, 48.9, 39.6, 35.1, 33.1, 30.2, 17.3, -0.6 
(3C); MS (EI) m/z  (relative intensity) 437 (M+, 24), 422 (15), 382 (23), 332 (13), 246 (15), 185 
(80), 73 (100), HRMS (EI) m/z calcd for C22H35NO6Si 437.2234, found 437.2233. 
(2S,7aR,7aaR,10S,10aR)-10a-Hydroxy-8-(ethylene)-dioxo-4-oxo-10-
(trimethylsilanylmethyl)-1,2,4,7,7a,8,9,10,10a,10b-decahydroazepino[3,2,1-hi]indole-2-
carboxylic acid methyl ester (141). To a solution of 140 (1.35 g, 3.09 mmol) in CH2Cl2 (1 L) 
was added second-generation Grubb’s catalyst128 (131 mg, 0.150 mmol) at room temperature. 
The reaction mixture was heated at reflux for 20 h, cooled to room temperature and concentrated 
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 under reduced pressure. The crude residue was purified by chromatography on SiO2 
(Hexanes/EtOAc, 1:3) to give 141 (1.22 g, 94%) as a white foam: [α]D +5.5 (c 1.0, CH2Cl2); IR 
(neat) 3421, 2945, 2883, 1752, 1721, 1593, 1450, 1316, 1250 cm-1; 1H NMR δ 6.21 (dt, 1 H, J = 
12.6, 4.2 Hz), 5.88 (dt, 1 H, J = 12.6, 2.1 Hz), 4.58 (d, 1 H, J = 9.9 Hz), 4.29 (s, 1 H, -OH), 4.20-
3.85 (m, 4 H), 3.78 (s, 3 H), 3.72 (d, 1 H, J = 9.7 Hz), 2.65-2.40 (m, 2 H), 2.35-2.10 (m, 2 H), 
2.10-2.00 (m, 1 H). 1.92 (d, 1 H, J = 14.1 Hz) 1.75 (dd, 1 H, J = 13.8, 3.6 Hz), 1.20 (t, 1 H, J = 
13.6 Hz), 1.07 (dd, 1 H, J = 14.3, 2.7 Hz), 0.24 (dd, 1 H, J = 14.4, 11.5 Hz), 0.00 (s, 9 H); 13C 
NMR δ 175.5, 166.6, 140.0, 123.8, 108.4, 82.6, 69.2, 65.8, 64.5, 57.7, 53.0, 47.6, 38.2, 36.0, 
33.0, 29.3, 16.9, -0.6 (3C); MS (EI) m/z  (relative intensity) 409 (M+, 1), 394 (13), 350 (100), 73 
(48), HRMS (EI) m/z calcd for C20H31NO6Si 409.1921, found 409.1917. 
(2S,7aR,7aaR,10S,10aR)-10a-Hydroxy-8-(ethylene)-dioxo-4-oxo-10-
(trimethylsilanylmethyl)-dodecahydroazepino[3,2,1-hi]indole-2-carboxylic acid methyl 
ester (142). To a solution of 141 (1.15g, 2.81 mmol) in MeOH (20 mL) was added 10 % Pd-C 
(100 mg). The solution was hydrogenated in a Parr-hydrogenator at 40 psi H2 for 3 h, filtered 
through silica pad and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (EtOAc) to give 142 (1.02 g, 89%) as a white foam: [α]D −6.4 (c 1.0, 
CH2Cl2); IR (neat) 3431, 2955, 2884, 1726, 1650, 1455, 1419, 1183 cm-1; 1H NMR δ 4.47 (bs, 1 
H, -OH), 4.42 (d, 1 H, J = 10.4 Hz), 4.05-3.85 (m, 4 H), 3.79 (d, 1 H, J = 6.7 Hz), 3.77 (s, 3 H), 
2.60-2.40 (m, 2 H), 2.35-2.00 (m, 3 H), 2.00-1.80 (m, 2 H), 1.72 (dd, 1 H, J = 13.9, 3.8 Hz), 
1.65-1.35 (m, 3 H), 1.17 (t, 1 H, J = 13.7 Hz), 1.04 (dd, 1 H, J = 14.3, 2.6 Hz), 0.20 (dd, 1 H, J = 
14.3, 11.4 Hz), 0.00 (s, 9 H); 13C NMR δ 175.8, 174.9, 108.6, 82.2, 71.6, 65.7, 64.5, 57.3, 53.0, 
48.0, 38.7, 36.9, 35.8, 33.1, 28.6, 23.0, 17.1, -0.6 (3C); MS (ESI) m/z  (relative intensity) 434 
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 ([M+Na]+, 1), 394 (35), 355 (30); HRMS (ESI) m/z 434.1975 calcd for C20H33NO6SiNa (M+Na), 
found 434.1989. 
(2S,7aR,7aaR,10S,10aR)-Hydroxy-4,8-dioxo-10-(trimethylsilanylmethyl)-
dodecahydroazepino[3,2,1-hi]indole-2-carboxylic acid methyl ester (143). To a solution of 
142 (0.28 g, 0.68 mmol) in MeOH (13 mL) was slowly added concentrated HCl (1.3 mL) at 
room temperature. The reaction mixture was stirred for 2 d at room temperature, quenched with 
saturated aqueous NaHCO3 solution (50 mL) and extracted with EtOAc (100 mL). The organic 
layer was dried (MgSO4) and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (Hexanes/EtOAc, 1: 4) to give 143 (226 mg, 96%) as a 
white foam: [α]D −23.5 (c 1.0, CH2Cl2); IR (neat) 3431, 2946, 2889, 1754, 1716, 1639, 1455, 
1440, 1245,1224, 1188 cm-1; 1H NMR δ 4.54 (d, 1 H, J = 10.3 Hz), 3.80 (d, 1 H, J = 12.9 Hz), 
3.78 (s, 3 H), 2.65-2.45 (m, 3 H), 2.40-2.25 (m, 1 H), 2.25-1.90 (m, 5 H), 1.60-1.30 (m, 2 H), 
1.15 (d, 1 H, J  = 14.3 Hz), 0.33 (dd, 1 H, J = 14.3, 9.3 Hz), 0.00 (s, 9 H); 13C NMR δ 206.4, 
175.3, 174.5, 81.8, 73.3, 57.2, 53.2, 52.7, 44.8, 38.9, 36.7, 33.0, 29.5, 22.4, 18.5, -0.7 (3C); MS 
(EI) m/z  (relative intensity) 367 (M+, 3), 352 (55), 308 (100), 292 (18), 73 (19); HRMS (EI) m/z 
calcd for C18H29NO5Si 367.1815, found 367.1830. 
(3S,9R,9aR)-9-[3-Acetoxy-4-(trimethylsilanyl)-butyryl]-1,5-dioxooctahydro-
pyrrolo[1,2-a]azepine-3-carboxylic acid methyl ester (145). A solution of 143 (88 mg, 0.24 
mmol) in CH2Cl2 (5 mL) was treated with PhI(OAc)2 (230 mg, 0.714 mmol) and I2 (180 mg, 
0.709 mmol) at room temperature. The reaction mixture was stirred for 2 d, diluted with EtOAc 
(50 mL) and washed with saturated aqueous Na2S2O3 solution (25 mL). The organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (Hexanes/EtOAc, 1:3) to give 145 (20 mg, 25 %) as a colorless oil: 
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 [α]D −24.3 (c 1.0, CH2Cl2); IR (neat) 2943, 1736, 1705, 1654, 1434, 1403, 1368,1238, 1163 cm-
1; 1H NMR (mixture of diastereomers) δ 5.40-5.25 (m, 1 H), 4.90-4.75 (m, 1 H), 4.71 (dd, 1 H, J 
= 10.9, 10.1 Hz), 3.76 (s, 3 H), 3.00-2.80 (m, 2 H), 2.75-2.45 (m, 5 H), 2.02, 2.00 (2s, 3 H), 1.95-
1.75 (m, 2 H), 1.75-1.55 (m, 2 H), 1.06 (dd, 2 H, J  = 9.7, 7.2 Hz), 0.06 (s, 9 H); 13C NMR 
(mixture of diastereomers) δ 208.8, 208.5, 206.2, 174.6, 174.5, 172.1, 170.0, 69.1, 63.3, 63.0, 
55.3, 53.9, 53.0, 50.0, 49.3, 38.8, 38.7, 36.2, 30.1, 23.2, 21.5, 20.4, 20.2, −0.8; MS (EI) m/z 
(relative intensity) 425 (M+, <1), 365 (40), 296 (42), 236 (70), 73 (100); HRMS (EI) m/z calcd 
for C20H31NO7Si 425.1870, found 425.1889. 
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117. The stereochemistry of 96 was determined by the coupling constant of protons at C(7) 
and C(7a) of compounds 96-104 in 1H NMR based on the previous 1H NMR assignment 
of compound 1 (see references 86(a) and 76(c)). The stereochemistry of 105 (96-1) was 
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Efforts to obtain a single crystal, including chemical derivatizations, failed to provide 
crystals suitable for X-ray analysis. 
125. Only a single diastereomer was isolated after work-up and purification by 
chromatography on SiO2. The stereochemistry of this reaction could be interpreted by the 
preference of axial alkylation of 128: 
N
Cbz
CO2Me
OH
TMS
E
LiO
E = allyl bromide
128  
The stereochemistry of 132 was determined by 2D NMR analyses of 139. Major 
interactions in the NOESYof 139: 
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 HN
O
CO2Me
SiMe3
OH
H21
H19
17H
H3 H2
NOE effect  in NOESY spectra
H3 and H21
H2 and H21
H19 and H17
139  
126. (a) Ozonolysis of 133 led to an unidentified product. (b) For an improved procedure, 2,6-
lutidine was used, see: Yu, W.; Mei, Y.; Kang, Y.; Hua, Z.; Jin, Z. Org. Lett. 2004, 6, 
3217. 
127. The stereochemistry of 138 was tentatively determined by previous results in our group. 
See reference (94). 
128. We could not determine the exact stereochemistry at C4 of 137 and it was hard to tell 
whether we obtained 137 as a single diastereomer or a mixture of diastereomers due to the 
low resolution of NMR spectra of 137 in CDCl3. 137 readily decomposed at 373°K in 
DMSO-d6. 
129. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953. 
130. In contrast to 130 and 131, compound 145 was obtained as a ~1:1 mixture of 
diastereomers. This result prevented us from making a tentative assignment of the 
stereochemistry of these fragmentation products. 
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